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A B S T R A C T
Background
Acute low back pain (LBP) is a common health problem. Non-steroidal anti-inflammatory drugs (NSAIDs) are oIen used in the treatment of
LBP, particularly in people with acute LBP. In 2008, a Cochrane Review was published about the eFicacy of NSAIDs for LBP (acute, chronic,
and sciatica), identifying a small but significant eFect in favour of NSAIDs compared to placebo for short-term pain reduction and global
improvement in participants with acute LBP. This is an update of the previous review, focusing on acute LBP.
Objectives
To assess the eFects of NSAIDs compared to placebo and other comparison treatments for acute LBP.
Search methods
We searched CENTRAL, MEDLINE, Embase, PubMed, and two trials registers for randomised controlled trials (RCT) to 7 January 2020. We
also screened the reference lists from relevant reviews and included studies.
Selection criteria
We included RCTs that assessed the use of one or more types of NSAIDs compared to placebo (the main comparison) or alternative
treatments for acute LBP in adults (≥ 18 years); conducted in both primary and secondary care settings. We assessed the eFects of treatment
on pain reduction, disability, global improvement, adverse events, and return to work.
Data collection and analysis
Two review authors independently selected trials to be included in this review, evaluated the risk of bias, and extracted the data. If
appropriate, we performed a meta-analysis, using a random-eFects model throughout, due to expected variability between studies. We
assessed the quality of the evidence using the GRADE approach. We used standard methodological procedures recommended by Cochrane.
Main results
We included 32 trials, with a total of 5356 participants (age range 16 to 78 years). Follow-up ranged from one day to six months. Studies
were conducted across the globe, the majority taking place in Europe and North-America. Africa and the Eastern Mediterranean region
were not represented. We considered seven studies at low risk of bias. Performance and attrition were the most common biases. There
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was oIen a lack of information on randomisation procedures and allocation concealment (selection bias); studies were prone to selective
reporting bias, since most studies did not register their trials. Almost half of the studies were industry-funded.
There is moderate quality evidence that NSAIDs are slightly more eFective in short-term (≤ 3 weeks) reduction of pain intensity (visual
analogue scale (VAS), 0 to 100) than placebo (mean diFerence (MD) -7.29 (95% confidence interval (CI) -10.98 to -3.61; 4 RCTs, N = 815).
There is high quality evidence that NSAIDs are slightly more eFective for short-term improvement in disability (Roland Morris Disability
Questionnaire (RMDQ), 0 to 24) than placebo (MD -2.02, 95% CI -2.89 to -1.15; 2 RCTs, N = 471). The magnitude of these eFects is small and
probably not clinically relevant. There is low quality evidence that NSAIDs are slightly more eFective for short-term global improvement
than placebo (risk ratio (RR) 1.40, 95% CI 1.12 to 1.75; 5 RCTs, N = 1201), but there was substantial heterogeneity (I2 52%) between studies.
There is very low quality evidence of no clear diFerence in the proportion of participants experiencing adverse events when using NSAIDs
compared to placebo (RR 0.86, 95% CI 0.63 to 1.18; 6 RCTs, N = 1394). There is very low quality evidence of no clear diFerence between
the proportion of participants who could return to work aIer seven days between those who used NSAIDs and those who used placebo
(RR 1.48, 95% CI 0.98 to 2.23; 1 RCT, N = 266).
There is low quality evidence of no clear diFerence in short-term reduction of pain intensity between those who took selective COX-2
inhibitor NSAIDs compared to non-selective NSAIDs (mean change from baseline -2.60, 95% CI -9.23 to 4.03; 2 RCTs, N = 437). There is
moderate quality evidence of conflicting results for short-term disability improvement between groups (2 RCTs, N = 437). Low quality
evidence from one trial (N = 333) reported no clear diFerence between groups in the proportion of participants experiencing global
improvement. There is very low quality evidence of no clear diFerence in the proportion of participants experiencing adverse events
between those who took COX-2 inhibitors and non-selective NSAIDs (RR 0.97, 95% CI 0.63 to 1.50; 2 RCTs, N = 444). No data were reported
for return to work.
Authors' conclusions
This updated Cochrane Review included 32 trials to evaluate the eFicacy of NSAIDs in people with acute LBP. The quality of the evidence
ranged from high to very low, thus further research is (very) likely to have an important impact on our confidence in the estimates of eFect,
and may change the estimates.
NSAIDs seemed slightly more eFective than placebo for short-term pain reduction (moderate certainty), disability (high certainty), and
global improvement (low certainty), but the magnitude of the eFects is small and probably not clinically relevant.
There was no clear diFerence in short-term pain reduction (low certainty) when comparing selective COX-2 inhibitors to non-selective
NSAIDs.
We found very low evidence of no clear diFerence in the proportion of participants experiencing adverse events in both the comparison of
NSAIDs versus placebo and selective COX-2 inhibitors versus non-selective NSAIDs.
We were unable to draw conclusions about adverse events and the safety of NSAIDs for longer-term use, since we only included RCTs with
a primary focus on short-term use of NSAIDs and a short follow-up. These are not optimal for answering questions about longer-term or
rare adverse events.
P L A I N   L A N G U A G E   S U M M A R Y
Anti-inflammatory drugs for acute low back pain
Review question
We examined the eFect of non-steroidal anti-inflammatory drugs (NSAIDs), such as diclofenac, ibuprofen, and naproxen, for people with
acute low back pain. Acute low back pain is defined as the presence of pain in the back, below the ribs and above the buttocks, for under
12 weeks. We compared NSAIDs to placebo, paracetamol, other NSAIDs, other drugs, and non-drug treatments.
Background
Acute low back pain is common, and causes pain and disability. Physicians oIen prescribe NSAIDs to treat acute low back pain. DiFerent
types of NSAIDs are available, both over-the-counter and as prescription drugs.
Study characteristics
We searched for randomised controlled trials that were published or registered before 7 January 2020. We included 32 trials with 5356
participants. Trial participants were 16 to 78 years old and had acute low back pain. Study length varied from one day to six months. The
studies took place in many diFerent countries. More than half of the studies was done in Europe and North-America.
Key results
NSAIDs were slightly more eFective than placebo for pain reduction in the first three weeks. On average, the pain intensity decreased by
7.3 points on a 100-point scale. This means there was a small diFerence between the two treatments, but it was not clinically relevant.
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People receiving NSAIDs also scored 2.0 points better on a 24-point disability scale than those receiving placebo. This is unlikely to be of
real-world benefit. There was a similar number of side eFects between people receiving NSAIDs and people receiving placebo. However,
the type of studies that we investigated are not designed to find side eFects. Therefore, we should be careful about drawing conclusions
based upon these findings.
We also compared two diFerent types of NSAIDs; non-selective NSAIDs versus COX-2 inhibitors. We found no clear diFerences in eFect.
There was also a similar number of reported side eFects of the digestive system, such as abdominal pain, nausea, diarrhoea, or stomach
symptoms.
Quality of the evidence
There is moderate quality evidence that NSAIDs are slightly more eFective than placebo for reducing short-term pain, and high quality
evidence that they are slightly more eFective than placebo for reducing disability in acute low back pain. The magnitude of the eFect is
very small.
Non-steroidal anti-inflammatory drugs for acute low back pain (Review)














































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   NSAIDs compared to placebo in people with acute low back pain
NSAIDs compared to placebo in people with acute low back pain
Patient or population: adults (≥ 18 years of age) with acute low back pain
Setting: primary and secondary care settings, mainly general practice and outpatient clinics
Intervention: NSAIDs
Comparison: placebo
Anticipated absolute effects* (95% CI)Outcomes

















VAS (0 to 100; lower = better)
Follow-up: ≤ 3 weeks (range 7 to 15 days)
The mean pain intensity in
the placebo group ranged
from 7.9 to 33.9
The mean pain intensity in the
NSAID group was









on a 0 to
100 scale
Disability
RMDQ (0 to 24; lower = better)
Follow-up: ≤ 3 weeks (range 7 to 14 days)
The mean disability in
the placebo group ranged
from 6.0 to 7.3
The mean disability in the NSAID
group was









on a 0 to
24 scale
Study populationProportion of participants experiencing global
improvement
Various dichotomised Likert scales; lower = better
Follow-up ≤ 3 weeks (range 1 to 15 days)










Study populationProportion of participants experiencing adverse
events
Follow-up range 1 day to 12 weeks











Study populationReturn to work (%)


















































































































































*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; VAS: visual analogue scale; RMDQ: Roland Morris Disability Questionnaire; RR: risk ratio; RCT: randomised controlled trial; MID: minimal important
difference
GRADE Working Group grades of evidence
High certainty. We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty. We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty. Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect
Very low certainty. We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect
aDowngraded one level due to risk of bias. More than 25% of the included participants were from studies with a high risk of bias.
bDowngraded one level due to inconsistency. There is moderate to substantial heterogeneity with an I2 of 52% and a wide variance in point estimates across studies.
cDowngraded one level due to indirectness. Two studies (three treatment arms) included a small percentage of participants with additional sciatic complaints (diFerent
population). NSAID tablets, capsules or intramuscular injections were used (diFerent intervention). Treatment time and timing of outcome assessments ranged (diFerences in
outcome), which could make the results less generalisable.
dDowngraded one level due to inconsistency. On visual inspection, there is a wide variance in point estimates across studies. Follow-up duration to measure and report adverse
events varied greatly, and was probably too short in a few studies to adequately detect all adverse events.
eDowngraded one level due to indirectness. Two studies (three treatment arms) included a small percentage of participants with additional sciatic complaints (diFerent
population). Most studies had a relatively short follow-up time (ranging from 1 day to 2 to 3 weeks), except for one study (follow-up time 12 weeks). Therefore, it is unclear if the
follow-up time frame was suFicient to measure and report all relevant outcomes regarding adverse events.
fDowngraded one level due to imprecision. The total number of events was less than 300.
gDowngraded two levels due to imprecision. Only one study was included in the comparison, with a total number of events far less than 300. The 95% CI includes both no eFect
and the threshold of appreciable benefit.
 
 
Summary of findings 2.   Selective COX-2 inhibitors compared to non-selective NSAIDs for acute low back pain
Selective COX-2 inhibitors compared to non-selective NSAIDs for acute low back pain
Patient or population: adults (≥ 18 years of age) with acute low back pain (LBP)
Setting: primary and secondary care settings, mainly general practice and outpatient clinics
Intervention: selective COX-2 inhibitors
Comparison: non-selective NSAIDs
Anticipated absolute effects* (95% CI)Outcomes
























































































































































Change in pain intensity from base-
line
VAS (0 to 100; lower = better)
Follow-up ≤ 3 weeks (range 7 to 10
days)
The mean change in pain intensity from
baseline in the non-selective NSAID group
ranged from 38 to 41
The mean change in pain intensi-
ty from baseline in the COX-2 in-
hibitors group was 2.60 lower (9.23







on a 0 to
100 scale
Disability
ODI (0 to 50; lower = better)
Follow-up ≤ 3 weeks (range 7 to 10
days)
One trial reported a mean difference in disability score of -7.00 (95% CI -13.15 to
-0.85) after 10 days, showing a statistically significant and clinically relevant dif-
ference in favour of the nimesulide arm.
One trial reported a mean decrease in baseline disability of 32% in both the









on a 0 to
50 scale
Proportion of participants experi-
encing global improvement
% of dichotomized Likert scale
Follow-up ≤ 3 weeks (7 days)
One trial reported the percentage of participants who reported their pain relief
as 'a lot better' or 'completely better' at 1 week follow-up, which was similar in
both the valdecoxib (80%) and diclofenac (81%) arm, showing no clear differ-






Study populationProportion of participants experi-
encing adverse events
Follow-up range 10 to 37 days











Return to work (%)
Follow-up: N/A
Not reported - - N/A  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; VAS: visual analogue scale; ODI: Oswestry Disability Index; RR: risk ratio; RCT: randomised controlled trial; N/A: not available; MID: minimal impor-
tant difference
GRADE Working Group grades of evidence
High certainty. We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty. We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty. Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect
Very low certainty. We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect








































































































































bDowngraded one level due to inconsistency. There is moderate to substantial heterogeneity with an I2 of 57%, and a wide variance in point estimates.
cDowngraded one level due to imprecision. The total number of events was far less than 300, leading to a wide confidence interval.
dDowngraded two levels due to imprecision. The total number of events was far less than 300, leading to a wide confidence interval. The 95% confidence interval includes both
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B A C K G R O U N D
Description of the condition
Low back pain (LBP) is one of the most prevalent health problems
worldwide, and still one of the leading causes of years lived
with disability, according to the most recently published global
burden of disease study (GBD 2016). It is usually defined as pain,
muscle tension, or stiFness localised below the costal margin
and above the inferior gluteal folds (Koes 2006). The lifetime
prevalence of non-specific LBP is estimated at 60% to 70% in
industrialised countries (Hoy 2010). This aFects personal lives,
causing activity limitations and work absence, but also brings
with it an economic burden, with high socioeconomic costs
(Hoy 2010; Lidgren 2003); especially when a chronic state of
LBP develops (Steenstra 2005). In the first six weeks, recovery
occurs in a substantial number of participants. However, there is
increasing debate about the numbers of recurrent pain episodes
and chronicity, since participants continue to report pain aIer one
year (Costa 2012; Itz 2013; Manchikanti 2014; Pengel 2003). Current
guidelines on the treatment of non-specific LBP are consistent
in their focus on early and gradual activation, patient education,
avoiding bedrest, and addressing psychosocial factors to prevent
chronicity; and on prescribing analgesic medication for short
periods, where necessary, in the case of acute LBP (Oliveira 2018).
Description of the intervention
As stated above, most guidelines recommend staying active.
Better pain control may ease this process, therefore, the use
of non-steroidal anti-inflammatory drugs (NSAIDs) can be of
value. If pain medication is considered, NSAIDs are recommended
(Oliveira 2018). Previously, guidelines recommended various types
of analgesics (Koes 2010). Recently, an updated review on
paracetamol for LBP found high-quality evidence that paracetamol
(4 g per day) is no better than placebo for relieving acute LBP
(Saragiotto 2016). In some adapted guidelines, this new evidence is
already incorporated, for instance, the National Institute for Health
and Care Excellence (NICE) guidelines from the UK (Bernstein
2017). The most recent guidelines from the USA recommend non-
pharmacological treatments first, given that most people with
(sub)acute LBP improve over time, regardless of treatment. But if
pharmacological treatment is considered, then NSAIDs or muscle
relaxants are recommended as first line options (Qaseem 2017).
In such circumstances, NSAIDs are oIen recommended because of
their known analgesic and anti-inflammatory eFects. However, the
drawback is that they are also associated with a variety of potential
adverse events, particularly gastrointestinal and cardiovascular
eFects (Brune 2015).
How the intervention might work
The main therapeutic eFects of NSAIDs derive from their ability to
inhibit the production of prostaglandins. The first enzyme in the
pathway of prostaglandin synthesis is cyclooxygenase (COX). Both
COX-1 and COX-2 contribute to the production of prostaglandins
when inflammation and pain are present, and for autoregulation
and homeostasis of the human body. COX-1 is the dominant
source for the production of prostaglandins that are responsible for
gastric epithelial protection and haemostasis. COX-2 is important
for prostaglandin synthesis induced by cytokines and stress.
NSAIDs inhibit the COX enzyme, and thus block the synthesis of
prostaglandins, reducing inflammation, pain, and fever (Grosser
2011). Two types of NSAIDs are available: non-selective NSAIDs that
inhibit both COX-1 and COX-2 enzymes (e.g. ibuprofen, diclofenac,
naproxen); and selective COX-2 inhibitors that only inhibit
the COX-2 enzyme (e.g. nimesulide, celecoxib). The latter was
developed because non-selective NSAIDs were oIen associated
with gastrointestinal adverse events. Blocking COX-1 also reduced
gastric protection, leading to an increased risk for gastrointestinal
complications (e.g. gastric ulcer, perforation, stomach bleeding
(Sostres 2013)). Selective COX-2 inhibitors decrease this risk,
however they increase the risk for cardiovascular adverse events.
For instance, rofecoxib, a selective COX-2 inhibitor, was withdrawn
from the market for this reason. Similar concerns arose around
the cardiovascular safety of traditional NSAIDs (CNT Collaboration
2013; Trelle 2011; Walker 2018). There is evidence that this risk is
duration- and dose-dependent (Pepine 2017). Therefore, whenever
NSAIDs are prescribed, one should always take into account the risk
for gastrointestinal or cardiovascular adverse events (Brune 2015;
Walker 2018), and if possible, choose the shortest duration and
lowest eFective doses (Pepine 2017). NSAIDs vary in their degree
of COX-2 selectivity. The choice of the best fitting NSAID further
depends on patient characteristics, their medical history, and the
type of complaint.
Why it is important to do this review
This Cochrane Review is part of a series on the eFect of NSAIDs for
LBP, and is an update of a Cochrane Review first published in 2000
(van Tulder 2000). The previous update included 65 randomised
controlled trials on acute LBP, chronic LBP, and sciatica (Roelofs
2008). Due to the high number of trials, we split the review into
three separate Cochrane Reviews on the use of NSAIDs for diFerent
types of LBP. The response to NSAIDs may diFer for acute LBP,
compared to chronic LBP or sciatica. The reviews on chronic LBP
(Enthoven 2016), and sciatica (Rasmussen-Barr 2016), have been
published. This review focuses on the eFicacy of NSAIDs for acute
LBP.
O B J E C T I V E S
To assess the eFects of non-steroidal anti-inflammatory drugs
compared to placebo and other comparison treatments for acute
low back pain.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials, conducted in both
primary and secondary care settings. The original protocol of this
review included only English, German, and Dutch studies. The
present update had no language restrictions.
Types of participants
We included subjects aged 18 years or older, treated for acute
non-specific low back pain (LBP). We defined LBP as pain below
the costal margin and above the inferior gluteal folds. Acute LBP
was defined as having LBP symptoms for less than 12 weeks.
Within acute LBP, we included both acute (less than six weeks)
and subacute LBP (6 to 12 weeks). If the study authors did not
describe the duration of LBP, but LBP was labelled as acute, we
also included the study. If a study included mixed populations (like
Non-steroidal anti-inflammatory drugs for acute low back pain (Review)
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acute or subacute and chronic LBP), we only included the study
if they presented data for acute LBP separately. If a minor part of
the study population (< 10%) experienced pain radiating to one
or both legs to the knee, or a flare-up (acute exacerbations of
chronic LBP), we included the study and performed a sensitivity
analysis at a later stage, if applicable. We excluded studies on
subjects with chronic LBP, flare-ups, or sciatica, as well as studies
that included participants with LBP caused by specific pathological
entities, such as infection, neoplasm, metastasis, osteoporosis,
rheumatoid arthritis, or fractures.
Types of interventions
We included trials that assessed one or more types of non-steroidal
anti-inflammatory drugs (NSAID). Additional interventions were
allowed if there was a contrast for NSAIDs in the trial. For
example, studies comparing NSAIDs plus muscle relaxants versus
muscle relaxants alone would be included, while studies comparing
NSAIDs plus muscle relaxants versus NSAIDs alone were not. We
also excluded studies if they combined NSAIDs with other drugs,
making it diFicult to distinguish the actual eFect of the NSAID, e.g. a
study comparing NSAIDs plus muscle relaxants versus paracetamol
would be excluded. We included studies that compared NSAIDs
to another type of NSAID. We excluded a study if it compared an
NSAID to the same NSAID with the mode of delivery as the only
diFerence, or if diFerent NSAIDs were used in the same group, and
no distinction was made in the analysis.
We clustered comparisons of NSAIDs versus reference treatments
into the following categories:
• NSAIDs versus placebo (the main comparison)
• Selective COX-2 inhibitors versus non-selective NSAIDs
• NSAIDs versus paracetamol
• NSAIDs versus other drug treatment
• NSAIDs versus non-drug treatment
The NSAID arm could include both selective and non-selective
NSAIDs, except for the comparison of selective COX-2 inhibitors
versus non-selective NSAIDs, where this was specified.
Types of outcome measures
As outcome measures, we used the four primary outcomes that
were already defined in the protocol and previous version of the
Cochrane review (Roelofs 2008). We added adverse events as a fiIh
primary outcome. These outcomes are described below. We set the
minimal duration of follow-up at one day, with at least one outcome
measured in the first three weeks. We divided the timing of outcome
assessment into two main categories:
1) Short-term follow-up: ranging from one day to three weeks. If
there were more outcome assessments around this time point, we
used the strategy of including outcomes closest to three weeks.
2) Long-term follow-up: ranging from longer than three and up to 12
weeks. If there were more outcome assessments around this time
point, we used the strategy of including outcomes closest to twelve
weeks.
Primary outcomes
Primary outcome measures were:
1) pain intensity (e.g. Visual Analogue Scale (VAS) or Numerical
Rating Scale (NRS))
2) back pain-specific functional status (e.g. Roland Morris Disability
Questionnaire (RMDQ), Oswestry Disability Index (ODI))
3) global measure (e.g. overall improvement, proportion of
participants recovered)
4) adverse events (proportion of participants experiencing adverse
events)
5) return to work (e.g. return to work status, number of days oF
work)
We evaluated pain intensity and disability as continuous outcomes.
We considered a between-group diFerence of more than 10%
of the scale (e.g. 10 points on a 0 to 100 scale) to be clinically
relevant. A mean diFerence smaller than this was considered not
clinically relevant. For the global measure of improvement, we
used dichotomous outcomes; if there were categories in range of
improvement, we counted categories such as 'almost recovered'
and 'completely recovered', 'good' and 'very good or excellent', and
'a lot' to 'complete recovery' responses as recovered. For adverse
events and return to work, we used dichotomous outcomes, usually
proportion of participants.
Secondary outcomes
There were no secondary outcomes.
Search methods for identification of studies
Electronic searches
We identified RCTs that met our inclusion criteria by searching the
following databases, with no language restrictions, to 7 January
2020:
• Cochrane Central Register of Controlled Trials (CENTRAL, 2020,
Issue 1) in the Cochrane Library; includes the Back and Neck
Group Trials Register; CRS Web (searched 7 January 2020);
• MEDLINE Ovid Epub Ahead of Print, In-Process & Other Non-
Indexed Citations, MEDLINE(R) Daily and MEDLINE(R) (1946 to 7
January 2020);
• Embase (1980 to 2020 Week 01);
• PubMed (1946 to January 2016);
• ClinicalTrials.gov (searched 7 January 2020);
• ICTRP (searched 7 January 2020).
We conducted searches in May 2012 (for publications between June
2007 and May 2012), and repeated them annually until January
2020. Search strategies are presented in Appendix 1, Appendix
2, Appendix 3, Appendix 4. We searched PubMed in 2015 and
2016 for studies not in MEDLINE, using the strategy recommended
by DuFy 2014. We began searching MEDLINE Ovid (Epub Ahead
of Print, In-Process & Other Non-Indexed Citations, MEDLINE(R)
Daily, and MEDLINE(R)) in 2017 because it allowed us to search
several MEDLINE databases in one search. In 2017, we began
searching CENTRAL and the Cochrane Back and Neck (CBN) Group
Trials Register in CRS Web; previously they were searched in CRS
standalone. An experienced information specialist developed the
strategies following the updated methods guideline of the CBN and
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the Cochrane Handbook for Systematic Reviews of Interventions (the
Handbook (Furlan 2015; Higgins 2011)).
Searching other resources
We screened the reference lists of all included trials, as well as
(systematic) reviews on NSAIDs for acute LBP. We also reassessed
the studies on acute low back pain included in the previous version
of this review (Roelofs 2008).
Data collection and analysis
Selection of studies
Two review authors (BK and PR, PR and WG, or WG and WE)
independently screened all search results. We excluded clearly
ineligible studies based on title and abstract. We retrieved full-
text articles for all remaining studies, and two review authors
independently conducted the screening for inclusion. We resolved
disagreements via consensus, and consulted a third review author
(WG, WE or PR) in case of uncertainty, or if disagreements persisted.
Data extraction and management
Two review authors (WG and PR) independently extracted the data
using a standardized data extraction form provided by the CBN. We
extracted data on:
• study characteristics: type of study and randomisation,
population, setting, description of interventions, and reference
treatments, follow-up time, trial registration, funding
• characteristics of participants: number of participants, gender,
mean age, duration of current symptoms, inclusion and
exclusion criteria
• primary outcomes and any relevant additional information
We extracted follow-up data at several time points, and defined
an outcome assessment as relevant if it was measured between
one day and 12 weeks of follow-up. We contacted corresponding
authors for further information if potentially relevant information
was missing or not available, for data extraction due to a diFerent
format. We resolved any disagreement through consensus.
Assessment of risk of bias in included studies
Two review authors (WG and WE, or WG and PR) independently
assessed the risk of bias of the included studies using a stepwise
approach. First, we used the thirteen criteria recommended
by Furlan 2015, described in Table 1 and Table 2. Since this
review evaluated the eFicacy of specific medication for acute
LBP, namely NSAIDs, we added an additional criterion concerning
funding or sponsorship. We separately scored these fourteen
criteria as yes, no, or unsure, and reported these in the 'Risk
of bias' tables, including the rationale for our decision. In cases
of unsure judgement of the risk of bias, we attempted to
contact corresponding authors of newly included trials for extra
information. We did not contact authors of previously included
trials, since earlier attempts to contact these authors for the
previous version of this review were unsuccessful.
Each of these fourteen criteria corresponds to a specific type of
bias at the domain level. Therefore, as a second step, we assessed
the risk of bias at domain level: selection bias (criteria 1, 2, 9),
performance bias (criteria 3, 4, 10, 11), detection (or measurement)
bias (criteria 5, 12), attrition bias (criteria 6, 7), reporting bias
(criteria 8), and other (potential) biases (criteria 13, 14). We resolved
disagreements by consensus, and consulted a third review author
(PR or WE) if disagreements persisted.
Measures of treatment e:ect
Following the recommendations in the Handbook (Higgins 2011),
we analysed dichotomous outcomes by calculating the risk ratio
(RR). We analysed continuous outcomes by calculating the mean
diFerence (MD) when the same instrument was used to measure
outcomes, or the standardized mean diFerence (SMD) when
diFerent instruments were used. We expressed the uncertainty with
95% confidence intervals (CI).
Unit of analysis issues
We included cross-over trials if the data from the first phase
(until the cross-over) were available, to aid comparability. Cluster-
randomized trials were analysed based on the level of allocation,
for example, a cluster of participants.
Some of the included studies had more than two study arms.
To avoid unit of analysis error, we split the control group to
prevent overestimation of the number of participants for the same
intervention. For example, in the Dreiser 2003 and Babej-Dolle
1994 studies, we divided the placebo group into two subgroups,
by dividing the number of events and number of cases by two
for dichotomous outcomes, or by dividing the sample size by two,
and assuming similar mean and standard deviations reported for
continuous outcomes in both subgroups.
Dealing with missing data
For trials that were included in the previous review: data that were
not reported in the study, nor added in the previous review aIer
consultation of the study authors, were considered missing for this
update. In case of unclear or mixed duration or location of back
pain, with no subgroup analyses presented, we moved the study
to 'Studies awaiting classification', while we tried to contact the
authors. In a future update, these studies could either be moved
to 'Included' or 'Excluded' studies, depending on the trial author
response.
For new trials: in case of missing data, we e-mailed the
corresponding author. Additional data provided by authors were
used in the analyses. If data were not described in the text, but
were shown in graphs, two review authors (PR and WG) collected
the data from the graphs by estimation. If needed, we recalculated
data to provide standard deviations. We performed the calculations
according to the Handbook (Higgins 2011).
Assessment of heterogeneity
Statistical heterogeneity was assessed with the I2 statistic. Values
of I2 below 40% suggested no important heterogeneity, above
75% suggested considerable heterogeneity. If values of I2 were
between 40% and 75%, moderate to substantial heterogeneity
could be present (Furlan 2015; Higgins 2011). We performed visual
inspection of the forest plot and the overlap of confidence intervals.
If the I2 value was below 40%, we pooled the results; if it was above
75%, we did not pool. For values between 40% and 75%, we based
the decision for pooling on the evaluation of the heterogeneity.
Clinical heterogeneity was assessed for all included studies that
reported similar outcomes. We judged the studies on the setting,
population source of the participants, and the intervention. For
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the latter, we took variations in the type of NSAIDs that were
used, dosage, mode of delivery, and duration of treatment into
account. If studies were clinically too heterogeneous, we did not
pool them. If pooling was feasible, we used a random-eFects model
throughout this review, due to expected variability between studies
(e.g. diFerences in populations and interventions as described
above).
Assessment of reporting biases
According to CBN, publication bias should be examined when at
least ten studies are included in the meta-analysis (Furlan 2015).
No comparisons included more than six trials, therefore, it was
not possible to construct a funnel plot or to draw conclusions
concerning publication bias. There were no language restrictions to
prevent reporting bias due to language.
Data synthesis
We assessed the overall quality of the evidence for each outcome
using the GRADE approach, as recommended in the Handbook,
and adapted in the CBN's updated method guidelines (Furlan 2015;
GRADE Working Group 2004; Guyatt 2008; Higgins 2011; Appendix
5). We determined the quality of evidence for each outcome based
on five domains: limitations in study design and implementation
(risk of bias), inconsistency (heterogeneity), indirectness (inability
to generalise), imprecision (insuFicient or imprecise data), and
publication bias. We judged these five domains for all studies that
measured a particular outcome and could be included in a meta-
analysis. The quality of the evidence for a specific outcome could
be reduced by one or more levels, depending on the performance of
the studies against these five factors. For the considerations used to
define the level of evidence, refer to Appendix 5. The overall quality
of the evidence for each outcome is the result of the combination
of this assessment of all domains.
The GRADEpro GDT enabled us to import data from Review Manager
5.3 to create the 'Summary of findings' tables for the main
comparison (GRADEpro GDT; Review Manager 2014).
'Summary of findings' tables
We considered 'NSAIDs versus placebo' our main comparison. We
added a second 'Summary of findings' table for 'Selective COX-2
inhibitors versus non-selective NSAIDs', since we considered this
a clinically important comparison. We considered all five primary
outcome measures important, and as such, we presented all
of them in the 'Summary of findings' tables. We presented the
outcomes in the short-term (follow-up ≤ 3 weeks), which was
deemed most relevant in the case of acute LBP, except for the
reporting of adverse events, which had no limitations in follow-up
time.
Subgroup analysis and investigation of heterogeneity
We planned subgroup analyses on the analysis of NSAIDs versus
non-drug treatment (one subgroup for physiotherapy and spinal
manipulation, and one subgroup for bedrest), but these were not
applicable, due to lack of available data. A subgroup analysis
of selective versus non-selective NSAIDs was planned but not
completed, due to lack of data.
Sensitivity analysis
We planned two sensitivity analyses for each comparison. In the
first sensitivity analysis, we excluded studies with a final judgement
of a high risk of bias from the analysis. The second sensitivity
analysis included the studies with solely acute LBP participants.
We leI studies with a case-mix of participants with acute LBP and
a small subgroup of the study population (< 10%) with additional
sciatic or flare-up complaints out of this analysis. We could only
perform both sensitivity analyses in a few comparisons, most oIen
for NSAIDs versus placebo. In some comparisons this was not
possible because all studies were judged as having a high risk of
bias, or available data were lacking.
R E S U L T S
Description of studies
Results of the search
For this update, we identified 5786 references through database
and trial registry searches (Figure 1). AIer removing duplicates, we
screened 4680 titles and abstracts, and subsequently assessed 96
full-text publications. In total, we included 32 publications in the
present update: 26 studies that focused on acute low back pain
(LBP) from the previous review (Aghababian 1986; Agrifoglio 1994;
Amlie 1987; Babej-Dolle 1994; Bakshi 1994; Brown 1986; Colberg
1996; Dreiser 2003; Hosie 1993; Innes 1998; JaFe 1974; Lacey
1984; Metscher 2001; Nadler 2002; Orava 1986; Pohjolainen 2000;
Postacchini 1988; Schattenkirchner 2003; Stratz 1990; Szpalski
1990; Szpalski 1994; Videman 1984; Waterworth 1985; Wiesel 1980;
Ximenes 2007; Yakhno 2006); and six new publications (Hancock
2007; Miki 2018; Plapler 2016; Shin 2013; von Heymann 2013; Zippel
2007).
 
Non-steroidal anti-inflammatory drugs for acute low back pain (Review)









Cochrane Database of Systematic Reviews
Figure 1.   Study flow diagram
 
There are 16 studies still awaiting classification. We contacted
the authors of these studies to ask for clarification, unless we
were unable to find any currently active contact information.
The reasons for not being classified were: an unclear or mixed
duration of pain (Aoki 1983; Borghi 2018; Davoli 1989; Famaey
1998; Hingorani 1970; Hingorani 1975; Jacobs 1968; Sweetman
1987; Waikakul 1995; Waikakul 1996; Zolotovskaya 2015); an
unclear or mixed location of pain (Basmajian 1989; Milgrom 1993;
Predel 2019); the use of diFerent non-steroidal anti-inflammatory
drugs (NSAID) in one treatment arm that was not specified
(NCT01374269); or a completed pilot study for which we are
awaiting the results (TCTR20141027001). Usually, there was no
subgroup analysis presented, or the reported data were insuFicient
to be used in our analyses. By retrieving more information from the
authors, we aimed to clarify if subgroup analyses would be possible
in a future update. Further details of the studies can be found in the
'Characteristics of studies awaiting classification' table.
There were four ongoing studies recruiting participants, thus
no results were available for this review (CTRI/2018/11/016371;
NCT03861611; NCT04111315; TCTR20151118003). Further details
can be found in the 'Characteristics of ongoing studies' table.
Included studies
We included 32 trials with a total of 5356 participants (sample
size ranged from 30 to 372). Ages of included participants ranged
from 16 to 78 years; one trial had no age limits, but did not
specify the age range of the back pain subgroup (Lacey 1984).
All of the included studies were published in English, except for
one which was in German (Metscher 2001). The studies were
conducted in Germany (six studies), USA (four studies), UK (three
studies), Finland (three studies), Belgium (two studies), Italy
(two studies), Brazil, Norway, Austria, France, Australia, Canada,
Japan, South-Korea, New Zealand and Russia (one study each).
One study was conducted in three European countries (Belgium,
Germany, Poland), while one study took place in nine Latin-
American countries (Brazil, Venezuela, Ecuador, Argentina, Chile,
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Mexico, Colombia, Costa Rica, and Peru). Settings were most oIen
general practice or outpatient clinics. In some cases, the setting was
the emergency department or an occupational health centre. For
further details of the studies refer to the 'Characteristics of included
studies' table.
Comparisons were as follows:
• nine trials compared one or more types of NSAIDs with a placebo
(Amlie 1987; Babej-Dolle 1994; Dreiser 2003; Hancock 2007;
Lacey 1984; Nadler 2002; Postacchini 1988; Szpalski 1994; von
Heymann 2013);
• three trials compared one or more types of NSAIDs with
paracetamol (Miki 2018; Nadler 2002; Wiesel 1980);
• seventeen trials compared diFerent types of NSAIDs
(Aghababian 1986; Agrifoglio 1994; Babej-Dolle 1994; Bakshi
1994; Colberg 1996; Dreiser 2003; Hosie 1993; JaFe 1974; Orava
1986; Plapler 2016; Pohjolainen 2000; Schattenkirchner 2003;
Stratz 1990; Wiesel 1980; Ximenes 2007; Yakhno 2006; Zippel
2007); two of these trials compared selective COX-2 inhibitors
with non-selective NSAIDs (Pohjolainen 2000; Ximenes 2007);
• four trials compared one or more types of NSAIDs with other
drugs (Brown 1986; Innes 1998; Metscher 2001; Videman 1984);
• seven trials compared one or more types of NSAIDs with non-
drug treatment (Hancock 2007; Nadler 2002; Postacchini 1988;
Shin 2013; Szpalski 1990; von Heymann 2013; Waterworth 1985).
Three studies had multiple groups of NSAID treatment, comparing
two diFerent types of NSAIDs to other treatment (Babej-Dolle 1994;
Dreiser 2003; Wiesel 1980). Comparators in the group of other
drugs were acetaminophen with codeine, tramadol hydrochloride,
and meptazinol. Comparators in the group of non-drug treatment
were spinal manipulation, physiotherapy, bedrest, heat wrap, and
motion style acupuncture treatment.
The duration of follow-up ranged from one day to six months.
Most studies only reported short-term results (follow-up one day to
three weeks). We defined long-term follow-up as longer than three
weeks and up to 12 weeks. Only five trials had a follow-up duration
longer than three weeks (Hancock 2007; Miki 2018; Postacchini
1988; Shin 2013; von Heymann 2013).Of these five trials, von
Heymann 2013 reported that they completed assessments at 12
weeks, but they did not report the data; Postacchini 1988 only
reported a combination score of improvement in pain, disability,
and spinal mobility (all three combined in one 'global measure')
at two months; Miki 2018 only presented a mean pain diFerence
score between groups at four weeks. Shin 2013 presented long-
term outcomes at four weeks, but in both study arms, they allowed
participants to pursue other treatments of their choice once they
completed the intervention treatment session (reportedly due to
ethical reasons). This implies the results aIer the first follow-up
at 30 minutes may be diFicult to interpret or generalize. Hancock
2007 presented long-term follow-up outcomes (84 days) while
maintaining the intervention groups throughout the follow-up
period.
In four studies, a part of the study population had sciatic complaints
or a flare-up of chronic back complaints (Babej-Dolle 1994; Bakshi
1994; JaFe 1974; Orava 1986); in one study, none of the screened
people were excluded, despite the strict exclusion criteria (Plapler
2016); one study used a very selected population of young male
army trainees (Wiesel 1980). One study used an inadequate dosage
of the reference medication (Yakhno 2006).
Fourteen studies were industry-sponsored. The pharmaceutical
companies that funded the studies were most oIen the developer
of the study drug (Aghababian 1986; Amlie 1987; Babej-Dolle 1994;
Bakshi 1994; Brown 1986; Dreiser 2003; Hosie 1993; Innes 1998;
Nadler 2002; Plapler 2016; Pohjolainen 2000; Schattenkirchner
2003; Ximenes 2007; Zippel 2007). One study, with spinal
manipulation as a comparison was funded by two organisations for
manual therapy (von Heymann 2013). A few studies clearly stated
they were funded by sponsors that did not have any influence
on data collection, management, analysis, and reports (Hancock
2007); by a hospital foundation (Waterworth 1985); a national
association for musculoskeletal pain studies (Miki 2018); or that
they received an unrestricted grant (Yakhno 2006). The remaining
fourteen studies did not mention their funding sources.
For declarations of (and potential conflicts of) interest: one
author of a study with motion-style acupuncture treatment as a
comparison was supported by an Asian medicine institute (Shin
2013); one study was written by a paid consultant and co-authored
by employees of the health sciences institute of a pharmaceutical
company (Nadler 2002); one study received statistical help from an
employee of a pharmaceutical company (Lacey 1984); one study
received editorial support (Ximenes 2007). One study was funded
by a local pharmaceutical company that was involved in study
design, protocol development, obtaining and evaluating the data,
and writing the manuscript together with the authors, and all
authors received grants and consulting fees for this (Plapler 2016).
Excluded studies
We described the reasons for excluding studies in the
'Characteristics of excluded studies' table. There were four main
categories:
• Not a randomised controlled trial (RCT; e.g. no intervention, a
clinical series, case report, review or commentary (Anaya 2014;
Arul Prakasam 2011; Buchbinder 2010; Day 2013; Shikhkerimov
2016; von Uberall 2013; Yastrebov 2012));
• Not acute LBP (i.e. LBP was of longer duration, or it did not
concern LBP in general (Blazek 1986; Chrubasik 2003; Coats
2004; Driessens 1994; Evans 1980; Ingpen 1969; Matsumo 1981;
Muckle 1986; Shell 2012; Siegmeth 1978));
• NSAIDs were not evaluated separately (e.g. NSAIDs were added
for blinding purposes only, or the comparison group only
involved the mode of administration (Allegrini 2009; Altan
2019; Berry 1988; Borenstein 1990; Bruggemann 1990; Cohen
2017; Costantino 2011; Dehghan 2014; Dehghan 2015; Friedman
2015; Friedman 2016; Friedman 2018; Geller 2016; Górska 2005;
Ilic 2009; IRCT2013052213146N2; Kuhlwein 1990; Listrat 1990;
Ostojic 2017; Stark 2014; Vetter 1988; Voicu 2019));
• Other reasons (e.g. no (or insuFicient) study results were
available because we did not find the original study results (Pena
1990), the study terminated early (Schreijenberg 2017); or the
duration of follow-up was less than one day (Eken 2014; Lee
2008; Serinken 2016)).
Risk of bias in included studies
We presented the assessment of the risk of bias of included studies
at the domain level in Figure 2 and Figure 3. Domains included
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selection, performance, detection, attrition, reporting, and other
biases. AIer final assessment at the domain level, we determined
there were seven studies with an overall judgement of low risk of
bias (Babej-Dolle 1994; Dreiser 2003; Hancock 2007; Innes 1998;
Pohjolainen 2000; Szpalski 1994; Yakhno 2006).
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Figure 2.   'Risk of bias' summary per domain: review authors' judgements about each 'Risk of bias' item for each
included study
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Figure 2.   (Continued)
 
 
Figure 3.   'Risk of bias' graph per domain: review authors' judgements about each 'Risk of bias' item presented as
percentages across all included studies
 
Allocation
Of the 32 included studies, 12 reported an adequate randomisation
procedure (Babej-Dolle 1994; Hancock 2007; Innes 1998; Miki 2018;
Plapler 2016; Pohjolainen 2000; Schattenkirchner 2003; Shin 2013;
von Heymann 2013; Ximenes 2007; Yakhno 2006; Zippel 2007). Ten
studies adequately concealed treatment allocation (Babej-Dolle
1994; Dreiser 2003; Hancock 2007; Miki 2018; Pohjolainen 2000;
Schattenkirchner 2003; Shin 2013; von Heymann 2013; Ximenes
2007; Yakhno 2006). The majority of studies did not report the
method of randomisation or allocation concealment, thus, we
scored these studies as unclear risk on both items.
Two-thirds of the studies showed similar characteristics at baseline
(Agrifoglio 1994; Amlie 1987; Bakshi 1994; Colberg 1996; Dreiser
2003; Hancock 2007; Hosie 1993; Innes 1998; Miki 2018; Nadler
2002; Orava 1986; Plapler 2016; Pohjolainen 2000; Shin 2013;
Szpalski 1994; Videman 1984; von Heymann 2013; Waterworth
1985; Ximenes 2007; Yakhno 2006; Zippel 2007). The other studies
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either did not report baseline characteristics, or did not provide
enough details to compare them. Several studies reported that
baseline characteristics were similar, however, they did not provide
details of the actual baseline characteristics for the acute LBP
subgroup. We scored these as unclear risk of bias.
Overall, we determined 12 studies to have a low risk of selection
bias (Babej-Dolle 1994; Dreiser 2003; Hancock 2007; Innes 1998;
Miki 2018; Plapler 2016; Pohjolainen 2000; Schattenkirchner 2003;
Shin 2013; von Heymann 2013; Ximenes 2007; Yakhno 2006).
Blinding
Performance bias
FiIeen studies adequately blinded participants (Amlie 1987; Bakshi
1994; Dreiser 2003; Hancock 2007; Hosie 1993; Innes 1998; Lacey
1984; Orava 1986; Pohjolainen 2000; Stratz 1990; Szpalski 1994;
Videman 1984; von Heymann 2013; Yakhno 2006; Zippel 2007).
Twelve trials adequately blinded careproviders (Amlie 1987; Babej-
Dolle 1994; Bakshi 1994; Dreiser 2003; Hosie 1993; Innes 1998; Lacey
1984; Pohjolainen 2000; Schattenkirchner 2003; Szpalski 1994;
Videman 1984; Yakhno 2006). Thirteen studies adequately blinded
outcome assessors (Babej-Dolle 1994; Brown 1986; Dreiser 2003;
Hancock 2007; Hosie 1993; Innes 1998; Nadler 2002; Pohjolainen
2000; Szpalski 1994; Videman 1984; von Heymann 2013; Yakhno
2006; Zippel 2007). The remaining studies either (i) had inadequate
blinding of participants, careproviders, and outcome assessors
(scored at high risk); or (ii) provided insuFicient details to determine
adequacy of blinding (scored as unclear risk). In two studies,
blinding of careproviders was not possible, since they had to
perform either real or sham spinal manipulation; however, in both
studies, the outcome assessors were blinded (Hancock 2007; von
Heymann 2013).
Regarding co-interventions: we allowed paracetamol as rescue
medication. No other analgesics or anti-inflammatory drugs were
allowed. Five studies allowed the use of paracetamol as rescue
medication (Amlie 1987; Metscher 2001; von Heymann 2013;
Yakhno 2006; Zippel 2007), whereas in one study, the use of
rescue medication terminated trial participation (Dreiser 2003).
In one study, all participants received 1g of paracetamol four
times a day (Hancock 2007). Three studies prescribed bedrest to
all participants (Szpalski 1990; Szpalski 1994; Wiesel 1980). We
scored 14 studies that avoided co-interventions at low risk of
bias (Aghababian 1986; Amlie 1987; Babej-Dolle 1994; Bakshi 1994;
Brown 1986; Hancock 2007; Hosie 1993; Metscher 2001; Pohjolainen
2000; Schattenkirchner 2003; Stratz 1990; von Heymann 2013;
Waterworth 1985; Zippel 2007). We scored one study at high risk
of bias because they did not restrict co-interventions aIer the first
follow-up at 30 minutes, and participants could choose between
inpatient and outpatient treatment, which influenced the amount
of additional treatment for each participant (Shin 2013). We scored
the remaining studies as unclear risk of bias.
Most studies provided insuFicient information on compliance,
therefore, we scored them as unclear risk of bias. Four studies
either reported that compliance was acceptable or provided details
regarding compliance (Babej-Dolle 1994; Dreiser 2003; Hancock
2007; Stratz 1990).
Overall, we determined twelve studies to be at low risk of
performance bias (Amlie 1987; Babej-Dolle 1994; Bakshi 1994;
Dreiser 2003; Hancock 2007; Hosie 1993; Innes 1998; Lacey 1984;
Pohjolainen 2000; Szpalski 1994; Videman 1984; Yakhno 2006).
Detection bias
The majority of studies adequately reported the timing of outcome
assessments, and this timing was similar in most cases; therefore,
we scored 28 studies at low risk of bias. Four studies either did not
report clearly on the timing of the outcome assessment (and we
scored them as unclear risk of bias (Brown 1986; Shin 2013)); or they
had diFerent timing of outcome assessment between participants
(and we scored them at high risk of bias (Babej-Dolle 1994; Stratz
1990)). This domain also concerned the adequate blinding of the
outcome assessor, which we listed above (see Performance bias; we
scored 13 trials at low risk).
Overall, we determined twelve studies to have a low risk of
detection bias (Brown 1986; Dreiser 2003; Hancock 2007; Hosie
1993; Innes 1998; Nadler 2002; Pohjolainen 2000; Szpalski 1994;
Videman 1984; von Heymann 2013; Yakhno 2006; Zippel 2007).
Incomplete outcome data
We scored most studies at low risk of bias concerning dropout
rates. However, three studies did not adequately report dropouts
and we scored them as unclear risk of bias (Lacey 1984; Shin 2013;
Wiesel 1980); five studies reported substantial drop-out rates or
clear diFerences between groups, and we scored them at high risk
of bias (Aghababian 1986; Miki 2018; Plapler 2016; Postacchini 1988;
von Heymann 2013). Twelve studies performed an intention-to-
treat (ITT) analysis and we scored them at low risk of bias (Babej-
Dolle 1994; Bakshi 1994; Colberg 1996; Dreiser 2003; Hancock 2007;
Schattenkirchner 2003; Shin 2013; Szpalski 1994; von Heymann
2013; Ximenes 2007; Yakhno 2006; Zippel 2007). The remaining
trials either did not report (unclear risk of bias), or did not perform
an ITT analysis (high risk of bias).
Overall, we determined ten studies to have a low risk of attrition
bias (Babej-Dolle 1994; Bakshi 1994; Colberg 1996; Dreiser 2003;
Hancock 2007; Schattenkirchner 2003; Szpalski 1994; Ximenes
2007; Yakhno 2006; Zippel 2007).
Selective reporting
Three RCTs registered their study protocol in an accessible clinical
trial registry, published it, or made their study protocol available
on request (Hancock 2007; Shin 2013; von Heymann 2013). We
scored registered trials at low risk for reporting bias. If there was
no study protocol, we scored the risk of bias as unclear. We scored
two studies at high risk of bias for selective reporting: Nadler 2002
had a study protocol available, but several outcomes of the primary
treatment groups were not compared, and they did not report the
results of two comparison groups; and Postacchini 1988 reported
they intended to recruit a control group of untreated participants,
but did not include this group in the final analyses because not
enough participants agreed to enrol in this group, and most of them
were lost to follow-up. They reported this in the discussion section,
but not in the methods section.
Therefore, we determined only three studies at low risk for the
domain of reporting bias (Hancock 2007; Shin 2013; von Heymann
2013).
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Other potential sources of bias
We did not find any other potential sources of bias. Therefore, we
determined all studies to be at low risk for the domain of other
potential sources of bias.
Summary
To summarise, the most common sources of bias were due
to insuFicient information, for instance, on the method of
randomisation, allocation concealment (selection bias), and
blinding (performance and detection bias). OIen, there was no
information available as to whether they performed an ITT analysis
(attrition bias). Most did not register their study protocols, which
increases the risk for selective reporting (reporting bias). Lastly, it
remains unclear if there was publication bias.
E:ects of interventions
See: Summary of findings for the main comparison NSAIDs
compared to placebo in people with acute low back pain; Summary
of findings 2 Selective COX-2 inhibitors compared to non-selective
NSAIDs for acute low back pain
We used a random-eFects model to pool results throughout this
review, assuming some between-study variation, when taking into
account the diFerences in population, types and frequency of
NSAIDs used, follow-up duration, and the country where the trial
was performed. This approach provided us with a slightly more
conservative estimate of the 95% confidence interval (CI). We
planned subgroup analyses, but we could not conduct these due to
lack of available data.
1. NSAIDs compared to placebo
See Summary of findings for the main comparison for this
comparison.
Nine studies compared NSAIDs with placebo (Amlie 1987; Babej-
Dolle 1994; Dreiser 2003; Hancock 2007; Lacey 1984; Nadler
2002; Postacchini 1988; Szpalski 1994; von Heymann 2013), two
of which compared two diFerent NSAIDs with placebo (Babej-
Dolle 1994; Dreiser 2003). Diclofenac was the most common
NSAID evaluated (Babej-Dolle 1994; Dreiser 2003; Hancock 2007;
Postacchini 1988; von Heymann 2013). Other studies evaluated
ibuprofen (two studies), piroxicam, dipyrone, and tenoxicam. We
considered four studies at low risk of bias (Babej-Dolle 1994;
Dreiser 2003; Hancock 2007; Szpalski 1994). Follow-up ranged from
one day to two months. Treatment duration ranged from one
day to four weeks. Most oIen, tablets or capsules were used as
the mode of delivery, except for Babej-Dolle 1994, which used
intramuscular injections, and Szpalski 1994, which started with
an intramuscular injection followed by capsules. Postacchini 1988
compared diclofenac tablets to an anti-edema gel that functioned
as a placebo.
One study added a placebo for blinding purposes only, and did
not report results for the comparison of NSAID versus placebo
(Nadler 2002). One study only reported a combination score of
improvement in pain, disability, and spinal mobility, which showed
no significant diFerences between NSAID and placebo aIer three
weeks and two months (Postacchini 1988). One study closed the
placebo arm early, aIer an interim analysis showing superiority of
both treatment arms (diclofenac or spinal manipulation) compared
to placebo (von Heymann 2013). They presented data of the
combined group of both active treatment arms compared to
placebo, without providing a subgroup analysis of diclofenac




Four studies (five treatment arms, N = 815) reported on short-term
pain reduction from baseline (visual analogue scale (VAS) 0 to 100)
and provided data at a time point relevant for our review that could
be pooled (Amlie 1987; Dreiser 2003; Hancock 2007; Szpalski 1994).
One study reported on pain intensity at a maximum of six hours
follow-up only, and was excluded from the comparison (Babej-
Dolle 1994). NSAIDs reduced pain intensity more than placebo
(mean diFerence (MD) -7.29, 95% CI -10.98 to -3.61; I2 35%; Analysis
1.1; Figure 4). The magnitude of the eFect is small and probably
not clinically relevant. The quality of this evidence is moderate; we
downgraded the evidence one level due to risk of bias.
 
Figure 4.   Forest plot of comparison: 1 NSAIDs versus placebo, outcome: 1.1 Pain intensity on 100-mm VAS. Follow-
up ≤ 3 weeks.
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Disability
Two studies (three treatment arms, N = 471) reported on short-
term change in disability from baseline (Roland Morris Disability
Questionnaire (RMDQ) 0 to 24 scale) during three weeks follow-up
(Dreiser 2003; Hancock 2007). NSAIDs reduced disability more than
placebo (MD -2.02, 95% CI -2.89 to -1.15; I2 0%; Analysis 1.2; Figure
5). The diFerence is small and probably not clinically relevant. The
quality of this evidence is high; we did not downgrade the evidence.
 




Five studies (seven treatment arms, N = 1201) reported on
the proportion of participants experiencing global improvement
(Babej-Dolle 1994; Dreiser 2003; Hancock 2007; Lacey 1984;
Szpalski 1994). There was a greater likelihood that those who
received NSAIDs experienced global improvement over those who
took placebo (risk ratio (RR) 1.40, 95% CI 1.12 to 1.75; I2 52%;
Analysis 1.3; Figure 6). The eFect size is probably not clinically
relevant. The heterogeneity could not be explained, but some
diFerences existed between the studies: diFerent cutoF points
to define improvement; diFerent scales and types of outcome
measures; varied timing of outcome assessments (ranged from two
days to two weeks); and diFerent modes of delivery. The quality of
this evidence is low; we downgraded the evidence two levels due to
inconsistency and indirectness.
 
Figure 6.   Forest plot of comparison: 1 NSAIDs versus placebo, outcome: 1.3 Proportion of participants experiencing
global improvement. Follow-up ≤ 3 weeks.
 
Adverse events
Six studies (eight treatment arms, N = 1394) reported on the
proportion of participants experiencing adverse events (Amlie
1987; Babej-Dolle 1994; Dreiser 2003; Hancock 2007; Lacey 1984;
Szpalski 1994). The results between the NSAID and placebo groups
were inconclusive for experiencing adverse events (RR 0.86, 95% CI
0.63 to 1.18; I2 0%; Analysis 1.4). The quality of this evidence is very
low; we downgraded the evidence three levels due to risk of bias,
inconsistency, indirectness, and imprecision.
Return to work
One study (N = 266) reported data on return to work (Amlie 1987).
The results for return to work were inconclusive between the NSAID
and placebo groups (RR 1.48; 95% CI 0.98 to 2.23); the diFerence
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was not clinically relevant. The quality of this evidence is very low;
we downgraded the evidence three levels due to risk of bias (one
level), and imprecision (two levels).
Long-term follow-up & sensitivity analyses
Two studies provided long-term follow-up data. Hancock 2007
showed no significant diFerences between NSAIDs and placebo
on the mean pain score, mean disability score, and mean global
perceived eFect score aIer 12 weeks. Postacchini 1988 used a
combination score of improvement in pain, disability, and spinal
mobility, which showed no significant diFerences between NSAIDs
and placebo aIer two and six months.
We performed one sensitivity analysis for pain intensity; removing
the studies at high risk of bias did not change the results (Amlie
1987; Lacey 1984).
We performed two sensitivity analyses for global improvement;
removing the study at high risk of bias did not change the
result (Lacey 1984). Removing studies with mixed participant
population increased the heterogeneity, and the result was no
longer statistically significant (RR 1.29, 95% CI 0.97 to 1.72; I2 58%;
Babej-Dolle 1994; Lacey 1984).
We performed two sensitivity analyses for adverse events; (i)
removing the studies at high risk of bias (Amlie 1987; Lacey 1984),
and (ii) removing studies with a mixed participant population
(Babej-Dolle 1994; Lacey 1984). This did not change the results in
either analyses.
We did not conduct sensitivity analyses for the other outcomes.
2. Selective COX-2 inhibitors compared to non-selective
NSAIDs
See Summary of findings 2 for this comparison.
Seventeen studies compared NSAIDs to other NSAIDs (Aghababian
1986; Agrifoglio 1994; Babej-Dolle 1994; Bakshi 1994; Colberg
1996; Dreiser 2003; Hosie 1993; JaFe 1974; Orava 1986; Plapler
2016; Pohjolainen 2000; Schattenkirchner 2003; Stratz 1990;
Wiesel 1980; Ximenes 2007; Yakhno 2006; Zippel 2007), two
of which compared a selective COX-2 inhibitor to a non-
selective NSAID (Pohjolainen 2000; Ximenes 2007). We considered
four studies at low risk of bias (Babej-Dolle 1994; Dreiser
2003; Pohjolainen 2000; Yakhno 2006). Diclofenac was the
most common NSAID used for comparison (Agrifoglio 1994;
Babej-Dolle 1994; Bakshi 1994; Colberg 1996; Dreiser 2003;
Schattenkirchner 2003; Stratz 1990; Yakhno 2006; Zippel 2007).
The other types of NSAIDs used were naproxen, ibuprofen,
indomethacin, diflunisal, meloxicam, lornoxicam, aceclofenac,
felbinac, ketorolac-trometamol, etofenamat, dexketoprofen, and
phenylbutazone. The latter NSAID (phenylbutazone) was
withdrawn from the market for safety reasons. Follow-up time
ranged from one day to two weeks; this was similar for treatment
duration. Most oIen, NSAIDs were used in the form of tablets
or capsules, except for Babej-Dolle 1994, Stratz 1990, and Zippel
2007, which used intramuscular injections; Colberg 1996, which
started with either an intramuscular diclofenac injection or an
intravascular meloxicam injection followed by tablets; and Hosie
1993, which compared ibuprofen capsules with a felbinac foam.
For further information on the results of the fiIeen studies
comparing non-selective NSAIDs to each other, refer to the
subheading 'Non-selective versus non-selective NSAIDs' below.
When focusing on the two studies that compared selective
COX-2 inhibitors versus non-selective NSAIDs, Pohjolainen 2000
compared nimesulide to ibuprofen (10 days) in a double-blind,
double-dummy concept, and we considered it at low risk of bias.
Ximenes 2007 compared valdecoxib versus diclofenac (7 days) in a
double-blind but not double-dummy concept, and we considered
it at high risk of bias.
Primary outcomes
Pain intensity
Two studies (N = 437) reported on short-term pain reduction from
baseline (Pohjolainen 2000; Ximenes 2007). The I2 statistic was
57%, indicating moderate to substantial statistical heterogeneity.
On a clinical level, these studies were suFiciently comparable to
pool results. The pooled mean change in pain intensity score
from baseline was -2.60 (95% CI -9.23 to 4.03), indicating no clear
diFerence in pain reduction (Analysis 2.1). The quality of this
evidence is low; we downgraded the evidence two levels due to risk
of bias and inconsistency.
Disability
Both studies (N = 437) used the Oswestry Disability Index (0 to
50 scale). Pohjolainen 2000 reported a substantial improvement
in mean disability score within both groups at 10-day follow-up.
Nimesulide reduced disability more than ibuprofen (MD -7.00, 95%
CI -13.15 to -0.85); this amount was clinically relevant. Ximenes
2007 reported similar improvement in both groups at one-week
follow-up, with a mean decrease in baseline disability of 32% in
both the valdecoxib and diclofenac arm, and no clear diFerence
between study arms. The quality of this evidence is moderate; we
downgraded the evidence one level due to risk of bias.
Global improvement
Ximenes 2007 (N = 333) reported that at day 7, the percentage of
participants reporting pain relief as 'a lot' or 'complete' was 80% in
the valdecoxib arm versus 81% in the diclofenac arm, showing no
clear diFerence between study arms. The quality of this evidence
is low; we downgraded the evidence two levels due to risk of bias
and imprecision. Pohjolainen 2000 did not report data on global
improvement.
Adverse events
Both studies (N = 444) reported on the proportion of participants
experiencing adverse events. There was no clear diFerence
between the treatment arms (RR 0.97, 95% CI 0.63 to 1.50; I2
22%; Analysis 2.2). The quality of this evidence is very low; we
downgraded the evidence three levels due to risk of bias (one
level), and imprecision (two levels). Both studies reported on the
proportion of participants experiencing gastrointestinal adverse
events. The results were inconclusive (RR 0.60, 95% CI 0.33 to 1.09;
I2 14%; Analysis 2.3).
Return to work
There were no data reported for this outcome.
Long-term follow-up & sensitivity analyses
There was no long-term follow-up for either study.
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We performed a sensitivity analysis removing the study with high
risk of bias (Ximenes 2007) from the results for pain intensity,
adverse events, and gastrointestinal adverse events (Analysis 2.1;
Analysis 2.2; Analysis 2.3). This did not change the overall results
and conclusion.
We did not perform the second sensitivity analysis since the studies
did not include mixed participant populations.
3. Non-selective versus non-selective NSAIDs
As previously mentioned, fiIeen studies compared a non-
selective NSAID to another non-selective NSAID (Aghababian
1986; Agrifoglio 1994; Babej-Dolle 1994; Bakshi 1994; Colberg
1996; Dreiser 2003; Hosie 1993; JaFe 1974; Orava 1986; Plapler
2016; Schattenkirchner 2003; Stratz 1990; Wiesel 1980; Yakhno
2006; Zippel 2007), three of which we considered at low risk of
bias (Babej-Dolle 1994; Dreiser 2003; Yakhno 2006). Diclofenac
was used as a comparison drug in nine studies (Agrifoglio
1994; Babej-Dolle 1994; Bakshi 1994; Colberg 1996; Dreiser
2003; Schattenkirchner 2003; Stratz 1990; Yakhno 2006; Zippel
2007), and was compared to many diFerent NSAIDs: aceclofenac
(twice), dipyrone, piroxicam, meloxicam, ibuprofen, etofenamat,
lornoxicam, and dexketoprofen. Other NSAIDs used in comparisons
were ibuprofen (twice), diflunisal (twice), indomethacin (twice),
naproxen, aspirin, ketorolac-trometamol, phenylbutazone (oF the
market), and felbinac foam. We will descriptively summarise the
results of these studies below.
Primary outcomes
Pain intensity
Two studies reported on pain intensity at a maximum of six hours
follow-up only; we excluded them from this comparison (Babej-
Dolle 1994; Zippel 2007).
Thirteen studies (N = 1823) reported data on pain intensity at a
relevant time point. Ten studies showed no clear diFerence in pain
relief on diFerent scales (either 4- or 5-point ordinal scales, 100-mm
VAS, 11-point numeric rating scale (NRS), or pain point calculations)
aIer three to eight days (Agrifoglio 1994; Bakshi 1994; Colberg 1996;
Dreiser 2003; Hosie 1993; JaFe 1974; Orava 1986; Plapler 2016;
Stratz 1990; Wiesel 1980).
Two studies explored acelofenac and diclofenac. Schattenkirchner
2003 (N = 227) reported that aceclofenac reduced pain intensity
more than diclofenac; the results were statistically significant but
not clinically relevant (between-group diFerence of 5.5 on 100-mm
VAS). Agrifoglio 1994 (N = 100) found no clear diFerence between
the two NSAIDs.
Aghababian 1986 (N = 56) reported that 100% of those who took
diflunisal reported none or mild pain aIer two weeks compared to
88% of those who took naproxen, but no significance tests were
reported, and the diFerence was not clinically relevant.
Yakhno 2006 (N = 220) reported a sum of pain intensity diFerences
from baseline to day six of 4.2 for those who took lornoxicam versus
3.8 for those who took diclofenac, a statistically significant but not
clinically relevant diFerence.
The quality of this evidence is moderate; we downgraded the
evidence one level due to risk of bias.
Disability
Five studies (N = 1006) reported data on disability at a relevant
time point, four of which showed no clear diFerence in disability or
functional status between groups, measured with either the RMDQ
(Dreiser 2003; Zippel 2007), or a 4-point ordinal scale (JaFe 1974;
Orava 1986).
One study showed that aceclofenac reduced pain more than
diclofenac by a between-group diFerence of 4.5% on the 100-
point Quebec Back Pain Disability Score; the trail authors stated
the results were statistically significant but not clinically relevant
(Schattenkirchner 2003).
The quality of this evidence is moderate; we downgraded the
evidence one level due to risk of bias.
Global improvement
Seven studies (N = 987) reported data on the proportion of
participants who experienced global improvement, five of which
showed similar improvement between groups, with no statistically
significant or clinically relevant diFerences (Aghababian 1986;
Bakshi 1994; Colberg 1996; Dreiser 2003; Stratz 1990).
Agrifoglio 1994 (N = 100) reported that 87% of those who
took aceclofenac reported global improvement versus 79% of
participants who took diclofenac; a statistically significant but not
clinically relevant diFerence.
Babej-Dolle 1994 (N = 174) reported that 32% of those who received
dipyrone intramuscular injections were completely recovered aIer
two days versus 12% of the participants who received diclofenac
intramuscular injections; a statistically and clinically relevant
diFerence.
The quality of this evidence is moderate; we downgraded the
evidence one level due to risk of bias.
Adverse events
Fourteen studies (N = 2337) reported data on adverse events,
11 of which showed no clear diFerence between treatments
in the proportion of participants experiencing adverse events
(Aghababian 1986; Bakshi 1994; Colberg 1996; Dreiser 2003; Hosie
1993; JaFe 1974; Plapler 2016; Schattenkirchner 2003; Stratz 1990;
Yakhno 2006; Zippel 2007).
Aghababian 1986 (N = 56) reported no adverse events.
Three studies reported a diFerence in the proportion of participants
experiencing adverse events: Agrifoglio 1994 (N = 100) reported 2%
in the aceclofenac arm versus 12% in the diclofenac arm; Babej-
Dolle 1994 (N = 174) reported 5% in the dipyrone versus 1% in
the diclofenac arm; and Orava 1986 (N = 133) reported 18% in the
diflunisal arm versus 31% in the indomethacin arm; this diFerence
was considered both statistically significant and clinically relevant.
Schattenkirchner 2003 (N = 227) also evaluated aceclofenac and
diclofenac, but found no clear diFerence.
The quality of this evidence is moderate; we downgraded the
evidence one level due to risk of bias.
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Return to work
Wiesel 1980 (N = 30) found no clear diFerence for return to work
between those who took aspirin or phenylbutazone. The quality of
this evidence is very low; we downgraded the evidence three levels
due to risk of bias, indirectness, and imprecision.
4. NSAIDs compared to paracetamol
Three studies, with four treatment arms, compared NSAIDs to
paracetamol or acetaminophen (Miki 2018; Nadler 2002; Wiesel
1980). They respectively compared loxoprofen, ibuprofen, and
aspirin or phenylbutazone (two study arms) to paracetamol, all in
the form of capsules or tablets. We considered none of the studies
at low risk of bias. Follow-up ranged from four days to four weeks.
Treatment duration ranged from two days to four weeks.
Primary outcomes
Pain intensity
All studies reported on pain intensity, but not all in comparable
formats. Nadler 2002 used a mean change score (NRS scale 0 to
5), and did not directly compare ibuprofen versus acetaminophen;
similar to Miki 2018, which reported a pain diFerence score between
the two study arms. We pooled the results from these two studies
(N = 289) using the standardised mean diFerence (SMD), which
showed no clear diFerence between NSAID and paracetamol on
short-term pain relief (SMD -0.12, 95% CI -0.35 to 0.12; I2 0%;
Analysis 3.1). This is comparable with an MD of -0.07 (95% CI -0.25
to 0.11; I2 0%).
The quality of this evidence is low; we downgraded the evidence
two levels due to risk of bias and imprecision.
Wiesel 1980 used pain-point calculations, a sum score that
added ‘points’ each day, depending on the severity of back pain.
Therefore, we could not compare their results to the other studies,
although results were similar (i.e. no significant diFerences in
pain reduction at follow-up among two NSAID arms and one
paracetamol arm).
Disability
Nadler 2002 (N = 219) reported no clear diFerence in the mean
change scores in disability for NSAIDs compared to paracetamol
aIer four days. No other studies reported on disability outcomes.
The quality of this evidence is low; we downgraded the evidence
two levels due to risk of bias and imprecision.
Global improvement
There were no data reported on this outcome.
Adverse events
Two studies (N = 289) reported on the proportion of participants
who experienced adverse events. Nadler 2002 (N = 219) reported
10% in the NSAID arm versus 4% in the paracetamol arm, and no
serious side eFects. Miki 2018 (N = 70) reported 14% in the NSAID
arm versus 3% in the paracetamol arm (Analysis 3.2). We did not
pool these results because of considerable clinical heterogeneity.
Specifically, (i) Nadler 2002 had a short follow-up duration (four
days with two days of treatment), while Miki 2018 had a longer
follow-up (four weeks of treatment and follow-up); and (ii) Miki
2018 had high rates of loss to follow-up for reasons not reported.
The quality of this evidence is low; we downgraded the evidence
two levels due to risk of bias and imprecision.
Return to work
Wiesel 1980 (N = 45) reported data on return to work, showing
no clear diFerences among the three arms (three NSAID arms
and one paracetamol arm). The quality of this evidence is very
low; we downgraded the evidence three levels due to risk of bias,
indirectness, and imprecision.
Long-term follow-up & sensitivity analyses
One study reported data on the pain diFerence score aIer four
weeks, showing no clear diFerence between the two study arms
(Miki 2018).
We did not perform sensitivity analyses for this comparison, since
there were no studies at low risk of bias, and none with mixed
participant populations.
5. NSAIDs compared to other drug treatment
Four studies compared NSAIDs to other drugs (Brown 1986; Innes
1998; Metscher 2001; Videman 1984). Two of these compared
NSAIDs to acetaminophen with codeine (Brown 1986; Innes 1998);
Metscher 2001 compared NSAIDs to tramadol hydrochloride, and
Videman 1984 compared NSAIDs to meptazinol. We considered one
study at low risk of bias (Innes 1998). Follow-up ranged from seven
days to three weeks. Treatment duration ranged from seven days
(or until pain free) to a maximum of three weeks. The studies used
either tablets or capsules.
Primary outcomes
Pain intensity
All four studies (N = 391) reported on pain intensity, but data were
inadequately reported, and therefore, we were unable to conduct a
meta-analysis. Innes 1998 only reported a mean change score aIer
six hours, and we excluded it from this comparison. Brown 1986
used pain assessments by the participant on a 3-point ordinal scale,
showing a curve of slow improvement over 15 days. Metscher 2001
found that those who took NSAIDs reported a mean pain change
score (VAS 0 to 100 scale) of -6 (SD 4) aIer seven days compared
to those who took tramadol hydrochloride, which was statistically
significant but not clinically relevant. Videman 1984 reported a
mean pain reduction (VAS 0 to 100 scale) of 45 in the NSAID arm
versus 40 in the meptazinol arm (data extracted from graphs),
showing no clear diFerence between study arms. The quality of this
evidence is low; we downgraded the evidence two levels due to risk
of bias and imprecision.
Disability
There were no data reported on this outcome.
Global improvement
We pooled the results of two studies (N = 162) that used the same
reference drug as a comparison (acetaminophen with codeine
(Brown 1986; Innes 1998)). Both studies reported on the proportion
of participants who experienced global improvement within a
three-week follow-up time frame. The pooled RR was 1.01 (95%
CI 0.81 to 1.25; I2 0%; Analysis 4.1). The quality of this evidence
is moderate; we downgraded the evidence one level due to
imprecision.
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Adverse events
All four studies (N = 391) comparing NSAIDs to other drug
treatments reported on the proportion of participants experiencing
adverse events. Clinical heterogeneity was considerable, and
therefore, we decided not to pool these data. Those who took
NSAIDs were more likely to report adverse events than those who
took other drugs (RR ranged from 0.53 to 0.83, 95 % CI ranged
from 0.18 to 2.41; Analysis 4.2). The quality of this evidence is low;
we downgraded the evidence two levels due to risk of bias and
imprecision.
Return to work
There were no data reported on this outcome.
Long-term follow-up & sensitivity analyses
There was no long-term follow-up available for this comparison.
For global improvement, we performed a sensitivity analysis by
removing the study at high risk of bias (Brown 1986). This did not
change the results. We were unable to perform sensitivity analyses
for the other outcomes.
6. NSAIDs compared to non-drug treatment
Seven studies compared NSAIDs to non-drug treatment (Hancock
2007; Nadler 2002; Postacchini 1988; Shin 2013; Szpalski
1990; von Heymann 2013; Waterworth 1985). Specifically, four
studies compared NSAIDs to spinal manipulation (Hancock 2007;
Postacchini 1988; von Heymann 2013; Waterworth 1985); two
studies compared NSAIDs to physiotherapy (Postacchini 1988;
Waterworth 1985); two studies compared NSAIDs to bedrest
(Postacchini 1988; Szpalski 1990); one to heat wrap (Nadler 2002);
and one to motion style acupuncture treatment (MSAT (Shin 2013)).
We considered one study at low risk of bias (Hancock 2007). Follow-
up ranged from four days to six months, and treatment duration
from one day to four weeks. NSAIDs were generally administered
in tablet or capsule form, with the exception of Shin 2013, who
administered the NSAID as a single intramuscular injection. Due to
considerable clinical heterogeneity, we decided not to pool these
studies. Analyses are presented below, grouped according to the
non-drug comparison treatment. We were unable to perform the
planned sensitivity analyses for this comparison.
6a. NSAIDs compared to spinal manipulation or physiotherapy
Pain intensity
Four studies (six treatment arms, N = 353) compared NSAIDs
to spinal manipulation, physiotherapy, or both (Hancock 2007;
Postacchini 1988; von Heymann 2013; Waterworth 1985). We
considered one study at low risk of bias (Hancock 2007). All four
studies reported on pain reduction from baseline (VAS 0 to 100
scale) at a relevant time point. The I2 statistic was 94%, representing
substantial statistical heterogeneity, and consequently, we did not
pool the data.
Hancock 2007 showed no clear diFerence in pain reduction when
NSAIDs were compared with spinal manipulation (MD 0.80, 95%
CI -7.11 to 8.71; Analysis 5.1). In contrast, von Heymann 2013
showed that spinal manipulation reduced pain more than NSAIDs
(MD 18.31, 95% CI 15.62 to 21.00; Analysis 5.1); this was clinically
relevant.
Waterworth 1985 presented pain intensity scores on a 4-point
scale, and showed no clear diFerence aIer 12 days. Postacchini
1988 only presented a combination score of improvement in pain,
disability, and spinal mobility, and showed no clear diFerence
between NSAIDs and either spinal manipulation or physiotherapy,
aIer three weeks and two months. The quality of this evidence is
very low; we downgraded the evidence three levels due to risk of
bias, inconsistency, and imprecision.
Disability
Two studies (N = 193) reported on short-term disability (Hancock
2007; von Heymann 2013). von Heymann 2013 did not report
mean baseline data on disability, only median baseline values,
and the mean change in disability from baseline. von Heymann
2013 showed that spinal manipulation reduced disability more
than NSAIDs by a statistically significant and clinically relevant
diFerence; Hancock 2007 showed no clear diFerence in disability
reduction. The quality of this evidence is very low; we downgraded
the evidence three levels due to risk of bias, inconsistency, and
imprecision.
Global improvement
Two studies (three treatment arms; N = 180) reported on
global improvement (von Heymann 2013; Waterworth 1985).
von Heymann 2013 showed that those who received spinal
manipulation reported global improvement over NSAIDs by
a statistically significant and clinically relevant diFerence;
Waterworth 1985 showed no clear diFerence between study
arms (Analysis 5.2). The quality of this evidence is very low;
we downgraded the evidence three levels due to risk of bias,
inconsistency, and imprecision.
Hancock 2007 reported global perceived eFect, and found no clear
diFerence between study arms (NSAID, spinal manipulation, and
placebo spinal manipulation).
Adverse events
Two studies (N = 189) reported data on adverse events, showing no
clear diFerence between treatments (Hancock 2007; von Heymann
2013). von Heymann 2013 reported no adverse events, therefore
the risk ratio was not estimable and the data could not be
pooled (Analysis 5.3). The quality of this evidence is very low; we
downgraded the evidence three levels due to risk of bias, and
imprecision (two levels).
Waterworth 1985 reported two adverse events in the NSAID group
(indigestion and nausea), but did not measure or evaluate adverse
events in the comparison groups.
Return to work
One study reported the number of days oF-work, showing no clear
diFerence between NSAIDs and spinal manipulation (von Heymann
2013). The quality of this evidence is low; we downgraded the
evidence two levels due to risk of bias and imprecision.
Long-term follow-up
One study reported long-term follow-up data (Hancock 2007). AIer
12 weeks, there were no clear diFerences between NSAIDs and
spinal manipulation in mean pain score, mean disability score, and
mean global perceived eFect.
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6b. NSAIDs compared to bedrest
Two studies (N = 130) compared NSAIDs to bedrest. Postacchini
1988 presented a combination score of improvement in pain,
disability, and spinal mobility, and showed no clear diFerence
between NSAIDs and bedrest aIer three weeks and two months.
Szpalski 1990 did not present any relevant outcomes, except for
adverse events; they reported that two participants in the NSAID
group withdrew because of adverse events (1 participant with
gastric symptoms,1 participant with gastric symptoms and a skin
rash).
6c. NSAIDs compared to heat wrap
One study compared NSAIDs to a heat wrap (Nadler 2002; N = 371).
It showed that a heat wrap relieved pain better than NSAIDs (mean
pain relief 2.61 versus 1.68 aIer four days; NRS (0 to 5); statistically
significant and clinically relevant diFerence), and reduced disability
more than NSAIDs (mean disability reduction 4.9 versus 2.7 aIer
four days; RMDQ (0 to 24), but this diFerence was not large enough
to be considered clinically relevant. Global improvement was not
mentioned. The number of adverse events was similar among study
arms (heat wrap 6%, 7/113; and NSAID 10%, 11/106). There was no
long-term follow-up.
6d. NSAIDs compared to motion style acupuncture treatment
(MSAT)
One study compared one intramuscular NSAID injection to one
MSAT session (Shin 2013; N = 58). It showed that the MSAT session
reduced pain (mean (SD) pain intensity reduction from baseline
4.17 (3.05) versus 5.83 (2.61); NRS (0 to 10); and disability (mean
(SD) improvement in functional status from baseline 36.34 (29.1)
versus 56.41 (24.86); ODI (0 to 50)) more than NSAIDs aIer two
weeks; these diFerences were statistically significant and clinically
relevant.
AIer the first 30 minutes, the selection of treatment was no
longer restricted, thus participants were allowed to use any
other treatment (medication or otherwise), if they wished.
Therefore, results reported aIer the 30-minute follow-up should be
interpreted with caution. There were no adverse events.
D I S C U S S I O N
Summary of main results
In this updated Cochrane Review, aimed at assessing the eFicacy of
non-steroidal anti-inflammatory drugs (NSAID) for acute low back
pain (LBP), we included 32 trials with a total of 5356 participants,
ranging in age from 16 to 78 years old. We included 26 trials from
the previous review (Roelofs 2008), and added six trials from the
searches conducted between 2007 and 2020 (Hancock 2007; Miki
2018; Plapler 2016; Shin 2013; von Heymann 2013; Zippel 2007).
Follow-up was usually short (≤ 3 weeks). Almost half of the studies
were industry-funded. The most common biases in the 'Risk of bias'
assessment were performance and attrition bias. OIen, there was
a lack of information on randomisation procedures and allocation
concealment, which is a risk for selection bias, and studies were
prone to selective reporting bias, since most studies did not register
their trials. However, for the latter it is important to realise most
studies were published long before trial registries existed (around
2004). Therefore, most of the studies included in this review did not
have the possibility yet to register their trials.
There is moderate quality evidence that NSAIDs are slightly more
eFective than placebo for short-term pain reduction (0 to 100 visual
analogue scale (VAS)), with a pooled mean diFerence (MD) in pain
intensity of -7.29 (95% confidence interval (CI) -10.98 to -3.61;
I2 35%; 4 RCTs, 5 treatment arms, N = 815), a small diFerence,
which is likely not clinically relevant. There is high quality evidence
that NSAIDs are slightly more eFective than placebo for short-
term reduction of disability (0 to 24 Roland Morris Disability
Questionnaire (RMDQ)), with a pooled MD of -2.02 (95% CI -2.89
to -1.15; I2 0%; 2 RCTs, 3 treatment arms, N = 471), a small
diFerence, which is likely not clinically relevant. There is low quality
evidence that NSAIDs may be slightly more eFective for short-
term global improvement than placebo, with a pooled risk ratio
(RR) for experiencing global improvement of 1.40 (95% CI 1.12 to
1.75; I2 = 52%; 5 RCTs, 7 treatment arms, N = 1201). However,
there was moderate to substantial heterogeneity between studies,
and in a sensitivity analysis in which we removed two studies
with a mixed participant population, the result was no longer
significant (RR 1.29, 95% CI 0.97 to 1.72; I2 = 58%). There is very
low quality evidence of no clear diFerence in the proportion of
participants who experienced adverse events between those who
used NSAIDs and those who used placebo (RR 0.86, 95% CI 0.63
to 1.18; I2 = 52%; 6 RCTs, 8 treatment arms, N = 1394). Data on
adverse events are usually better documented in observational
studies. Most of the trials in this review studied participants for a
relatively short-term treatment and follow-up, which is expected
given the subject of acute LBP. Consequently, these may not be
optimal for answering questions about adverse events. There is
very low quality evidence that there is no clear diFerence between
the proportion of participants who could return to work aIer seven
days between those who used NSAIDs and those who used placebo
(RR 1.48, 95% CI 0.98 to 2.23; 1 RCT, N = 266).
There is low quality evidence that there is no clear diFerence
between selective COX-2 inhibitor NSAIDs and non-selective NSAIDs
in short-term pain reduction, with a pooled mean change in pain
intensity from baseline of -2.60 (95% CI -9.23 to 4.03; I2 = 57%; 2
RCTs, N = 437). There is moderate quality evidence of conflicting
results for short-term improvement of disability (2 RCTs, N =
437). Low quality evidence from one trial (N = 333) found no
clear diFerence between groups in the proportion of participants
experiencing global improvement. Very low quality evidence found
no clear diFerence between groups for adverse events (RR 0.97,
95% CI 0.63 to 1.50; I2 = 22%; 2 RCTs, N = 444); or for specific
gastrointestinal adverse events (RR 0.60, 95% CI 0.33 to 1.09; I2 =
14%; 2 RCTs, N = 444). A sensitivity analysis in which we removed
the study with a high risk of bias did not change these results. No
data were reported on return to work.
Overall completeness and applicability of evidence
This was an update for the Cochrane Review on NSAIDs for LBP
(Roelofs 2008). In the previous review, we included trials on LBP of
all types and duration. This review focused on acute LBP, therefore,
we had strict criteria on duration and type of pain. We excluded
studies with a mixed population of acute with chronic or recurrent
LBP, or with a large percentage of participants with additional
sciatic complaints, in order to keep the results clear and specific.
Thus, fewer trials met the inclusion criteria for this update, but the
results may be more applicable.
Study populations were rather diverse and oIen heterogeneous,
including a broad range of participants who varied in age and
Non-steroidal anti-inflammatory drugs for acute low back pain (Review)









Cochrane Database of Systematic Reviews
amount of complaints. Both general practitioner (GP) practices and
outpatient clinics were used for the source population. In older
studies, the study population was sometimes even admitted to the
hospital for inpatient treatment. This makes it complex to draw
conclusions that fit all people with acute LBP. Furthermore, various
types of NSAIDs were used, with diFerent ways of administration,
frequencies, doses, and duration of use; adding to the complexity
of our attempt to compare a wide range of NSAIDs. The comparison
became too heterogeneous to pool, especially when NSAIDs were
compared to other drugs, or a combination of other drugs.
These diFerent sources of heterogeneity also limited the feasibility
of sensitivity or stratified analyses, for instance, regarding the
duration of LBP (acute versus subacute) or the dose, duration of
treatment, and the mode of delivery of the NSAID. Lastly, not all
outcome measures were equally reported. Work-related outcomes
(e.g. return to work status, number of days oF work) and long-term
follow-up (up to three months) were oIen unavailable, although
these could be relevant outcomes for people and their GPs, to help
predict the course and prognosis of an episode. Although, when
considering the longer-term outcomes, it is important to keep in
mind that the eFect of the (usually) short-term drug treatment may
be less relevant at those time points. Despite this variation in (and
sometimes lack of useful) outcome reporting, the results of our
review appear to be similar to the previous review, which showed
a small eFect in the quantitative analysis in favour of NSAIDs
compared to placebo on pain intensity and global improvement
(Roelofs 2008).
One could argue whether our main findings of a mean diFerence in
pain intensity of -7.29 on a 0 to 100 VAS scale and a reduction of 2.02
points on the 0 to 24 RMDQ in favour of NSAIDs over placebo are
clinically meaningful diFerences for an individual. A review of the
literature shows this is questionable. International consensus was
reached on minimal important change (MIC) values of frequently
used participant-reported outcome measures in the field of LBP to
aid practical guidance. Reasonable MIC values are -15.00 on a 0 to
100 VAS scale and -5.00 for the RMDQ. When measuring change from
baseline, a 30% improvement was considered a useful threshold
for identifying clinically meaningful improvement for each of these
measures (Ostelo 2008). However, these are considered to be
individual-level changes. What we consider a minimally important
between-group diFerence has not yet been established, and is
context-dependent. Other reviews in the field of back pain consider
diFerences in treatment eFect of less than 10% of the scale, or
9 points on a 100-point scale a small eFect, and not clinically
relevant. Thus, the eFect sizes shown in this review do not pass the
threshold of clinical relevance, or a clinical meaningful change in an
individual.
Adverse events rates for NSAIDs are better documented in
observational studies. Our review considered NSAIDs for acute LBP,
and most studies focused on short-term use of NSAIDs with a short
follow-up time. Most sample sizes were too small for evaluating
adverse events, or not suFiciently powered to detect rare adverse
events. It is possible that the proportion of adverse events was
underestimated, or that rare or uncommon adverse events were
missed. We should refrain from conclusions concerning adverse
events and the safety of NSAIDs for longer-term use.
Quality of the evidence
Sample sizes of the included RCTs diFered widely (ranging
from 30 to 372) and follow-up time was usually short. Relevant
information was not always mentioned, for instance, the method
of randomisation was not reported and allocation concealment
was not adequately described. About half of the studies did not
report suFiciently on blinding, so we judged them at high risk of
bias because of lack of blinding. Most studies did not register their
trials in a publicly accessible clinical trial registry, mostly because
they were published before these existed. Therefore, reporting bias
is oIen unclear and cannot be excluded. About half of the trials
avoided co-interventions, the others we considered unclear or at
high risk. One trial had no treatment restrictions at all aIer the
first 30 minutes. Compliance was oIen not mentioned or clearly
described, and was only reported by a few studies. A main problem
for many of the studies was funding. We scored half of the studies at
high risk of bias because of funding by a pharmaceutical company,
and oIen there were conflicts of interest for one or more of
the authors, or the sponsor was involved in data collection and
analysis, sometimes even writing the report. Two studies clearly
stated that the sponsor was not involved in data collection and
analysis, and had no influence on the report; these we scored at low
risk of bias.
One of the problems we encountered during data-extraction was
that similar outcomes were presented in very diFerent ways
across studies. For example, there was substantial variation in
the definition and cutoF points for 'global improvement'. Over
the years, trials moved from reporting mainly physiological
outcomes that combined Likert scales of pain, disability, and global
improvement, to reporting separate outcomes, and pain- and
disability-specific measurement tools. However, even more recent
studies do not always report their outcome measures in a standard
way, which impedes the ability to easily compare studies and
pool data. Greater consistency in reporting would facilitate higher
quality comparisons of studies on acute LBP. A task force of the NIH
(National Institutes of Health) Pain Consortium developed research
standards for chronic LBP regarding definitions, a minimal data
set, reporting outcomes, and future research (Deyo 2014). Recently,
an international steering committee developed a preliminary
core outcome measurement set that specifies instruments to
be included in every clinical trial involving people with non-
specific LBP, which will be useful for studies reporting on acute
LBP (Chiarotto 2018). Hopefully, this will further improve the
comparability of outcomes in future research in acute LBP, and
increase the quality of the body of evidence according to the GRADE
criteria.
To conclude, there is moderate to high quality evidence that
NSAIDs are slightly more eFective than placebo in reducing pain
and disability, respectively, in the short-term. We downgraded
the evidence for pain intensity because of high risk of bias. The
magnitude of the diFerence was small, and oIen there were
methodological shortcomings. However, when we only included
the studies with a low risk of bias in a sensitivity analysis, the
results were consistent, and did not change. The present findings
regarding the eFicacy of NSAIDs for acute LBP seem to be in line
with the results of the previous Cochrane Review (Roelofs 2008).
Potential biases in the review process
We aimed to present a complete overview of the eFicacy of
NSAIDs for acute LBP, and therefore, the review process was
thorough, and we tried to be transparent in all steps taken.
We used the current guidelines recommended by the Cochrane
Back and Neck Group (CBN) and the Cochrane Handbook for
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Systematic Reviews of Interventions, and graded the quality of the
evidence using the GRADE approach (Furlan 2015; GRADE Working
Group 2004; Guyatt 2008; Higgins 2011). The information specialist
from the CBN conducted a comprehensive literature search. All
abstracts were carefully and independently screened by two review
authors. Moreover, we checked the references of all included and
possibly relevant studies, and of other reviews published from 2008
onwards. It is still possible that we did not identify all studies
(due to publication bias or non-registered trials), but with extensive
searches and checks, we tried to reduce this risk to a minimum.
The original review protocol stated that only trials published in
English, German or Dutch would be included. To be sure of overall
completeness, there were no restrictions on language for this
review update. However, we did not re-screen all foreign language
abstracts from prior to 2008, so there is a probability that we
missed a foreign language study from before 2008 that could have
been included. We also included studies with NSAIDs that were
no longer available on the market (e.g. phenylbutazone), aiming
to provide a complete overview. A potential drawback could be
that the results are less applicable to NSAIDs currently on the
market. AIer analysis, this concerned one study, which could not
be included in a meta-analysis, and did not influence the results or
conclusions of this review.
We tried to be strict on the inclusion criteria for this review to
retrieve results that were as 'clean' and reliable as possible. For
instance, we excluded recurrent LBP to prevent possible bias. Our
underlying assumption was that people with recurrent LBP are
most probably people with chronic LBP, who may have already tried
several therapies, unsuccessfully. They may be non-responsive to
therapy, and thus, belong to a diFerent trial population than people
with acute LBP. Still, in many of the (mostly) older studies, the
inclusion criteria concerning the type and location of LBP were not
mentioned in a very specific manner, or not stated clearly. In reality,
the eligibility criteria for the study population might not have been
too strict at that time. Sometimes, this was not completely clear,
and it was up to us, as review authors, to make a decision whether
to include or exclude the study. Main considerations to include
were a clearly stated majority of people in the study population
who suFered from acute LBP, with only a small minority that may
have had additional leg pain, for instance. In a sensitivity analysis,
we checked if excluding these from the analysis would change the
results. We intended to be transparent in this process, and to make
understandable and reproducible decisions. However, it may be
that someone else would have decided diFerently. In case of a
clearly mixed study population (either type of back pain, e.g. acute,
chronic or recurrent, sciatica; or location of back pain, e.g. also
upper back or neck), or if it was unclear what type of (low) back
pain the study population had, we included the study as 'awaiting
classification'. Usually, there was no subgroup analysis, and the
reported data were insuFicient to use. We contacted trial authors
for clarification, with plans to include these data in a future update.
The sixteen studies currently awaiting classification could have had
an impact on the results of this review.
Publication bias was diFicult to assess due to the limited number
of trials included in the meta-analysis. Almost half of the included
trials were supported by pharmaceutical companies, as stated
before. Another 43% did not provide (suFicient) information
regarding funding. A recent systematic review showed that
sponsorship of drug and device studies by the manufacturing
company leads to more favourable eFicacy results and conclusions,
when compared to non-industry sponsored studies (e.g. any other
source of sponsorship). The review authors suggest the existence of
an 'industry bias' that cannot be explained by standard 'Risk of bias'
assessments (Lundh 2017). In other words, a form of publication
bias could be likely.
Agreements and disagreements with other studies or
reviews
A review on NSAIDs for spinal pain had similar findings (Machado
2017). They found moderate quality evidence that NSAIDs were
eFective in reducing pain and disability in the immediate term
(less than 2 weeks) compared to placebo, in participants with
acute LBP, but the magnitude of the diFerence was small, and did
not exceed the threshold for a clinically relevant treatment eFect.
Their findings are consistent with our review. A recently published
overview of clinical practice guidelines for non-specific LBP showed
that all eight included guidelines currently recommend NSAIDs
for acute LBP, either as a first or second choice medication
(Schreijenberg 2019). Usually, they recommend to take into
consideration potential adverse events or contra-indications,
and to give the lowest eFective dose for the shortest possible
period of time. Newer guidelines tend to move towards non-
pharmacological treatments, with short-term use of NSAIDs in
addition to usual care, only aIer careful consideration.
If we compare our results with the other two recently published
Cochrane Reviews on NSAIDs for diFerent subgroups of LBP, we
observe that the quality of most of the evidence is comparable (low
to very low (Enthoven 2016; Rasmussen-Barr 2016)). However, two
of our outcomes only contained studies at low risk of bias, with
suFicient numbers of participants to be assessed as moderate to
high quality evidence. In agreement with the review on chronic
LBP, there is moderate to high (respectively low in Enthoven
2016) quality evidence that NSAIDs are slightly more eFective
than placebo regarding pain intensity and disability, but it is
questionable whether this eFect is clinically meaningful. There
were no diFerences in eFicacy between diFerent types of NSAIDs.
This seems in line with our results. According to the review on
NSAIDs for sciatica, there was low quality evidence that global
improvement was slightly better in participants with NSAIDs,
compared to placebo (Rasmussen-Barr 2016). This is in agreement
with our review, although in a sensitivity analysis in which we
removed the studies with a mixed participant population, the result
was no longer significant. Furthermore, there was very low quality
evidence that the eFicacy of NSAIDs for pain reduction was not
significant, which is in disagreement with our review.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
For people with acute low back pain (LBP), non-steroidal anti-
inflammatory drugs (NSAIDs) were found to be slightly better in
reducing pain (moderate quality evidence) and disability (high
quality evidence) than placebo in the short-term. However, the
magnitude of the eFect is small and probably not clinically
relevant. There is low quality evidence that there is no clear
diFerence between selective COX-2 inhibitor NSAIDs and non-
selective NSAIDs in reducing pain in the short-term. In all cases,
potential (gastrointestinal) adverse events should be taken into
account.
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Implications for research
Almost half of the studies in this review were industry-sponsored,
and oIen they were relatively old. The quality of the evidence
ranged from high to very low. Since acute LBP is a frequent
condition and morbidity is high, future research is needed to
establish strong, and high-quality evidence regarding the use
of NSAIDs in acute LBP. We encourage researchers to use the
previously mentioned preliminary core outcome sets for clinical
trials on non-specific LBP recently developed by an international
steering committee, and to report all outcomes that are deemed
clinically relevant to acute LBP to improve the comparability of
results (Chiarotto 2018).
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods RCT, open-label. Randomisation procedure not described
Follow-up time: 14 days
Participants Population: 56 participants, 11 women, 22 men
Setting: people presenting at the emergency department of the University of Massachusetts Medical
Center (1 site)
Inclusion criteria: mild to moderate acute LBP, age 18 to 60 years
Exclusion criteria: taking analgesics, chronic back pain, pain longer than 72 hours, history of bleeding
disorders, high blood pressure, heart, kidney, liver, or ulcer disease, pregnant or breast feeding, allergic
reactions to analgesics or NSAIDs
Interventions NSAID (i): diflunisal capsules, 1000 mg initially, 500 mg every 8 to 12 hrs, 2 wks (N = 16)
NSAID (ii): naproxen capsules, 500 mg initially, 250 mg every 6 to 8 hrs, 2 wks (N = 17)
Outcomes No. of participants (%) reporting none or mild pain (on a ordinal 4-point scale) after 2 weeks (i) 16/16
(100%) (ii) 15/17 (88%). No. of participants (%) reporting global improvement (on a ordinal 4-point
scale) after 2 weeks (i) 16/16 (100%) (ii) 15/17 (88%)
No significance tests reported
No adverse experiences were reported by the participants
Funding Funding by Merck Sharp & Dohme, developer of diflunisal
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation procedure not described
Allocation concealment
(selection bias)




Unclear risk Not mentioned
Aghababian 1986 
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All outcomes - care-
providers
Unclear risk Not mentioned
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
High risk High drop-out rate: 32/65 participants (49%). 14 lost to FU; 2 withdrew after
initial evaluation; 7 were withdrawn (5 took other medication in addition to
the study medication; 2 suffered from chronic LBP, not acute)
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
High risk No ITT analysis performed
Selective reporting (re-
porting bias)
Unclear risk No study protocol
Similarity at baseline char-
acteristics
Unclear risk No table with baseline characteristics
Co-interventions avoided
or similar
Low risk Additional treatment of both groups included bedrest, local application of
heat, rehabilitative exercise, and other measures as appropriate
Compliance acceptable Unclear risk Not mentioned
Timing outcome assess-
ments similar
Low risk Timing similar




Methods RCT; multicentre, single-blind (observer blind), randomised, parallel group study Randomization pro-
cedure not described
Follow-up time: 8 days
Participants Population: 100 participants, 40 women, 60 men. Mean age 42.2 years (range 19 to 68)
Setting: enrolled from 5 centres in Italy
Inclusion criteria: acute lumbago, onset less than 48 hours ago, age 18 to 70 years, pain intensity at
least 50 mm on VAS
Exclusion criteria: any disorder which might interfere with the study drug, usage of anticoagulants or
other drugs which may interfere with the treatment assessment, pregnancy, breastfeeding, or hormon-
al contraception
Agrifoglio 1994 
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Interventions NSAID (i): aceclofenac 150 mg IM b.i.d. for 2 days + 100 mg tablets b.i.d. for 5 days + 1 placebo tablet for
5 days (N = 50)
NSAID (ii): diclofenac 75 mg IM b.i.d. for 2 days + 50 mg tablets t.i.d. for 5 days (N = 50)
Outcomes Mean improvement in pain intensity (VAS; 0 to 100 mm) after 8 days: (i) 65 (ii) 62
Global improvement good/very good in (i) 87% and (ii) 79% of participants




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation procedure not described
Allocation concealment
(selection bias)




All outcomes - partici-
pants




All outcomes - care-
providers
Unclear risk Not mentioned
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
Low risk (i) 9/50 withdrew = 18%
(ii) 8/50 withdrew = 16%
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Unclear risk No ITT analysis mentioned
Selective reporting (re-
porting bias)
Unclear risk No study protocol
Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar
Co-interventions avoided
or similar
Unclear risk Not mentioned
Agrifoglio 1994  (Continued)
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Compliance acceptable Unclear risk Not mentioned
Timing outcome assess-
ments similar
Low risk Timing similar




Methods RCT; double-blind, parallel placebo-controlled multicentre trial. Randomisation procedure not de-
scribed
Follow-up time: 7 days
Participants Population: 282 participants, 116 women, 166 men
Setting: 27 GPs, company doctors, and rheumatologists participated in the trial, conducted in Norway
Inclusion criteria: acute LBP, onset within the previous 48 hours, free from LBP for the last 3 months,
age 18 years to 60 years
Exclusion criteria: radicular symptoms, ankylosing spondylitis, rheumatoid arthritis, history of peptic
ulcer or severe dyspepsia, hypersensitivity to aspirin or other NSAIDs, pregnancy or lactation; and any
other hematologic, hepatic, renal, pulmonary, cardiac, or systemic disease
Interventions NSAID (i): piroxicam 20 mg capsules, single daily dose of 40 mg (2 capsules) for the first two days, then
single daily dose of 20 mg (1 capsule) for the next 5 days; 7 days (N = 140).
Reference treatment (ii): placebo capsules, single daily dose of 40 mg (2 capsules) for the first two
days, then single daily dose of 20 mg (1 capsule) for the next 5 days; 7 days (N = 142).
Outcomes (i) More pain relief than (ii) measured with visual analogue scale after 3 days. After 7 days no significant
differences
Consumption of additional analgesics: (i) 49 (N = 134) versus (ii) 62 (N = 132), with a mean consumption
of 3.2 (i) versus 5.9 (ii) tablets after 7 days. Return to work after 7 days: (i) 42 (N = 134) versus (ii) 28 par-
ticipants.
Adverse effects: similar (i) 18 (13%) (ii) 24 (17%)
Funding Study supported by Pfizer, developer of Piroxicam
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation procedure not described
Allocation concealment
(selection bias)




All outcomes - partici-
pants
Low risk To maintain double-blind conditions, placebo capsules of identical appear-
ance were administered in the same way as the study drug.
Amlie 1987 
Non-steroidal anti-inflammatory drugs for acute low back pain (Review)













All outcomes - care-
providers
Low risk Double-blind, double-dummy
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
Low risk Low dropout rate: 5,6%.
(i) 6/140 withdrew. (ii) 10/142 withdrew. (16/242)
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
High risk No ITT analysis performed
Selective reporting (re-
porting bias)
Unclear risk No study protocol
Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar
Co-interventions avoided
or similar
Low risk Paracetamol 500 mg, maximum 6 to 8 tablets a day, was used as rescue med-
ication. In a very few cases, a combination of paracetamol and codeine was
permitted for more severe pain. The consumption of rescue analgesics was
recorded for each participant during the trial.




Low risk Timing similar




Methods RCT; observer-blind, multicentrer study
Follow-up time: 1 to 2 days (depending on amount of injections)
Participants Population: 260 participants, 126 women, 134 men
Setting: 16 medical offices of GPs throughout Germany, May 1990 to December 1990
Inclusion criteria: age 18 years or older; lumbago or sciatic pain
Exclusion criteria: hypersensitivity to drugs or drug-related malfunction of liver or kidney, polyneu-
ropathy, previous disk surgery or vertebral fractures, psychiatric disease, alcohol and drug abuse, preg-
nancy or lactation. No use of other analgesics, spasmolytics, or NSAIDs besides study medication.
Interventions NSAIDs (i): dipyrone IM, 5 mL (= 2.5 g), once daily, 1 to 2 injections, 1 to 2 days (N = 88)
NSAIDs (ii): diclofenac IM, 3 mL (= 75 mg), once daily, 1 to 2 injections, 1 to 2 days (N = 86)
Babej-Dolle 1994 
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Reference treatment (iii): placebo, 5 mL isotonic saline, once daily, 1 to 2 injections, 1 to 2 days (N =
86)
Outcomes Mean (SD) pain intensity (VAS) at baseline and after 6 hours: (i) 80.2 (15.4), 33.4 (25.5); (ii) 79.2 (14.5),
41.7 (25.9); (iii) 78.2 (14.8), 54.8 (25.3). (i) significantly better than (ii) and (iii)
No. (%) of participants recovered after 2 days (characterising their general well-being as 'very well'): (i)
27 (32%); (ii) 10 (12%); (iii) 7 (9%)
Adverse events: (i) 4 participants (1 withdrew), (ii) 1 participant, (iii) 2 participants
Funding The study was funded by Hoechst AG, developer of Dipyrone
Notes Some participants with sciatic pain, not clear how many, although 22 were pretreated because of this;
no subgroup analysis
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation using a random number generator
Allocation concealment
(selection bias)
Low risk Drugs were randomised, pre-packed and provided by pharmaceutical compa-
ny in individualised participant's kits, which were assigned by the investigator




All outcomes - partici-
pants
Low risk There was no possibility of using matched preparations, therefore, treatments




All outcomes - care-
providers
Low risk There was no possibility of using matched preparations, but the preparation of
the injection and the injection itself were carried out by two different persons.
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Low risk Treatments were given observer-blind to three parallel groups of outpatients;
and assessments were performed by someone from the investigational staF
who was unaware of the drug administered.
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
Low risk Low dropout rate (14/260 = 5.4%)
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Low risk ITT analysis performed
Selective reporting (re-
porting bias)
Unclear risk No study protocol
Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar; 22 participants with sciatic complaints were
pre-treated with NSAIDs, they had an even distribution among the 3 groups: (i)
7 participants, (ii) 9 participants, (iii) 6 participants
Babej-Dolle 1994  (Continued)
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Co-interventions avoided
or similar
Low risk Sciatic pain was pre-treated in 22 participants (mostly with diclofenac, pirox-
icam, or ibuprofen). Besides the study medication, no other analgesics, spas-
molytics, or anti-inflammatory drugs were allowed.
Compliance acceptable Low risk Compliance acceptable
Timing outcome assess-
ments similar
High risk Similar timing of outcome assessments, but if a participant was pain-free,
there was no second injection. Maximum follow-up was set on 24 hours after
the last injection. This implies some participants had 24 hours of follow-up
and others 48 hours.




Methods RCT; double-blind, multicentre study. Randomisation procedure not described.
Follow-up time: 14 days
Participants Population source: 132 participants, 62 men, 70 women
Setting: 7 outpatient clinics in Austria
Inclusion criteria: acute back pain less than 1 week, moderate to severe pain (> 50 mm on VAS), at
least 2 objective signs of lumbosacral pathology (tenderness, limited ROM, or SLR < 75 degrees), LBP
due to mechanical cause
Exclusion criteria: hypersensitivity to aspirin or NSAIDs, gastroduodenal ulcer, history of gastroin-
testinal bleeding, severe cardiac, hepatic, or renal insufficiency, severe hypertension, history of
haemopoietic or bleeding disorders, pregnancy, sensory or motor deficits in lower extremities, and in-
fective, inflammatory, neoplastic, metabolic, or structural cause
Interventions NSAIDs (i): diclofenac 75 mg b.i.d., 14 days (N = 66)
NSAIDs (ii): piroxicam 20 mg b.i.d. 2 days and after that, once a day plus a placebo capsule once a day
for 12 days (N = 66)
Outcomes Mean pain intensity at rest (VAS) at baseline and after 4, 8, and 15 days: (i) 70.0, 43.3, 30.6, 22.7; (ii) 67.1,
44.5, 27.8, 21.0
No. (%) of participants improved after 14 days: (i) 54 (82%), 58 (88%). Not significant
Adverse events (i) 13 participants (1 withdrawal), (ii) 12 participants (4 withdrawals)
Funding Funding by Ciba-Geigy (now Novartis), developer of diclofenac resinate
Notes Some participants with additional radicular symptoms, not clear how many; no subgroup analysis
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation procedure not described
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Bakshi 1994 
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All outcomes - partici-
pants




All outcomes - care-
providers
Low risk Matching capsules were provided to maintain double-blind conditions.
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
Low risk Dropout rate 18% (24/132)
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Low risk ITT analysis was performed
Selective reporting (re-
porting bias)
Unclear risk No study protocol
Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar
Co-interventions avoided
or similar
Low risk Administration of analgesic/anti-inflammatory drugs other than the study
medication was not permitted during the trial. In the 3 days preceding the tri-
al, only paracetamol was allowed.
Compliance acceptable Unclear risk Not mentioned
Timing outcome assess-
ments similar
Low risk Timing similar




Methods RCT; open-label. Randomisation procedure not described
Follow-up time: 15 days
Participants Population: 47 participants, 22 women, 18 men. Mean age 29 years (range 18 to 59)
Setting: University of Maryland Health Center
Inclusion criteria: initial or recurrent mild to moderate acute LBP, age 18 to 59 years
Exclusion criteria: pregnant or nursing women, allergy to aspirin or other NSAIDs, history of peptic ul-
cer, gastrointestinal bleeding or bleeding disorders, significant hypertension; cardiovascular, renal,
Brown 1986 
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or hepatic disease, recurrent chronic pain, neurologic signs or symptoms, fracture of the lumbosacral
spine
Interventions NSAID (i): diflunisal (500 mg tablets), initial dose 2 tablets (1000 mg), followed by 1 tablet (500 mg)
every 12 hrs, 15 days (N = 19)
Reference treatment (ii): acetaminophen with codeine (300 mg + 30 mg tablets), initial dose 2 tablets
(660 mg), followed by 1 tablet (330 mg) every 4 hours, 15 days (N = 21)
Outcomes Pain assessments by participant and investigator on 3-point ordinal scale showed similar improvement
curves (data in graphs)
No. of participants rating drugs as excellent or very good (i) 9 (ii) 9. No significant differences
Side effects: more side effects in (ii) 10 (in 5 participants) than in (i) 3 (in 3 participants). No participants
withdrew because of side effects.
Funding Study supported by a grant from Merck Sharp & Dohme (developer of diflunisal)
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation procedure not described
Allocation concealment
(selection bias)




All outcomes - partici-
pants




All outcomes - care-
providers
High risk Not blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Low risk Study co-ordinator dispensed all medications and was not involved in partici-




All outcomes - dropouts
Low risk Dropout rate 14.8% (7/47)




All outcomes - ITT analy-
sis
High risk No ITT analysis performed
Selective reporting (re-
porting bias)
Unclear risk No study protocol
Brown 1986  (Continued)
Non-steroidal anti-inflammatory drugs for acute low back pain (Review)









Cochrane Database of Systematic Reviews
Similarity at baseline char-
acteristics
Unclear risk No table with baseline characteristics
Co-interventions avoided
or similar
Low risk No other analgesic/anti-inflammatory treatment was allowed. Each partici-
pant did the same postural exercises from day 3 on.
Compliance acceptable Unclear risk Compliance not mentioned
Timing outcome assess-
ments similar
Unclear risk Timing similar




Methods RCT; randomised, controlled, parallel, open multicentre study. Randomisation procedure not de-
scribed.
Follow-up time: 8 days
Participants Population: 183 participants, 103 men, 80 women
Setting: 12 centres of orthopaedic surgeons, internal specialists, and general practitioners in Germany
Inclusion criteria: age 18 years or older, acute lumbago, onset within 48 hours prior to treatment
Exclusion criteria: chronic or chronically recurrent LBP, disc prolapse, whiplash injury or direct trau-
ma, history of, or active gastrointestinal ulcer, coagulation or bleeding disorders, hypersensitivity to
analgesics or NSAIDs, use of oral anticoagulants or lithium therapy, pregnant or breastfeeding women,
or women without adequate contraception
Interventions NSAIDs (i): meloxicam IV 1.5 mL (= 15 mg) IV on day 1 (1 injection), followed by 1 tablet (15 mg) daily for
7 days; 8 days (N = 92)
NSAIDs (ii): diclofenac IM 3ml (= 75 mg) IM on day 1 (1 injection), followed by 1 tablet (100 mg, slow-re-
lease) daily for 7 days; 8 days (N = 91)
Outcomes Percentage of participants with no or mild pain during movement after 8 days: (i) 91%; (ii) 88%
Percentage of participants recovered after 8 days, on overall improvement, functional status, and tol-
erance: (i) 89%, 67%, 96%; (ii) 91%, 54%, 95%




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation procedure not described
Allocation concealment
(selection bias)
Unclear risk Not mentioned
Colberg 1996 
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All outcomes - partici-
pants




All outcomes - care-
providers
Unclear risk Not mentioned
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
Low risk Low dropout rate: 5,5% (10/183)
In both groups, 3 withdrawals because of insufficient efficacy, and 2 because
of an adverse event; total withdrawals: 10 participants
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Low risk ITT analysis performed
Selective reporting (re-
porting bias)
Unclear risk No study protocol
Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar
Co-interventions avoided
or similar
Unclear risk Not mentioned
Compliance acceptable Unclear risk Compliance was assessed by the dispensing record and the number of trial
medication tablets taken, but not mentioned in results.
Timing outcome assess-
ments similar
Low risk Timing similar




Methods RCT; double-blind; double-dummy randomised, placebo-controlled, parallel group; multicentre
Follow-up time: 8 days
Drugs were randomised according to a random scheme in blocks of 3, provided by pharmaceutical
company; the lowest available randomisation number was assigned to the participants at each site
when entering the study.
Participants Population: 372 participants, 187 women, 182 men. Mean age approximately 40 years
Setting: 54 clinics of general practitioners in France
Dreiser 2003 
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Inclusion criteria: age 18 to 60 years, with untreated acute low back pain, onset within 2 days, pain ≥
50 mm on 100-mm VAS, not due to an associated radiculalgia; not radiating below gluteal fold, pain in-
termittent or constant, and aggravated by mechanical factors
Exclusion criteria: hypersensitivity to diclofenac, ibuprofen, paracetamol, aspirin; current disease sta-
tus that could interfere with safety or efficacy of study medication; drug or alcohol abuse; anticoagu-
lant therapy or other concomitant treatments; pregnant or nursing; sensory or motor deficits in lower
extremities; previous episode of LBP within 3 months; chronic LBP, or an infective, inflammatory, neo-
plastic, metabolic or structural cause for back pain
Interventions NSAID (i): diclofenac-K 12.5 mg, initial dose 2 tablets (25 mg), 7 days flexible dose 1 to 2 tablets every 4
to 6 hours, maximum 6 tablets a day; 8 days (N = 124)
NSAID (ii): ibuprofen 200 mg, initial dose 2 tablets (400 mg), 7 days flexible dose 1 to 2 tablets every 4
to 6 hours, maximum 6 tablets a day; 8 days (N = 122)
Reference treatment (iii): placebo, initial dose 2 tablets, 7 days flexible dose 1 to 2 tablets every 4 to 6
hours, maximum 6 tablets a day; 8 days (N = 126)
Outcomes Pain intensity, mean changed score (SD), 100 mm VAS, after 7 days: (i, N = 122) -48.4 (26.1); (ii, N = 119)
-48.8 (24.0); (iii, N = 121) -37.5 (26.9); (i) vs (iii) and (ii) vs (iii) significantly lower (P < 0.001)
Roland-Morris Back Pain Questionnaire (0 to 24, no to maximal disability) mean changed score (SD) af-
ter 7 days: (i, N = 119) -8.6 (5.7); (ii, N = 118) -8.1 (5.2); (iii, N = 116) -5.7 (5.3); (i) vs (iii), and (ii) vs (iii) sig-
nificantly lower (P < 0.001)
Global improvement: a lot/complete in (i) 53/119 (45%) and (ii) 48/119 (40%)
Adverse events: (i) 16 participants (4 withdrew); (ii) 14 participants (4 withdrew); (iii) 20 participants (8
withdrew)
Funding Study supported by Novartis Consumer Health (developer of diclofenac-K (Voltaren K))
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Unclear how the study sponsor arranged the sequence generation process
Allocation concealment
(selection bias)
Low risk Adequate: drugs were randomised according to a random scheme in blocks
of 3, provided by the study sponsor; the lowest available randomisation num-
ber was assigned to the participants at each site when entering the study. Each
package of study medication looked equal and was labelled with a randomi-
sation number. Sealed decoding envelopes were supplied to the sites for un-





All outcomes - partici-
pants




All outcomes - care-
providers
Low risk Double-blind, double-dummy
Blinding of outcome as-
sessment (detection bias) 
Low risk Double-blind, double-dummy
Dreiser 2003  (Continued)
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All outcomes - dropouts
Low risk Low dropout rate: 7% (26/369 withdrew)
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Low risk ITT analysis performed
Selective reporting (re-
porting bias)
Unclear risk No study protocol registered
Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar
Co-interventions avoided
or similar
Unclear risk Rescue medication consisted of 1 or 2 tablets of paracetamol (500 mg); the use
of rescue medication terminated the participation of the participant in the tri-
al. No even distribution among groups.
Compliance acceptable Low risk Daily use of study medication was recorded in participant diary, and study
medication leI at the end of the trial was counted.
Timing outcome assess-
ments similar
Low risk Timing similar




Methods RCT; randomised, double-blind, double-dummy, parallel trial with 4 arms
Follow-up time: 12 weeks (outcomes recorded at baseline, 1, 2, 4, and 12 weeks)
Participants Population: 240 participants, 105 women and 135 men. Mean age (SD) 40.7 years (15.6); mean duration
of current symptoms (SD) 9.13 days (9.31)
Setting: 19 GPs from 14 general practices in an urban population in Australia, recruitment between
June 2005 and October 2006
Inclusion criteria: all participants with low back pain (with or without leg pain) of less than 6 weeks
duration, causing moderate pain and moderate disability (measured by adaptations of items 7 and 8 of
SF-36)
Exclusion criteria: present episode of pain not preceded by a pain-free period of at least 1 month, in
which care was not provided; known or suspected serious spinal pathology; nerve root compromise
(with at least two of these signs: myotomal weakness, dermatomal sensory loss, or hyporeflexia of the
lower limb reflexes); presently taking NSAIDs or undergoing spinal manipulation; any spinal surgery
within the preceding 6 months; and contraindication to paracetamol, diclofenac, or spinal manipula-
tive therapy
Interventions All participants: paracetamol 1g four times daily (until recovery or for a maximum of 4 weeks) and ad-
vice given by the GP
NSAID (i): diclofenac 50 mg twice daily and placebo manipulative therapy (N = 60)
Hancock 2007 
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NSAID (ii): diclofenac 50 mg twice daily and spinal manipulative therapy (N = 60)
Reference treatment (iii): spinal manipulative therapy and placebo drug twice daily (N = 59; 1 exclud-
ed after randomisation)
Reference treatment (iv): double placebo (N = 60)
Outcomes Mean (SD) number of days to recovery, counted as the first pain-free day (pain score 0 or 1 on range 0 to
10)
Hazard ratio of (i) and (ii) vs (iii) and (iv): 1.09 (95% CI 0.84 to 1.42). No significant difference
Hazard ratio of (ii) vs (iv): 1.10 (95% CI 0.76 to 1.60, P = 0.609). No significant difference
Median days to recovery: (i) and (ii): 13 (95% CI 10 to 16); (iii) and (iv): 16 (95% CI 14 to 18). No significant
difference
The effects of NSAIDs and spinal manipulative therapy did not interact significantly.
Secondary outcomes (pain, disability, function, global perceived effect): no significant differences at
any time point
Adverse events: total 22 participants (22/239; 9%) (i, ii) 11 participants (1 withdrew); (iii, iv) 11 partici-
pants (none withdrew)
Additional data retrieved after contacting the author:
PI after 14 days, mean NRS (SD): (i, N = 59) 2.32 (2.367); (iii, N = 59) 2.24 (2.003); (iv, N = 60) 2.80 (2.602).
No significant differences
Disability after 14 days, mean RMDQ (SD): (i, N = 58) 4.86 (5.826); (iii, N = 59) 4.29 (5.408); (iv, N = 60) 5.98
(6.052). No significant differences
Global perceived effect after 14 days, mean global perceived effect (SD): (i, N = 59) 3.47 (1.716); (iii, N =
59) 3.73 (1.215); (iv, N = 60) 3.12 (2.059). No significant differences
PI after 84 days, mean NRS (SD): (i, N = 57) 1.05 (2.108); (iii, N = 58) 0.98 (2.098); (iv, N = 60) 0.93 (1.903).
No significant differences
Disability after 84 days, mean RMDQ (SD): (i, N = 57) 2.28 (5.095); (iii, N = 58) 2.03 (4.433); (iv, N = 60) 2.42
(5.093). No significant differences
Global perceived effect after 84 days, mean global perceived effect (SD): (i, N = 57) 4.32 (1.638); (iii, N =
58) 4.52 (1.525); (iv, N = 60) 4.35 (1.696). No significant differences
Funding Funding source (Australia's National Health and Medical Research Council) had no role in study design,
data collection, data analysis, data interpretation, or writing of the report. The active diclofenac was
donated by Alphapharm (a generic drug manufacturing company based in Australia).
Notes Declarations of interest: one of the authors was a member of an advisory board about paracetamol for
GlaxoSmithKline. Payments went to an audited hospital account for teaching and research purposes.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Low risk Sequentially numbered sealed opaque envelopes
Hancock 2007  (Continued)
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All outcomes - partici-
pants




All outcomes - care-
providers
High risk GPs were blinded, but the physiotherapist who would give either active or
placebo spinal manipulative therapy could obviously not be blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Low risk Outcome assessor was blinded
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
Low risk Low dropout rate (< 20% dropouts)
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Low risk ITT analysis was performed; the authors mentioned five participants who did
not get the correct spinal manipulative therapy intervention as allocated.
Selective reporting (re-
porting bias)
Low risk Trial was registered and study protocol was published.
Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar
Co-interventions avoided
or similar
Low risk Co-interventions similar in the active and placebo arms. Participants were
asked not to seek other treatments for their acute LBP during intervention and
follow-up, and a record of additional treatments was kept for any participants
who took other treatments within this time.
Compliance acceptable Low risk Compliance was acceptable. Unused medications were collected and compli-
ance was assessed using various methods.
Timing outcome assess-
ments similar
Low risk Timing of outcome assessments similar




Methods RCT; multicentre, double-blind, double-dummy. Randomisation procedure not described
Follow-up time: 2 weeks
Participants Population: 287 participants, 136 women, 151 men. Aged 18 to 63 years
Setting: 28 general practices in the UK
Inclusion criteria: acute low back injury/LBP, onset less than 1 month ago
Exclusion criteria: sciatica, 2 or more episodes of LBP in the previous 6 months, nerve root pressure,
previous vertebral fractures, spinal stenosis, spondylolisthesis, marked scoliosis, ankylosing spondyli-
Hosie 1993 
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tis, osteoarthritis, Paget's disease, metabolic bone disease, systemic connective tissue disorders, ma-
lignancy, infection, referred pain from intra-abdominal or intra-pelvic disease, pregnancy, lactation, al-
lergy to NSAIDs, history of bronchial asthma or peptic ulcer, gastrointestinal, renal, hepatic, cardiovas-
cular, metabolic, haematological, or dermatological disease
Interventions NSAID (i): ibuprofen (capsules, 400 mg) 3 times daily + placebo foam 3 times daily, 14 days (N = 147)
NSAID (ii): felbinac (foam, 3%) 3 times daily + placebo capsules 3 times daily, 14 days (N = 140)
Outcomes Participants (%) reporting none or mild severity after 1 and 2 weeks (i) 84, 92 (ii) 76, 88. No significant
differences between the groups
Adverse events (EA): No. of side effects (i) 22 AEs reported by 21 participants (8 withdrew), (ii) 26 AEs re-
ported by 22 participants (3 withdrew)
Funding Not mentioned. However, the address for correspondence is the Medical Department, Lederle Labora-
tories, and Traxam (felbinac) was a registered trademark of Lederle Laboratories, UK.
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation procedure not described
Allocation concealment
(selection bias)




All outcomes - partici-
pants




All outcomes - care-
providers
Low risk Double-blind, double-dummy
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Low risk Double-blind, double-dummy
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
Low risk Dropout rate 18% (52/287 withdrew)
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
High risk ITT analysis performed, based on available data, but for ITT-analysis dropout
too high (analysis based on 172 participants).
Selective reporting (re-
porting bias)
Unclear risk No study protocol
Hosie 1993  (Continued)
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Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar
Co-interventions avoided
or similar
Low risk participants were instructed not to use any other oral, injectable, or topical
analgesic or antiinflammatory medication, and to continue any ongoing phys-
iotherapy without change.
Compliance acceptable Unclear risk Not mentioned
Timing outcome assess-
ments similar
Low risk Timing similar




Methods RCT; double-blind; multicentre. Randomised according to computer-generated random allocation ta-
ble, exact procedure not described.
Follow-up time: 7 to 9 days
Participants Population: 122 emergency department participants with acute LBP, 26 women, 96 men. Mean age
(SD), 34.5 (10), range 19 to 62 years
Setting: 6 university and community hospital emergency departments in Canada
Inclusion criteria: acute musculoskeletal low back pain (moderate/severe), onset within the previous
72 hours, age 18 to 60 years, weight > 50 kg, well enough for discharge within 4 hours, requirement of
oral analgesics
Exclusion criteria: treatment with investigational drug in previous 4 weeks; adverse events due to
NSAIDs; hypersensitivity to analgesics, antipyretics, or NSAIDs; anti-coagulants use within 4 weeks,
concurrent treatment with other medications influencing pain intensity evaluations; active peptic ulcer
within 6 months; anticoagulant use; conditions requiring treatment beyond analgesics; pregnancy or
breastfeeding; alcohol or drug abuse; chronic or recurrent LBP or neurologic cause; interfering co-exist-
ing injury or illness
Interventions NSAID (i): Dose 1 to 4 per day: ketorolac tromethamine 10 mg (1 capsule) + placebo (1 capsule), every 4
to 6 hours as needed, up to 4 doses per 24 hours. Dose 5 and 6 per day, if required: acetaminophen 650
mg per dose (2 capsules); up to 7 days (N = 62).
Reference treatment (ii): Dose 1 to 4 per day: acetaminophen 300 mg + codeine 30 mg per capsule (2
capsules), every 4 to 6 hours as needed. Dose 5 and 6 per day, if required: acetaminophen 650 mg per
dose (2 capsules); up to 7 days (N = 60)
Outcomes Pain mean changed score (SD), 100-mm VAS, after 6 hours: (i, N = 55) -6.4 (17); (ii, N = 58) -5.4 (16), no
significant differences
% participants reporting 'a lot/complete' pain relief after 4 days: (i) 53%; (ii) 55%, no significant differ-
ences
% participants reporting 'no/mild' impairment after 4 days: (i) 67%; (ii) 62%, no significant differences
Adverse events: (i) 21 participants (0 withdrew); (ii) 38 participants (7 withdrew)
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation code
Allocation concealment
(selection bias)




All outcomes - partici-
pants




All outcomes - care-
providers
Low risk All drugs were prepared in identical capsules to preserve double-blinding.
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Low risk A blinded consultant entered all data and performed statistical analyses.
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
Low risk Dropout rate: 18.9% (23/122 withdrew)
16 (10 (i) and 6 (ii)) withdrew prematurely because of analgesic inefficacy, 7 (ii)
withdrew because of side effects
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
Unclear risk Unclear if pain relief and impairment was also measured after 7 days; it was
not mentioned. Study protocol locally approved, not registered.
Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar
Co-interventions avoided
or similar
Unclear risk Drug were packaged in blister cards that separated each day's drug supply into
six doses labelled 1 to 6. Each 'dose' consisted of two capsules.
Compliance acceptable Unclear risk Not mentioned if blister cards with used/unused medication were collected.
Participants were asked to record all medication intake in their study diary.
Timing outcome assess-
ments similar
Low risk Timing similar




Methods RCT; double-blind, between-participant study with matched pairs. Randomisation procedure not de-
scribed
Ja:e 1974 
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Follow-up time: 7 days
Information extracted from Group A (acute low back pain with or without sciatica)
Participants Population: subgroup of 30 participants (consecutive attenders at the surgery) with acute lumbar
pain, with or without sciatica, 20 women, 10 men. Mean age (SD), 40.5 (13.5) (i), 38.1 (10.6) (ii); range not
mentioned
Setting: surgery department in England
Inclusion criteria: acute LBP, with or without sciatica, of mechanical and/or degenerative origin
Exclusion criteria: peptic ulcer, renal or hepatic impairment, history of intolerance to study drugs,
children (no upper age limit)
Interventions NSAID (i): alclofenac capsules 1 g t.i.d.; 7 days (N = 15)
NSAID (ii): indomethacin capsules 50 mg t.i.d.; 7 days (N = 15)
Outcomes Mean (SEM) change score in pain intensity (5-point scale, 0 to 4) and functional status (4-point scale, 0
to 3) after 7 days for acute LBP: (i) 1.46 (0.28), 1.80 (0.03); (ii) 1.45 (0.27), 1.53 (0.23). Not significant
Adverse events: no data presented on adverse events for subgroup with acute LBP. These are the AEs in
the whole group (60 participants), consisting of both acute and chronic LBP: (i) 5 participants; (ii) 3 par-
ticipants (none withdrew).
Funding Not mentioned. Berk Pharmaceuticals Limited is the manufacturer of alclofenac (Prinalgin) and provid-
ed the capsules.
Notes Part of the population had additional sciatica complaints. Not mentioned how many, no subgroup
analysis.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not mentioned
Allocation concealment
(selection bias)





All outcomes - partici-
pants




All outcomes - care-
providers
Unclear risk Double-blind, details not mentioned
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
Low risk Low dropout rate: 3,3% (1/30 lost to follow-up)
Ja:e 1974  (Continued)
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All outcomes - dropouts
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
Unclear risk No study protocol
Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar
Co-interventions avoided
or similar
Low risk 'Patients were instructed to take no other pain-killing medication unless they
informed the clinician'. Follow-up of this advice not mentioned
Compliance acceptable Unclear risk Not mentioned
Timing outcome assess-
ments similar
Low risk Timing similar




Methods RCT; double-blind, placebo-controlled. Randomisation procedure not described.
Follow-up time: 14 days
Information extracted from subgroup with acute back sprain
Participants Population: subgroup of 337 participants with acute back or sacroiliac pain (< 72 hours). Age and sex
ratio unknown
Setting: 215 participating general practitioners, conducted in the United Kingdom
Inclusion criteria: acute back or sacroiliac pain, diagnosed within the last 72 hours or less
Exclusion criteria: not mentioned
Interventions NSAID (i): piroxicam 10 mg capsules, four times per day first two days, two times per day next 12 days;
14 days (N = 168)
Reference treatment (ii): identical placebo capsules, four times per day first two days, two times per
day next 12 days; 14 days (N = 169)
Outcomes Participant (%) improved after 1 week only in subgroups with initial moderate/severe pain (i) 82%/49%
(ii) 53%/38%. No differences for subgroup with mild initial pain. Results after 2 weeks not reported.
No data presented on adverse events for subgroup with back pain. The overall numbers, including oth-
er musculoskeletal disorders, were similar: (i) 12% (3% withdrew) (ii) 9% (2,5% withdrew).
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation procedure not described
Allocation concealment
(selection bias)




All outcomes - partici-
pants




All outcomes - care-
providers
Low risk Double-blind, identical placebo capsules
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
Unclear risk Not mentioned for subgroup
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
Unclear risk No study protocol
Similarity at baseline char-
acteristics
Unclear risk Baseline characteristics not mentioned for subgroup
Co-interventions avoided
or similar
Unclear risk Not mentioned
Compliance acceptable Unclear risk Not mentioned
Timing outcome assess-
ments similar
Low risk Timing similar




Methods RCT; double-blind, randomised, controlled, multicentre. Article in German. Randomisation procedure
not described.
Follow-up time: 7 days (outcome measurements at baseline, after 3 and 7 days)
Metscher 2001 
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Participants Population: 192 participants, 87 women, 105 men. Median age 47 years (range 20 to 70)
Setting: 24 centres in Germany, from November 1998 until March 1999
Inclusion criteria: age 18 to 70 years; acute LBP; pain 100-mm VAS ≥ 50 mm; onset within 48 hours; not
indicated for other than analgesic treatment
Exclusion criteria: not mentioned
Interventions NSAID (i): dexketoprofen-trometamol 25 mg t.i.d.; 7 days (N = 97)
Reference treatment (ii): tramadol hydrochloride 50 mg t.i.d.; 7 days (N = 95)
Outcomes Pain difference, mean changed score, 100-mm VAS, after 7 days: (i, N = 81) vs (ii, N = 79) -6 (4) (P < 0.05)
Adverse events: (i) 13 participants; (ii) 22 participants
Funding Not mentioned
Notes Unclear presentation of results (data on pain scores extracted from graph)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation procedure not described
Allocation concealment
(selection bias)




All outcomes - partici-
pants




All outcomes - care-
providers
Unclear risk Not mentioned
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
Low risk Dropout rate 17.1% (33/193 withdrew: 1 only baseline measurements; 10
stopped therapy prematurely or failed therapy; 22 protocol violations)
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
Unclear risk No study protocol
Metscher 2001  (Continued)
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Similarity at baseline char-
acteristics
Unclear risk Not mentioned, no table 1
Co-interventions avoided
or similar
Low risk Paracetamol was allowed as rescue medication, maximum 4 tablets of 500 mg
Compliance acceptable Unclear risk Compliance was assessed by the recordings in the participant diaries. Unused
medication was not collected.
Timing outcome assess-
ments similar
Low risk Timing similar




Methods RCT; open-label, non-inferiority trial. Computer-generated randomisation
Follow-up time: 4 weeks
Participants Population: 127 participants, 84 women, 43 men. Mean age (SD) (i) 66.73 (2.29) (ii) 63.5 (19.4)
Setting: 1 outpatient hospital in Japan, recruitment from July 2014 until September 2017
Inclusion criteria: age older than 20 years old and initiation of LBP in the 4 weeks prior to study entry
Exclusion criteria: seeking a second opinion for a prior consultation, cancer-related pain, presence of
neurological symptoms (e.g. pain radiating down the leg), traumatic cases, such as falls, evidence of
bone fractures, surgery within the prior 6 months, current use of full, regularly recommended doses of
an analgesic, pregnancy, autoimmune diseases, inflammatory rheumatic disordered, cardiopulmonary
restrictions, severe kidney or liver function disorders, acute duodenal or ventricular ulcer, psychiatric
disorders, or the presence of laboratory data outside the normal limits
Interventions NSAID (i): loxoprofen 60 mg, 3 times daily; 4 weeks (N = 63)
Reference treatment (ii): acetaminophen 600 mg, 4 times daily; 4 weeks (N = 64)
Outcomes Pain difference mean changed score, NRS, after 2 weeks: (i) vs (ii) -0.51 (95% CI -1.70 to 0.67), not signifi-
cant. After 4 weeks: (i, N = 35) vs (ii, N = 35) -0.80 (95% CI -2.08 to 0.48), not significant
Adverse events: (i) 1 participant (GI complaints); (ii) 5 participants (of which 3 GI complaints)
Funding The study was funded by a Japanese association for the study of musculoskeletal pain.
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation
Allocation concealment
(selection bias)
Low risk The randomisation procedure was performed by a person not involved in the
treatment of participants.
Miki 2018 
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All outcomes - partici-
pants




All outcomes - care-
providers
High risk Not blinded; open-label trial
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
High risk Additional information by authors: treatment was performed by a single or-
thopaedist, and outcomes were assessed by the same physician.
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
High risk High dropout rate 44.9% (57/127 withdrew)
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
High risk No ITT analysis, only a PP analysis performed
Selective reporting (re-
porting bias)
Unclear risk Trial was registered at local ethics committee; (inter)national trial registry not
mentioned. The primary outcome pain intensity (NRS) after 2 and 4 weeks was
not presented clearly in the results section of the article.
Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar
Co-interventions avoided
or similar
Unclear risk External medication for pain was not allowed, with the exception of topical
anaesthetics. No other supplementary analgesic medication was given during
the treatment period.
Compliance acceptable High risk Additional information by authors: compliance was not measured. Partici-
pants were told that they could stop the medication if their symptoms im-
proved, or if any adverse events occurred.
Timing outcome assess-
ments similar
Low risk Timing similar




Methods RCT; randomised, single (investigator) blind, multicentre study. Stratified randomisation, allocation
procedure not described
Follow-up time: 4 days (2 days treatment time)
Participants Population: 371 participants, 216 women, 155 men. Mean age (SD): 36 (10.59) years
Setting: 11 sites, conducted in the USA
Nadler 2002 
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Inclusion criteria: age 18 to 55 years, acute nonspecific LBP; pain intensity ≥ 2 on 6-point scale (at least
moderate intensity); no low back trauma within the preceding 48 hours; an answer of "yes" to the ques-
tion "Do the muscles in your low back hurt?"
Exclusion criteria: radiculopathy or other neurologic deficits; history of back surgery; fibromyalgia;
diabetes mellitus; hypersensitivity for NSAIDs, acetaminophen, or heat; peptic ulcer or gastrointesti-
nal bleedings; renal or hepatic disorders; anticoagulant treatment; pregnancy; daily back pain for more
than three consecutive months
Interventions NSAID (i): ibuprofen 200 mg, 2 tablets t.i.d. + 2 placebo tablets once a day; 2 days (N = 106)
Reference treatment (ii): acetaminophen 500 mg, 2 tablets q.i.d.; 2 days (N = 113)
Reference treatment (iii): heat wrap, 40 °C, approximately 8 hours of wear per day; 2 days (N = 113)
Reference treatment (iv): unheated wrap, 8 hours/day; 2 days (N = 19), no outcome measures pre-
sented
Reference treatment (v): placebo, 2 tablets q.i.d.; 2 days (N = 20), no outcome measures presented
Outcomes Pain mean changed score (NRS scale 0 to 5), after 4 days: (i) -1.7; (ii) -2.0; (iii) -2.6; (i) vs (ii) not present-
ed; (i) vs (iii) significantly less effective (P < 0.001)
RMDQ (scale 0 to 24, none to maximal disability), mean changed score after 4 days: (i, N = 101) -2.7, (ii, N
= 104) -2.9, (iii, N = 110) -4.9; (i) vs (ii) not presented; (i) vs (iii) significantly less effective (P < 0.001)
Adverse events: no serious side effects occurred. Systemic adverse events: (i) 10.4% (11/106; 1 with-
drew), (ii) 4.4% (5/113), (iii) 6.2% (7/113)
Funding Funding by the Procter and Gamble company (developer of the used ThermaCare Heat Wrap).
Notes Declarations of interest: Dr. Nadler is a paid consultant for Procter & Gamble and most of the co-au-
thors are employees of the Procter and Gamble Health Sciences Institute.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stratified randomisation, procedure not described
Allocation concealment
(selection bias)




All outcomes - partici-
pants
Unclear risk The participants using tablets (i, ii, v) were blinded for which tablet group they
were in; the participants using wraps (iii, iv) were blinded for which wrap they




All outcomes - care-
providers
Unclear risk Not mentioned
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors




Low risk Low dropout rate: 2.2% (8/371 withdrew)
Nadler 2002  (Continued)
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All outcomes - dropouts
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Unclear risk ITT analysis performed, but data not presented. Results of ITT population




High risk Study protocol available, but several data from primary treatment groups
were not compared, and results of reference treatment (iv) and (v) were not
presented.
Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar
Co-interventions avoided
or similar
Unclear risk Subjects were asked not to use other treatments.
Compliance acceptable Unclear risk Not mentioned
Timing outcome assess-
ments similar
Low risk Timing similar




Methods RCT; double-blind, multicentre. Randomization procedure not described.
Follow-up time: 1 week.
Participants Population: 133 participants, 41 women, 92 men. Age range 18 to 71
Setting: multicentre investigation at 8 cities by 8 physicians, conducted in Finland
Inclusion criteria: acute lumbago, onset less than 2 weeks ago, bothersome LBP and considerable
functional disability, no previous use of analgesics, antiinflammatory, or muscle relaxing agents for this
episode
Exclusion criteria: stable, chronic LBP; LBP due to disorders of the pelvic region or spinal disorders
(prolapse/hernia of an intervertebral disc); pregnancy or nursing; hypersensitivity to salicylates or in-
domethacin; current treatment with systemic corticosteroids or anticoagulants; active peptic ulcer or
gastrointestinal haemorrhage; significant liver of kidney disease; haemopoietic disorders
Interventions NSAID (i): diflunisal 500 mg (capsules) b.i.d.; 7 days (N = 66)
NSAID (ii): indomethacin 50 mg (capsules) t.i.d.; 7 days (N = 67)
Outcomes Data shown in graphs, extracted from graphs.
Mean score difference in pain (4-point Likert scale, range 0 to 3, no pain to severe pain) 0 to 7 days: (i)
-1.0, (ii) -1.1 (at rest); (i) -1.6, (ii) -1.5 (on active movement). No significant differences
Mean score difference in functional disability (4-point Likert scale, range 0 to 3, no disability to severe
disability) 0 to 7 days: (i) -1.5, (ii) -1.55. No significant differences
Adverse events: (i) 12 participants = 18.2% (2 withdrew), (ii) 21 participants = 31.3% (6 withdrew)
Funding Not mentioned
Orava 1986 
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Notes Partially flare participants: 126 participants with acute lumbago, 7 participants with acute exacerba-
tion of chronic lumbago; no subgroup analysis
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation procedure not described
Allocation concealment
(selection bias)




All outcomes - partici-
pants




All outcomes - care-
providers
Unclear risk Not mentioned
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
Low risk Low dropout rate: 6% (8/133 withdrew)
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
Unclear risk No study protocol
Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar
Co-interventions avoided
or similar
Unclear risk Not mentioned
Compliance acceptable Unclear risk Not mentioned
Timing outcome assess-
ments similar
Low risk Timing similar
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Methods RCT; double-blind, randomised, double-dummy clinical trial (non-inferiority) Computer-generated ran-
domisation
Follow-up time: 10 days (maximum treatment duration 5 days). Outcome measurements at baseline,
60 minutes, 2 days, 4 days, 10 days
Participants Population: 83 participants, 216 women, 155 men. Mean age (SD): 36 (10.59) years
Setting: outpatient clinics of 2 research centres in Brazil
Inclusion criteria: diagnosed with moderate or severe acute LBP (VAS > 40 mm), aged 18 to 65 years,
able to give written informed consent; women of childbearing age had to agree to use contraceptive
methods throughout the study
Exclusion criteria: weight < 50 kg; severe congestive heart failure; current alcoholism or illegal drug
use; presence of fever or signs of infection; kidney disease; fracture; fibromyalgia; cancer; neuropsychi-
atric disease; rheumatologic disease; history of peptic ulcer disease; gastrointestinal bleeding or hem-
orrhagic diathesis; cerebrovascular disease; haemostatic disorders or use of anticoagulants; pregnan-
cy; lactation; postoperative people at high risk of bleeding; history of hypersensitivity to NSAIDs; nasal
polyps and asthma. No participation in another experimental study 6 months prior to study entry.
Interventions NSAID (i): ketorolac-trometamol sublingual 10 mg t.i.d.; 5 days (N = 66)
NSAID (ii): naproxen oral 250 mg, t.i.d.; 5 days (N = 67)
From 2nd to 5th day, if participant had VAS > 40 mm, an increased dose of four times per day was al-
lowed.
Outcomes VAS-scores are not mentioned separately, only combined scores are mentioned and focus on pain relief
by comparing VAS scores 1 hour before and after medication. Relevant outcomes (VAS-scores) at day 4
are not mentioned. No significant differences mentioned.
Adverse events: (i) 42 adverse events (1 withdrew); (ii) 35 adverse events (0 withdrew)
Funding EMS Sigma Pharma is a domestic pharmaceutical company in Brazil. This study was funded by EMS and
they were involved in study design, protocol development, obtaining the data, and evaluating the data
together with the authors. The manuscript was written by the authors, together with EMS medical writ-
ing services. All authors received grants and consulting fees from EMS Industry.
Notes 83 people were screened, none of them were excluded, despite the strict exclusion criteria.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated lottery, randomly assigned.,
Allocation concealment
(selection bias)
Unclear risk Each participant received a numbered kit in order of arrival. The trial design
says double-dummy and double-blind assignments; but NSAID (i) was admin-
istered sublingually and NSAID (ii) was administered orally, therefore, this





All outcomes - partici-
pants
Unclear risk It was written that both medical staF and participants were blinded to treat-
ment assignments; but different way of administering the medication and no
details were mentioned.
Plapler 2016 
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All outcomes - care-
providers
Unclear risk It was written that both medical staF and participants were blinded to treat-
ment assignments; but different way of administering the medication and no
details were mentioned.
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
High risk High dropout rate: 24% (20/83 lost to follow-up/withdrew)
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
High risk ITT analysis performed for adverse events only; PP analysis for effect
Selective reporting (re-
porting bias)
Unclear risk Trial was registered at local ethical committee. (inter)national trial registry not
mentioned. Not mentioned if pain outcome measure (RPR) was registered like
this.
Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar, except for weight
Co-interventions avoided
or similar
Unclear risk Not mentioned
Compliance acceptable Unclear risk Not mentioned
Timing outcome assess-
ments similar
Low risk Timing similar




Methods RCT; double-blind, double-dummy, multicentre. Randomised according to a list in permutation blocks,
concealed allocation
Follow-up time: 10 days
Participants Population: 104 participants, sex unknown. Mean age 42 years (range 19 to 63)
Setting: 1 hospital outpatient clinic and 1 occupational health care centre, both in Helsinki
Inclusion criteria: age 18 to 65 years; acute LBP, onset within 30 days
Exclusion criteria: chronic LBP for more than 4 weeks; sciatica syndrome (LBP with radiation to an ex-
tremity below the knee); secondary cause of LBP; osteoporotic fracture or a history of lumbar spine
surgery; pregnancy or lactation; significant systematic disease; history of peptic ulceration; allergy to
NSAIDs
Interventions NSAID (i): nimesulide 100 mg b.i.d. + placebo once a day; 10 days (N = 52)
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NSAID (ii): ibuprofen 600 mg t.i.d.; 10 days (N = 52)
Outcomes Oswestry LBP disability questionnaire, pre-mean (SD), post-mean day 10 (SD): (i, N = 52) 35.8 (15.0),
10.0 (10.8); (ii, N = 52) 35.1 (19.1), 16.5 (19.0), (i) vs (ii) significantly lower (P < 0.05)
Average pain intensity and relief scores (100-mm VAS), pre-mean (SD), post-mean day 10 (SD): (i, N =
52) 57.9 (20.6), 12.8 (15.4); (ii, N = 52) 55.2 (21.4), 18.5 (19.9). No significant differences
Adverse events: (i) 7 participants = 13% (2 withdrew); (ii) 11 participants = 21% (1 withdrew)
Funding Partially supported by Rhône-Poulenc, a pharmaceutical company. Drugs supplied by Helsinn Health-
care SA, patent holder of nimesulide.
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)








All outcomes - partici-
pants




All outcomes - care-
providers
Low risk Double-blind, double-dummy
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Low risk Double-blind, double-dummy
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
Low risk Low dropout rate: 4.8% (5/104 withdrew)
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
Unclear risk Trial registration not mentioned
Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar
Pohjolainen 2000  (Continued)
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Co-interventions avoided
or similar
Low risk No therapy other than the study medication was permitted during the trial. No
analgesics, muscle relaxants, topical preparations, local injections or non-drug
therapies (e.g. physiotherapy, massage, or bedrest) were permitted.
Compliance acceptable Unclear risk Participants were asked to return any unused medication. The monitor count-
ed the numbers of unused pills and decided whether the participant had been
compliant. Compliance criteria were assessed by the following: instances of




Low risk Timing similar




Methods RCT. Randomisation procedure not described
Follow-up time: 6 months (3 weeks, 2 and 6 months)
Information extracted from Group I, Subgroup A (acute low back pain) and Group II, Subgroup A (acute
back pain radiating to the buttocks and/or thighs and no neurological deficit)
Participants Population: Group I, Subgroup A = 76 participants and Group II, Subgroup A = 83 participants; in total
159 participants with acute LBP (Group I = 271 participants; Group II = 188 participants. Respectively
235 and 163 after retracting the participants lost to follow-up or who interrupted or changed their as-
signed treatment), 34 women, 42 men. Mean age 36.3 years (I A) and 37.7 (II A) (range 17 to 58)
Setting: two Low Back Clinics in Rome, Italy, between January 1985 and October 1986
Inclusion criteria: age 17 to 59 years; acute LBP of less than 4 weeks duration, no LBP in preceding six
months
Exclusion criteria: neoplastic or infectious diseases of the spine, pregnant or nursing women, serious
general diseases, psychiatric disturbances or medico-legal litigation
Interventions NSAID (i): diclofenac 'full dosage', 10 to 14 days (acute participants) (N = 16 and 18 (I A and II A))
Reference treatment (ii): chiropractic manipulation (N = 17 and 18 (I A and II A))
Reference treatment (iii): physiotherapy (N = 15 and 16 (I A and II A))
Reference treatment (iv): bedrest (N = 15 and 14 (I A and II A))
Reference treatment (v): placebo (anti-oedema gel; (N = 13 and 17 (I A and II A))
Outcomes Mean improvement on combined pain, disability, and spinal mobility score (range 5 to 32 from poor to
excellent clinical status) after 3 wks, 2 and 6 months
Group I subgroup A: (i) 3.0, 10.7, 14.0 (ii) 7.5, 9.7, 12.3 (iii) 5.0, 8.4, 10.2 (iv) 5.4, 7.5, 7.3 (v) 1.8, 7.3, 11.0.
(ii) significantly better than others after 3 wks; no other differences. After 2 and 6 months no significant
differences
Group II subgroup A: (i) 4.7, 8.7, 10.3 (ii) 6.3, 9.2, 12.1 (iii) 3.7, 6.0, 10.1 (iv) 4.1, 5.7, 10.3 (v) 2.2, 5.1, 9.8. (ii)
significantly better than others after 3 wks (P < 0.05). No other differences. After 2 and 6 months no sig-
nificant differences
No data on side-effects reported
Funding Not mentioned
Postacchini 1988 
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Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation procedure not described
Allocation concealment
(selection bias)
Unclear risk An approximately equal number of participants was assigned to each type of




All outcomes - partici-
pants




All outcomes - care-
providers
Unclear risk Not mentioned
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
High risk Dropout rate: 13% in Group I (36/271 withdrew), 13% in Group II (25/188 with-
drew). Unclear how many in Subgroup A.
"The present study did not include a control group of untreated patients, be-
cause only a few patients agreed to undergo no treatment and most of them
were lost to follow-up"; this additional placebo group not mentioned in re-
sults, not clear how many people in this group originally
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
High risk In the discussion, they mentioned that a control group of untreated partici-
pants was not included, because only a few participants agreed to undergo no
treatment and most of them were lost to follow-up. In the methods, they do
not mention this group.
Similarity at baseline char-
acteristics
Unclear risk Not mentioned in detail
Co-interventions avoided
or similar
Unclear risk Not mentioned
Compliance acceptable Unclear risk Not mentioned
Timing outcome assess-
ments similar
Low risk Timing similar
Postacchini 1988  (Continued)
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Methods RCT; double-blind; multicentre. Randomisation procedure not described
Follow-up time: 8 days
Participants Population: 227 participants, mainly from general practices, 85 women, 142 men. Mean age 45.3 (SD ±
10.1) years
Setting: 15 centres in Germany, (mainly) general practices, March 2000 to October 2000
Inclusion criteria: age 20 to 65 years; localised, uncomplicated, acute LBP associated with degenera-
tive spinal disorders; participants having pain without analgesic therapy during previous 24 hours; and
with a pain intensity score at rest of at least 60 on a 100-mm VAS
Exclusion criteria: suspicion of serious underlying spinal condition (e.g. sciatica), non-specific back
symptoms related to abdominal, pelvic, or thoracic pathology; prior neurological deficits in lower ex-
tremities; surgery for LBP; lumbosacral facet syndrome; history of haematological or bleeding disor-
ders; severe cardiac, hepatic, or renal insufficiency; severe hypertension; connective tissue diseases;
history of GI ulcer or bleeding; hypersensitivity to aspirin or NSAIDs; alcohol/drug abuse; pregnant/lac-
tating
Interventions NSAID (i): aceclofenac 100 mg b.i.d., 10 days or until asymptomatic (N = 114)
NSAID (ii): diclofenac 75 mg b.i.d., 10 days or until asymptomatic (N = 113)
Outcomes Mean change in pain score (100-mm VAS), from baseline, after 8 to 10 days (SD): (i, N = 114) -62.4 (24.5);
(ii, N = 113) -56.8 (22.6); (ITT analysis, N = 227).
QBPDS (functional disability score) change (%), from baseline, after 4 days (SD): (i, N = 100) 25.5 (14.8);
(ii, N = 105) 20.6 (12.1); (PP analysis, N = 205)
Adverse events: (i) 17 participants (14.9%); (ii) 18 participants (15.9%), none withdrew because of AEs
Funding Funding not mentioned. Sponsor UCB Pharma (developer of aceclofenac)
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Low risk Each drug package was identified by a unique code number and was delivered
to the participant according to the ascending order of their number. Sealed
emergency envelopes with identity of the drugs kept in a secure place, to be
opened only in case of a medical emergency, to be returned to the sponsor at




All outcomes - partici-
pants
Unclear risk Double-blind, no double-dummy
Schattenkirchner 2003 
Non-steroidal anti-inflammatory drugs for acute low back pain (Review)













All outcomes - care-
providers
Low risk Double-blind. No person conducting the trial had access to the randomisation
list before the study was unblinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
Low risk Low dropout rate: 4.4% (10/227 withdrew). (i) 6 early cure; (ii) 1 early cure, 2
lack of efficacy, 1 personal reasons
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Low risk ITT analysis performed
Selective reporting (re-
porting bias)
Unclear risk Study protocol mentioned in manuscript, but not registered
Similarity at baseline char-
acteristics
Unclear risk According to text, similar baseline characteristics in both treatment groups,
but data were not shown, no table 1.
Co-interventions avoided
or similar
Low risk During the study, participants were not allowed to take any other NSAIDs (ex-
cept for the study medication), muscle relaxants, benzodiazepines, analgesics,
corticosteroids, or coumarinics, or to receive physical or chirotherapy
Compliance acceptable Unclear risk Compliance was assessed by the recordings in the participant diaries. (Un-
used) study medication was not collected.
Timing outcome assess-
ments similar
Low risk Timing similar





Follow-up time: 24 weeks
Outcomes measured at baseline, 30 minutes, after 2, 4, and 24 weeks
Participants Population: 58 participants, 24 women and 34 men. Mean age (SD): 38.31 (7.97) years
Setting: 2 hospitals in South Korea
Inclusion: participants 20 to 60 years with acute LBP of < 4 weeks duration, with or without radiating
pain to the limb with an Oswestry Disability Index (ODI) value ≥ 60% as an indicator of severe disability
Exclusion: serious disease that could cause LBP (e.g. cancer, vertebral fracture, spinal infection);
chronic disease that could interfere with the effect of the treatment or the interpretation of treat-
ment results (e.g. cardiovascular disease, diabetic neuropathy, fibromyalgia); progressive neurologi-
cal deficit or severe neurological symptoms; conditions inappropriate or unsafe for acupuncture (e.g.
Shin 2013 
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haemorrhagic disease, blood coagulation disorders); current intake of corticosteroids, immunosup-
pressant drugs, psychiatric medicine; experience of gastrointestinal side effects after taking NSAIDs, or
current treatment for gastrointestinal disease; pregnancy; and reluctance to accept the treatment regi-
mens or examinations (e.g. X-ray, MRI) of this study
Interventions NSAID (i): NSAID injection group, received 1 IM injection of conventional diclofenac (N = 29); FU at 30
minutes, 2, 4, and 24 weeks
Reference treatment (ii): Motion Style Acupuncture Treatment (MSAT) group, received 1 session of
MSAT (N = 29); FU at 30 minutes, 2, 4, and 24 weeks
Outcomes Mean (SD) pain intensity change from baseline (NRS 0 to 10): (i) 4.17 (3.05), (ii) 5.83 (2.61), P = 0.0305 (2
weeks); (i) 6.84 (1.9), (ii) 6.64 (2.47), P = 0.7221 (24 weeks)
Mean improvement in functional status (Oswestry Disability Index) from baseline: (i) 36.34 (29.1), (ii)
56.41 (24.86), P = 0.0066 (2 weeks); (i) 80.83 (13.58), (ii) 73.23 (20.24), P = 0.0995 (24 weeks)
Patient global impression of change (PGIC; subjective assessment of improvement): no outcomes at
relevant time points
Adverse events: there were no adverse events reported
Funding Not mentioned
Notes In both groups, the selection of treatment after the initial treatment session was not restricted because
of ethical reasons. This implies the results after the first follow-up at 30 minutes are not clean, and are
difficult to generalise.
Declaration of interest: one of the authors was supported by the Korea Institute of Oriental Medicine.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random allocation sequence generated by statistician
not involved in data collection or analysis.
Allocation concealment
(selection bias)
Low risk Randomised numbers were kept in sealed envelopes by a researcher who had




All outcomes - partici-
pants
High risk Blinding of participants and practitioners was not possible because of the na-




All outcomes - care-
providers
High risk Blinding of participants and practitioners was not possible because of the na-
ture of the treatment.
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Unclear risk Assessor-blinding was achieved by blinding the assessor performing outcome
assessment and case report form (CRF) data entry to the random allocation.
Statistical analysis was performed by an independent statistician who was
blinded to the identification of each treatment group, but blinding of partici-
pants not possible; therefore unclear risk.
Incomplete outcome data
(attrition bias) 
Unclear risk Not clearly mentioned, but outcomes presented after 2, 4, 24 weeks for the fol-
lowing number of participants: (i) N = 23, 20, 27; (ii) N = 25, 21, 24.
Shin 2013  (Continued)
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All outcomes - dropouts
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Low risk ITT analysis was performed
Selective reporting (re-
porting bias)
Low risk Trial was registered
Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar
Co-interventions avoided
or similar
High risk Choice for participants for inpatient or outpatient treatment. Inpatients re-
ceived an integrative package (herbal medicine, Chuna manipulation, bee ven-
om pharmaco-acupuncture, acupuncture) for 5 sessions a week, outpatients
received 1 to 2 sessions a week. In both groups, the selection of treatment af-
ter the initial treatment session was not restricted because of ethical reasons.
This implies the results after the first follow-up at 30 minutes are not clean and
difficult to generalise.
Compliance acceptable Unclear risk Not applicable
Timing outcome assess-
ments similar
Unclear risk Timing similar




Methods RCT; single-blind, multicentre study. Randomization procedure not described. Article in German.
Follow-up time: 3-5 days (baseline and final measurements; maximum follow-up time 2 days after the
last IM injection).
Participants Population: 96 participants with acute LBP, 49 women, 47 men; mean age 50.8 years, aged between 16
and 78 years
Setting: participants visiting four participating physicians, conducted in Germany
Inclusion criteria: first episode of acute lumbago, or acute onset after a long symptom-free period
Exclusion criteria: age < 14 years, pregnancy or lactation, allergy, current use of corticosteroid or an-
ti-rheumatic treatment with half-life > 24 hours, other NSAIDs or anticoagulant treatment
Interventions NSAID (i): diclofenac-natrium IM 3 mL (= 75mg), 1 to 3 injections (with a minimum of 16 hours between
injections), 1 to 3 days (N = 47)
NSAID (ii): etofenamat (Rheumon®) IM 2 mL (= 1000 mg), 1 to 3 injections (with a minimum of 16 hours
between injections), 1 to 3 days (N = 49)
Outcomes Similar amount of IM injections was needed in both groups, no significant differences.
Mean pain score (11-point NRS), at baseline and after 3 to 5 days: (i) 5.3, 2.7, (ii) 5.3, 2.4
No. of participants recovered after 3 to 5 days (therapeutic success: 'good' or 'very good'): (i) 27/47, (ii)
34/49. Not significant
Adverse events: (i) 2 (none withdrew), (ii) 0 (none withdrew)
Stratz 1990 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation procedure not described
Allocation concealment
(selection bias)




All outcomes - partici-
pants




All outcomes - care-
providers
High risk Careproviders were not blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
Low risk Low dropout rate: 1/96 = 1%
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
Unclear risk No study protocol
Similarity at baseline char-
acteristics
Unclear risk Baseline characteristics similar according to text, but no Table 1 available.
Co-interventions avoided
or similar
Low risk No use of anti-rheumatica, anti-flogisti or analgesic medication other than
study drug. No use of corticosteroids. If further treatment with oral or topical
NSAIDs was necessary after injections, this was recorded. This was the case in
(i) 28/47 (60%) and (ii) 23/49 (47%) of the participants.
Compliance acceptable Low risk 1 person in group (i) (diclofenac IM) withdrew after the first injection, because




High risk Timing not similar; final measurements 2 days after last injection, this could be
either after the first, second, or third injection.
Stratz 1990  (Continued)
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Methods RCT; use of randomisation table
Follow-up time: 14 days (clinical assessment at days 0 and 14)
Participants Population: 110 participants, 51 women, 59 men. Mean age (SD): 40.2 (13.7) years
Setting: an outpatient department (October 1988 to March 1999), conducted in Belgium
Inclusion criteria: acute LBP, pain present < 2 weeks, asymptomatic period of at least 4 months
Exclusion criteria: LBP related to industrial accident covered by insurance, specific (spinal) pathology,
such as disc protrusion or spinal trauma
Interventions NSAID (i): tenoxicam 20 mg, 1 tablet daily (14 days), and bedrest (7 days strict, 7 days intermittent; (N =
49)
Reference treatment (ii): bedrest, (7 days strict, 7 days intermittent; (N = 50)
Outcomes Mean % improvement (SD) between baseline and 14 days in ROM (i) 123 (24), (ii) 114 (23); significant (P
< 0.05)
After 14 days of treatment: 86% (i) versus 70% (ii) no need for further treatment
Adverse events: (i) 2 participants (2 withdrew)
Funding Not mentioned
Notes Physical examination only outcome. Outcome presented as percentages, baseline values not present-
ed.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk A randomisation table was used
Allocation concealment
(selection bias)




All outcomes - partici-
pants




All outcomes - care-
providers
High risk Not blinded
Blinding of outcome as-
sessment (detection bias) 
High risk Not blinded
Szpalski 1990 
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All outcomes - dropouts
Low risk Low dropout rate: 10% (11/110)
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
Unclear risk No study protocol
Similarity at baseline char-
acteristics




Unclear risk Not mentioned
Compliance acceptable Unclear risk Not mentioned
Timing outcome assess-
ments similar
Low risk Timing similar




Methods RCT; double-blind, placebo-controlled. Randomisation procedure not described
Follow-up time: 15 days (clinical evaluation at days 1, 8, and 15)
Participants Population source: 73 participants, 26 women, 47 men. Mean age approximately 38 years
Setting: not mentioned
Inclusion criteria: acute LBP, pain present for less than 2 weeks, first presentation or first reappear-
ance after an asymptomatic period of at least 6 months
Exclusion criteria: work accident covered by worker's compensation, spinal pathology (e.g. herniated
disc or spinal trauma), pregnancy or lactation, hypersensitivity to NSAIDs, history of gastrointestinal ul-
ceration, current use of NSAIDs, anticoagulants, oral antidiabetics, or lithium
Interventions NSAID (i): tenoxicam 20 mg IM injection on day 1 + 20 mg capsules, 1 per day, for day 2 to 14 (+ 7 days
bedrest; (N = 37))
Reference treatment (ii): placebo IM injection on day 1 + placebo capsules, 1 per day, for day 2 to 14
(+ 7 days bedrest; (N = 36))
Outcomes Mean pain intensity on VAS on day 1, 8, and 15 (SD): (i) 7.4 (1.5), 1.9 (2.0), 0.6 (1.1); (ii) 7.1 (2.0), 2.8 (2.0),
0.8 (1.1). (i) significantly better on day 8 (P = 0.043).
Overall clinical assessment by the investigator after 1 week: (i) 27/33 (82%), (ii) 20/35 (57%) either
markedly improved or cured, no significant differences
Adverse events: (i) 1 participant (none withdrew)
Szpalski 1994 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation procedure not described
Allocation concealment
(selection bias)




All outcomes - partici-
pants
Low risk Double-blind, double-dummy: active and placebo tablets were matched in ap-




All outcomes - care-
providers
Low risk Double-blind, double-dummy
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Low risk Double-blind, double-dummy
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
Low risk Low dropout rate: 6.8% (5/73)
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Low risk ITT analysis performed. 5 participants were not evaluated as they did not re-
turn for follow-up after the baseline visit (4 from (i) and 1 from (ii)).
Selective reporting (re-
porting bias)
Unclear risk No study protocol
Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar
Co-interventions avoided
or similar
Unclear risk Not mentioned
Compliance acceptable Unclear risk Not mentioned
Timing outcome assess-
ments similar
Low risk Timing similar
Other bias Low risk None
Szpalski 1994  (Continued)
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Methods RCT; double-blind. Randomisation procedure not described.
Follow-up time: 3 weeks
Participants Population: 70 participants, 29 women, 41 men. Mean age 37 years (age range 20 to 64)
Setting: outpatient clinic, conducted in Finland
Inclusion criteria: acute LBP, duration from 1 day to 30 days
Exclusion criteria: pregnant or nursing women; haematological, renal, hepatic, respiratory, or circula-
tory disorders; history of peptic ulceration or gastro-intestinal upset; sensitivity or dependence to nar-
cotic analgesics or benzomorphan derivatives, weight < 45 kg or > 95 kg
Interventions NSAID (i): diflunisal 250 mg, 1 capsule q.i.d., and 1 placebo tablet q.i.d., 3 weeks (N = 35)
Reference treatment (ii): meptazinol 200 mg, 1 tablet q.i.d., and 1 placebo capsule q.i.d., 3 weeks (N =
35)
Outcomes Mean change in degree of pain on 100-mm visual analogue scale at three weeks (i) 45 (ii) 40. Similar im-
provement regarding capacity for daily tasks (data in graphs). No significant differences




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation procedure not described
Allocation concealment
(selection bias)




All outcomes - partici-
pants




All outcomes - care-
providers
Low risk Double-blind, double-dummy
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Low risk Double-blind, double-dummy
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
Low risk Low dropout rate: 2.9% (2/70)
Videman 1984 
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Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
Unclear risk No study protocol
Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar
Co-interventions avoided
or similar
Unclear risk Not mentioned
Compliance acceptable Unclear risk Not mentioned
Timing outcome assess-
ments similar
Low risk Timing similar




Methods RCT, double-blind, double-dummy design
Follow-up time: 12 weeks. Outcome measurements: before treatment, after 3 days, between 7 and 9
days after treatment
Participants Population: 101 participants randomised; 69 during initial 3-arm phase, 32 during 2-arm phase. N = 1:
no treatment registered; N = 100 received treatment
Setting: 5 outpatient orthopaedic or general practices in 4 different cities in Germany, between Febru-
ary 2003 and September 2008 (interim analysis June 2006)
Inclusion criteria: people aged 18 to 55 years, presenting with acute (for < 48 hr before randomisation)
LBP, and written informed consent
Exclusion criteria: known intolerance to NSAID or paracetamol, occurrence of LBP or spinal manipu-
lation for any cause within the last 3 months, known or suspected abuse of alcohol or drugs, metabol-
ic, or malignant, or any serious organic or neurological disease, atopic diathesis, any structural distur-
bances of the spine (osteoporosis, scoliosis, disc herniation, spondylolisthesis, hip dysplasia, and oth-
ers). Women with childbearing potential had to undertake effective contraception. For real sham ma-
nipulation, people with dysfunction of the sacroiliac joint (SIJ) were excluded (by functional and pain-
provocation tests).
Interventions NSAID (i): Sham manipulation and Diclofenac 50 mg, t.i.d.; 7 to 9 days (N = 37)
Reference treatment (ii): Spinal manipulation and diclofenac-like placebo, t.i.d.; 7 to 9 days (N = 38)
Reference treatment (iii): Sham manipulation and diclofenac-like placebo t.i.d.; 7 to 9 days (N = 25);
placebo-arm was closed after an interim-analysis with 69 subjects who completed the study
Outcomes Mean change in disability (RMDQ, 0 to 24) from baseline to 7 to 9 days (SD): (i) 4.75 (4.93), (ii) 7.71 (4.88)
Pain intensity 100-mm VAS: data shown in graph. Comparison between both active treatments and
placebo only, and comparison of diclofenac vs spinal manipulation
Quality of life (SF-12): data shown in graph
von Heymann 2013 
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Cumulative dose of and number of days of rescue medication taken: (i) 6.41 (10.67) and 1.92 (2.61); (ii)
2.22 (3.73) and 1.19 (1.77); no significant differences
OF-work time (days): (i) 1.80 (2.10), (ii) 1.24 (1.69); no significant differences
Overall clinical impression by blinded investigator after 3 and 7 to 9 days (complete relief or improved):
(i) 20/37 (54%) and 21/37 (57%); (ii) 30/35 (86%), 29/35 (83%)
Adverse events: none were registered
Funding Funding by the German Organization for Manual Medicin (Deutsche GesellschaI fúr Manuelle Medizin,
DGMM), and doctors seminar for manual spine- and extremities therapy (Aerzteseminar fúr Manuelle
Wirbelsaeulen- und Extremitaetentherapie, MWE). The first author is a member of the board of DGMM.
No other conflicts of interest regarding any medical measures tested.
Notes An interim analysis was performed when 69 participants completed the study. Due to statistically sig-
nificant superiority of active compared with placebo treatment, the placebo arm was closed. The trial
continued with 2 active treatment groups.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk participants were randomised using a phone call to the involved and responsi-
ble Institute of Biometrics.
Allocation concealment
(selection bias)
Low risk Numbered folders and numbered boxes with the trial medication; both di-
clofenac and placebo prepared in an identical way. After a phone call to the
biometric institute, the physician received the randomised number of the fold-




All outcomes - partici-
pants




All outcomes - care-
providers
High risk Sham manipulation could only be performed in single-blind manner. Outcome
assessment took place by another physician (blinded investigator).
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors




All outcomes - dropouts
High risk > 20% dropouts in placebo group
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Low risk ITT analysis performed: "93 subjects were evaluable and formed the collective
intention-to-treat (22 placebo, 36 diclofenac, 35 spinal manipulation)"
Selective reporting (re-
porting bias)
Low risk Protocol is available on request in German
von Heymann 2013  (Continued)
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Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar
Co-interventions avoided
or similar
Low risk Paracetamol 500 mg, maximum 6 tablets a day, was used as rescue medica-
tion. No other concomitant analgesic medication, acupuncture, or homeopa-
thy was allowed.




Low risk Timing of outcome assessments similar




Methods RCT. Randomisation procedure not described
Follow-up time: 12 days (clinical assessment day 0; after 3 to 4 days and 10 to 12 days)
Participants Population: 112 participants, 38 women, 70 men. Aged 18 to 50 years
Setting: participants with LBP presenting to their general practitioner, conducted in New Zealand
Inclusion criteria: sudden onset of moderate to severe LBP, with or without radiation to the back of
the thighs, aggravated by sitting or physical activity, relieved by rest, present for less than 1 month;
pain at least bothersome with a considerable degree of functional incapacity
Exclusion criteria: established spinal disorders; pregnant women; aspirin hypersensitivity; long-term
use of NSAIDs, steroids or anticoagulants; haematological, renal ,or hepatic disease; history of peptic
ulcer
Interventions NSAID (i): diflunisal 500 mg capsules: 1000 mg immediately, then 500 mg b.i.d., 10 days (N = 36)
Reference treatment (ii): physiotherapy: local heat, ultrasound, and exercises (5 weekly sessions of
45 minutes; (N = 34))
Reference treatment (iii): spinal manipulation and/or McKenzie therapy (5 sessions of 45 minutes
weekly; (N = 38))
Outcomes Mean change in pain intensity on 4-point scale after 4 and 12 days: (i) -0.9, -1.7 (ii) -0.9, -1.6 (iii) -1.1, -1.7.
No significant differences in pain and mobility.
Global improvement measured with a good or excellent overall response as rated by the participants:
(i) 77%, (ii) 70%, (iii) 73%
Adverse effects: (i) 2 participants; not measured in other groups
Funding Funding by the hospital foundation
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation procedure not described
Waterworth 1985 
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Allocation concealment
(selection bias)




All outcomes - partici-
pants




All outcomes - care-
providers
High risk Not blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
High risk Not blinded
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
Low risk Low dropout rate: 3.6% (4/112)
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Unclear risk Not mentioned
Selective reporting (re-
porting bias)
Unclear risk No study protocol
Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar
Co-interventions avoided
or similar
Low risk During the study period, daytime bedrest, muscle relaxant drugs, local anaes-
thetic or steroid infiltration into the back, acupuncture, etc. were not permit-
ted.
Compliance acceptable Unclear risk Not mentioned
Timing outcome assess-
ments similar
Low risk Timing similar




Methods RCT; randomisation procedure not described; prospective study
Follow-up time: 2 weeks
Participants Population: 45 participants admitted to a military hospital for bedrest, all men, aged 17 to 34 years
(mean age 23 years)
Setting: army hospital in the USA
Wiesel 1980 
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Inclusion criteria: non-radiating LBP, no previous back pain, normal neurologic and straight leg rais-
ing results, normal lumbar roentgenograms
Exclusion criteria: discovering entities, such as spina bifida, on the roentgenogram
Interventions All participants were admitted to the army hospital for bedrest.
NSAID (i): aspirin 625 mg capsules, 4 times per day, 2 weeks (N = 15)
NSAID (ii): phenylbutazone 100 mg capsules, 4 times per day (first 5 days), no further information (N =
15)
Reference treatment (iii): acetaminophen (dosage not given), twice daily, 2 weeks (N = 15)
Outcomes Mean no. of days before return to full activity (i) 5.7 (ii) 6.5 (iii) 5.7. No significant differences.
No data on side-effects given.
Funding Not mentioned
Notes Study population consisted of young, US army men (combat trainees), which is a different population
than usual.
Phenylbutazone was taken oF the market due to severe adverse effects.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation procedure not described
Allocation concealment
(selection bias)




All outcomes - partici-
pants




All outcomes - care-
providers
High risk Not blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
High risk Not blinded
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
Unclear risk Not mentioned
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Unclear risk Not mentioned
Wiesel 1980  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk No study protocol
Similarity at baseline char-
acteristics
Unclear risk Baseline characteristics not mentioned for study section on NSAIDs
Co-interventions avoided
or similar
Unclear risk Not mentioned
Compliance acceptable Unclear risk Not mentioned
Timing outcome assess-
ments similar
Low risk Timing similar




Methods RCT; double-blind, double-dummy; multicentre
Follow-up time: 7 days. Adverse events were monitored until 30 days after the final administration of
the study drug.
Participants Population: 340 participants, 173 women, 167 men. Mean age (SD): (i) 41.6 (11.7), (ii) 40.1 (12.7)
Setting: 31 centres in 9 Latin American countries (Brazil, Venezuela, Ecuador, Argentina, Chile, Mexico,
Colombia, Costa Rica, and Peru), November 2002 to May 2003
Inclusion criteria: age 18 to 65 years, acute LBP, duration of ≤ 72 hours, no previous episodes of acute
LBP in the previous 6 weeks, VAS pain score ≥ 50 mm (100-mm scale) and moderate to severe pain (cat-
egorical scale)
Exclusion criteria: back pain of neurologic etiology, back pain did not qualify as a Quebec Task Force
class 1a or 2a; presence of inflammatory conditions (e.g. arthritis), conditions of chronic pain, malig-
nancy or IBD; uncontrolled hypertensive, hepatic, or renal disorders; participants subject of active
workers compensation or litigation cases; history of allergic reactions to NSAIDs or sulfonamides; preg-
nant or lactating women
Interventions NSAIDs (i): valdecoxib 40 mg daily, with a second dose on day 1; 7 days (N = 170)
NSAIDs (ii): diclofenac 75 mg b.i.d.; 7 days (N = 170)
Outcomes Mean difference (95% CI) pain intensity scale (100-mm VAS) at 7 days; (i, N = 167 vs ii, N = 166) 0.26
(-3.76 to 4.28)
Mean difference (95% CI) Oswestry LBPDQ (0 to 24-point scale) at 7 days; (i vs ii) 0.02% (-3.21 to 3.16)
Adverse events (no of participants, % (95% CI)): (i, N = 170) 48 participants, 28.2% (21.7 to 35.7%), (0
withdrew); (ii, N = 170) 44 participants, 25.9% (19.6% to 33.3%), (4 withdrew)
Funding Funded by Pfizer Inc., manufacturer of Valdecoxib. Editorial support provided by C. Scott, MD at Parex-
el, (biopharmaceutical R&D company).
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Ximenes 2007 
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Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation schedule generated by the study sponsor
before the start of the study; stratified by categorical baseline pain intensity
(moderate or severe), 1:1
Allocation concealment
(selection bias)




All outcomes - partici-
pants
Unclear risk Double-blind concept, it was written that it was double-dummy, but the fre-
quency of administration differs between both types of NSAIDs (one or two
times a day). It is unclear how "all patients and study personnel were blinded




All outcomes - care-
providers
Unclear risk Double-blind concept, but unclear if it was double-dummy.
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Unclear risk Double-blind concept, but unclear if it was double-dummy.
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
Low risk Low dropout rate: 7% (24/340 withdrew)
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Low risk MITT (modified intention-to-treat) analysis performed
Selective reporting (re-
porting bias)
Unclear risk Study protocol not mentioned
Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar
Co-interventions avoided
or similar
Unclear risk Not mentioned
Compliance acceptable Unclear risk Not mentioned
Timing outcome assess-
ments similar
Low risk Timing similar




Methods RCT; double-blind, double-dummy; multicentre
Follow-up time: 7 days
Participants Population: 220 participants, sex not mentioned. Mean age (SD): (i) 39.3 (9.1); (ii) 40.3 (9.7)
Yakhno 2006 
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Setting: 6 centres in Russia
Inclusion criteria: age 18 to 55 years, nonspecific acute LBP, duration ≤ 5 days, pain score ≥ 5 on 11-
point NRS, requiring medical treatment
Exclusion criteria: pregnant or breastfeeding women; previous episode of LBP within the last 6
months; specific spinal pathology or symptoms related to other pathologies; intake of analgesics ≤ 3
hrs preceding inclusion; intake of antiepileptics, antidepressants, barbiturates, anxiolytics, or mus-
cle relaxants ≤ 24 hrs preceding inclusion; scheduled daily intake of one of the above medications;
concomitant treatment with anticoagulants or platelet-aggregation inhibitors; contraindication or al-
lergy to study drugs; alcohol/drug abuse/dependency; episodes of GI disorders, oedema, dizziness,
headache; history of aspirin-induced asthma
Interventions NSAIDs (i): lornoxicam on day 1: 16 mg once a day and 8 mg once a day; day 2 to 7: 8 mg b.i.d.; 7 days
(N = 110) + matching (diclofenac-like) placebo
NSAIDs (ii): diclofenac-k on day 1: 100 mg once a day and 50 mg once a day; day 2 to 7: 50 mg b.i.d.; 7
days (N = 110) + matching (lornoxicam-like) placebo
Outcomes Sum of pain intensity differences from baseline on day 1 to 6 (SE); (i, N = 109) 4.2 (0.17); (ii, N = 110) 3.8
(0.17); (i) significantly lower than (ii) P < 0.05
Adverse events (no of participants, %): (i) 27 participants (24.5%), 1 withdrew; (ii) 28 participants
(25.5%), 1 withdrew
Funding Study was supported by an unrestricted grant from Nycomed, manufacturer of lornoxicam.
Notes Inadequate dosage of diclofenac-k (50 mg b.i.d. instead of t.i.d.)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation schedule
Allocation concealment
(selection bias)
Low risk A computer-generated randomisation schedule assigned treatments in equal
ratio to sequential participants. Participants were assigned to the next consec-




All outcomes - partici-
pants




All outcomes - care-
providers
Low risk Double-blind, double-dummy
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Low risk Double-blind, double-dummy
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
Low risk Low dropout rate: 1.4% (3/220)
Yakhno 2006  (Continued)
Non-steroidal anti-inflammatory drugs for acute low back pain (Review)









Cochrane Database of Systematic Reviews
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Low risk ITT analysis performed
Selective reporting (re-
porting bias)
Unclear risk Study protocol registration not mentioned
Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar
Co-interventions avoided
or similar
Unclear risk Paracetamol (acetaminophen) was allowed as rescue medication.
Compliance acceptable Unclear risk Not mentioned
Timing outcome assess-
ments similar
Low risk Timing similar




Methods RCT, double-blind (non-inferiority study)
Follow-up time: 2 days
Participants Population: 370 participants, 202 women and 168 men; mean age ± SD (range): dexketoprofen group:
48.5 ± 13.31 (21 to 75), diclofenac group: 50.0 ± 13.26 (20 to 74)
Setting: multicentre trial conducted in 21 centres in Belgium, Germany, and Poland
Inclusion: male/female outpatients aged 18 to 75 years with acute low back pain of moderate to severe
intensity (≥ 50 mm on a visual analogue scale (VAS)), and of no more than 1 week's duration
Exclusion: low back pain secondary to systemic or degenerative diseases, vertebral fractures or com-
pressions; intervertebral disc hernia; neoplastic, infectious or metabolic diseases; and neurological
pain. General contraindications to the use of NSAIDs. Concomitant treatment with steroidal drugs, al-
ternative therapies, and use of any analgesic within 6 hours prior to inclusion in the study
Interventions NSAID (i): dexketoprofen 50 mg IM (Menarini, Florence, Italy), twice daily; 2 days (N = 183)
NSAID (ii): diclofenac 75 mg IM (Voltarol®, Novartis Pharmaceuticals Ltd, Horsham, West Sussex, UK),
twice daily; 2 days (N = 187)
Outcomes Outcomes in ITT population
Mean (± SD) changes in sum of analogue pain intensity difference scores (SAPID0-6) from baseline to 6
hours after the first dose
111.8 ± 116.54 (i) versus 112.7 ± 105.71 (ii). Adjusted mean 111.9 (i) and 112.7 (ii); Adjusted ratio of
means 0.993. 95% lower CI (two-sided) 0.79
Adjusted mean SAPID0-last score was 296.0 mm/h in (i) and 283.8 mm/h in (ii), with no statistical differ-
ences between treatments (P = 0.567).
The median change in RDQ scores was -6.0 for both treatment groups (P = 0.695), showing an improve-
ment on the disability scale
Zippel 2007 
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Rescue medication: taken by 39% of participants in (i) and 33% of participants in (ii), no statistical dif-
ferences between treatments (P = 0.235)
Adverse events: (i) 50/183 = 27% (4 participants withdrew), (ii) 58/187 = 31% (2 participants withdrew)
Funding Financially supported by a grant from Menarini Ricerche SpA, Florence, Italy (manufacturer of dexketo-
profen). Not mentioned if they had a role in study design, data collection, or analysis.
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)








All outcomes - partici-
pants
Low risk Study drugs were administered by a person from outside the investigational




All outcomes - care-
providers
Unclear risk Study drugs were administered by a person from outside the investigational
team. It was unclear if this was their own careprovider.
Blinding of outcome as-
sessment (detection bias) 
All outcomes - outcome
assessors
Low risk Study drugs were administered by a person from outside the investigational
team in order to maintain the double-blind nature of the study.
Incomplete outcome data
(attrition bias) 
All outcomes - dropouts
Low risk (i) 10/173 participants withdrew, (ii) 10/177 participants withdrew
Incomplete outcome data
(attrition bias) 
All outcomes - ITT analy-
sis
Low risk ITT analysis performed
Selective reporting (re-
porting bias)
Unclear risk Trial registration not mentioned
Similarity at baseline char-
acteristics
Low risk Baseline characteristics similar
Co-interventions avoided
or similar
Low risk Paracetamol 500 mg, maximum 3g a day, was used as rescue medication.
Compliance acceptable Unclear risk Compliance was not mentioned, (unused) study medication was not collected.
Zippel 2007  (Continued)
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Timing outcome assess-
ments similar
Low risk Timing similar
Other bias Low risk None
Zippel 2007  (Continued)
b.i.d. = twice a day; CI = confidence interval; CRF = case report form; FU = follow-up; GI = gastrointestinal; GP = general practitioner; IM =
intramuscular; ITT = intention-to-treat; IV = intravenous; LBP = low back pain; MRI = magnetic resonance imaging; NRS = numeric rating
scale; NSAID = non-steroidal anti-inflammatory drug; PI = pain intensity; PP = per protocol; QBPDS = Quebec Back Pain Disability Scale;
RCT = randomised controlled trial; RMDQ = Roland-Morris Disability Questionnaire; q.i.d.= four times a day; ROM = range of motion; SD
= standard deviation; SLR = straight-leg raise; SF-12/36 = 12 or 36-item Short Form Health Survey; t.i.d. = three times a day; VAS = visual
analogue scale; wks = weeks
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Allegrini 2009 NSAIDs used in both groups, comparison concerned only the mode of administration of the same
NSAID (piroxicam patch versus cream)
Altan 2019 NSAIDs were not evaluated separately: a combination of NSAIDs and myorelaxants was evaluated
Anaya 2014 Not a RCT; clinical series
Arul Prakasam 2011 Not a RCT; prospective study, no randomisation
Berry 1988 NSAIDs used in both groups; only addition of muscle relaxant evaluated
Blazek 1986 No acute LBP; sciatica
Borenstein 1990 NSAIDs used in both groups; only addition of muscle relaxant evaluated
Bruggemann 1990 NSAIDs used in both groups; only addition of vitamins B1/B6/B12 evaluated
Buchbinder 2010 No RCT; commentary on Cochrane Review
Chrubasik 2003 No acute LBP; chronic LBP in flare
Coats 2004 No acute LBP; chronic LBP in flare
Cohen 2017 The pharmacotherapy group could use different types of medication; no subgroup analysis of
NSAID users
Costantino 2011 NSAIDs used in both groups, comparison concerned only the way of administration (mesothera-
peutic versus systemic administration)
Day 2013 No RCT; case report and review
Dehghan 2014 NSAIDs were used in all three groups, no comparison group without NSAIDs. Only addition of ther-
motherapy or cryotherapy evaluated
Dehghan 2015 NSAIDs were used in both groups, no comparison group without NSAIDs. Only addition of
gabapentin evaluated
Driessens 1994 No acute LBP; chronic LBP
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Study Reason for exclusion
Eken 2014 No relevant timing of outcome assessments, follow-up time 30 minutes (minimum follow-up time
for this systematic review is 1 day)
Evans 1980 No acute LBP; chronic LBP in flare
Friedman 2015 NSAIDs were used in all three groups, no comparison group without NSAIDs. Only addition of either
cyclobenzaprine or oxycodone/acetaminophen evaluated
Friedman 2016 NSAIDs were used in both groups, no comparison group without NSAIDs. Only addition of di-
azepam versus placebo evaluated
Friedman 2018 NSAIDs were used in all three groups, no comparison group without NSAIDs. Only addition of either
orphenadrine or methocarbamol versus placebo evaluated.
Geller 2016 NSAIDs were used in both groups, no comparison group without NSAIDs. Only addition of B vita-
mins evaluated.
Górska 2005 NSAIDs used in both groups; no comparison group without NSAIDs. Only addition of muscle relax-
ant evaluated.
Ilic 2009 NSAIDs used in both groups; comparison concerned two generic formulations of the same NSAID
(nimesulide).
Ingpen 1969 No acute LBP; chronic LBP
IRCT2013052213146N2 NSAIDs were used in all groups, no comparison group without NSAIDs.
Kuhlwein 1990 NSAIDs used in both groups; only addition of vitamins B1/B6/B12 evaluated.
Lee 2008 No relevant timing of outcome assessments, follow-up time 1 hour (minimum follow-up time for
this systematic review was 1 day).
Listrat 1990 NSAIDs used in both groups, comparison concerned only the mode of administration of the same
NSAID (tenoxicam tablets versus intramuscular injections).
Matsumo 1981 No acute LBP; chronic LBP
Muckle 1986 No acute LBP; acute lumbar disc syndrome with an affected nerve root
Ostojic 2017 NSAIDs were used both groups, no comparison group without NSAIDs. Only addition of paraceta-
mol evaluated.
Pena 1990 Information derived from a review. The original trial of Bontoux was not found. The reported data
were not sufficient to be part of the current review.
Schreijenberg 2017 No study results available. Study was terminated early because of low recruitment rates.
Serinken 2016 No relevant timing of outcome assessments, follow-up time 30 minutes (minimum follow-up time
for this systematic review was 1 day). NSAIDs used in both groups, only additional topical NSAID gel
vs placebo tested.
Shell 2012 No acute LBP; chronic LBP lasting > 6 weeks, confirmed by corresponding author.
Shikhkerimov 2016 Not a RCT
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Study Reason for exclusion
Siegmeth 1978 No LBP; radiologically confirmed lumbar osteoarthritis. Presence and duration of LBP was not
mentioned.
Stark 2014 Oral NSAIDs were included for blinding purposes only (N = 5).
Vetter 1988 NSAIDs were used in both groups, no comparison group without NSAIDs.
Voicu 2019 A combination of medication was used; NSAIDs were not evaluated separately.
von Uberall 2013 Not a RCT; secondary analysis on 4 non-interventional studies on NSAIDs.
Yastrebov 2012 Not a RCT; no randomisation, intense lumbar pain syndrome, LBP not specifically mentioned.
NSAID = non-steroidal anti-inflammatory drug; LBP = low back pain; RCT = randomised controlled trial
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods RCT; double-blind. Randomisation procedure not described
Follow-up: 14 days. Outcome measurements after 1 and 2 weeks
Participants Population: 237 participants
Inclusion criteria: adults presenting at clinical centres with principal complaint LBP
Exclusion criteria: history of gastrointestinal, hepatic, or renal disease, those with complications
or requiring surgery, history of drug allergy, anticoagulants, abnormal baseline laboratory values,
pregnancy, nursing mothers and women with childbearing potential.
Interventions NSAID (i): piroxicam 20 mg capsules, once per day, 14 days (N = 116)
NSAID (ii): indomethacin 25 mg capsules, three times per day, 14 days (N = 114)
Outcomes Global improvement, adverse events
Notes 1. Duration of LBP is not clear (unspecified)




Methods RCT; double-blind, multicentre. Randomisation procedure not described
Follow-up: 7 days. Outcome measurements after 2, 4, and 7 days
Participants Population and setting: 175 participants from 18 clinics
Inclusion criteria: acute incidence of trauma or musculoskeletal strain, rigid criteria of clinical
pain and spasm for the previous 7 days were required
Interventions NSAID (i): diflunisal capsules 500 mg twice per day (N = 44)
NSAID plus muscle relaxant (ii): diflunisal capsules 500 mg + 5 mg cyclobenzaprine twice per day
(N = 43)
Basmajian 1989 
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Muscle relaxant (iii): cyclobenzaprine (flexeril) capsules 5 mg twice per day (N = 43)
Reference treatment (iv): placebo capsules twice per day (N = 45)
Outcomes Marked improvement, adverse events
Notes 1. Both LBP and neck pain included, no distinction was made; no subgroup analysis




Methods RCT; double-blind, placebo-controlled, cross-over study; computer-generated randomisation
Follow-up: 90 days. Outcome measurements at baseline, 5 minutes, 1, 6, 12, and 24 hours after
each injection; and after 5, 15, 30, and 90 days
Participants Population: 80 participants, May 2012 to April 2014
Inclusion criteria: people suffering from LBP of < 6 months duration, older than 18 years, written
informed consent; non-surgical lumbago including disc syndrome, spinal stenosis, postural back
pain
Exclusion criteria: paediatric patients, people with allergies to meloxicam (or other non-steroidal
drugs), people with contraindications to the local puncture (such as infection of the skin at the
puncture level), and people unable to express an informed consent to the treatment or available
for the follow-up
Interventions NSAID (i): periradicular meloxicam injections (N = 40)
Reference treatment (ii): periradicular saline injections (N = 20)
The amount of injections differed per participant depending on NRS score change (1 to 3 injec-
tions).
Outcomes Pain reduction, need for analgesic medication, level of physical activity, quality of sleep
Notes 1. LBP < 6 months included; no subgroup analysis of only (sub)acute LBP




Methods RCT; randomisation procedure not described
Follow-up: 7 days. Outcome measurements at baseline and after 7 days
Participants Population: 30 participants, 26 women and 4 men, mean age 62 years, range 45 to 80 years
Inclusion criteria: acute or recurrent low back pain, with or without radiation, degree of pain at
least 2 on a 5-point scale
Exclusion criteria: pregnant or lactating women, gastroduodenal ulcer, depression, severe hepat-
ic, renal or cardiovascular insufficiency (or both), severe alterations of blood chemistry, hypersen-
sitivity or intolerance to piroxicam, aspirin, or other NSAIDS, use of NSAIDs or corticosteroids in
previous 30 days
Interventions NSAID (i): etodolac 200 mg bid, 7 days (N = 15)
Davoli 1989 
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NSAID (ii): piroxicam-beta-cyclodextrin one 20 mg tablet, 7 days (N = 15)
Outcomes Pain, adverse events
Notes 1. Both acute and recurrent LBP included, no distinction made




Methods Open label randomised trial, multicentre; randomisation procedure not described
Follow-up: 4 weeks
Participants Population and setting: 196 outpatients, 123 female, 73 male
Inclusion criteria: people with subacute or chronic low back pain without a specific diagnosis,
such as root entrapment syndromes, with at least severe pain at either rest, motion, standing or at
night
Exclusion criteria: acute LBP; active or previous history of gastric or duodenal ulcers, renal, or he-
patic diseases, history of asprin or NSAID intolerance; treatment with corticosteroids.
Interventions NSAIDs (i): nimesulide 100 mg, b.i.d., 4 weeks (N = 95)
Reference treatment (ii): diclofenac sodium 50 mg b.i.d., 4 weeks (N = 101)
Outcomes Sum of participants with none, mild, moderate / sum of participants with severe, very severe pain
at: rest, motion, night, standing. Adverse events.
Notes 1. Only subacute and chronic LBP included; no distinction made; no subgroup analysis of subacute
LBP
2. We retrieved an e-mail address and contacted the author (21 October 2019) to ask for clarifica-
tion, but we received a message that the address no longer existed. We were unable to find other




Methods CCT; double-blind; not randomised
Follow-up: 7 days. Outcome measurements at baseline, and after 3 and 7 days
Participants Population and setting: 83 participants with acute low back pain warranting inpatient treatment,
59 men, 24 women
Inclusion criteria: pain in the lower back of acute or chronic onset
Exclusion criteria: neoplasms, myeloma, Paget's disease, collagen disease, rheumatoid arthritis,
ankylosing spondylitis, and people with contraindications to either drug
Interventions NSAID (i): indomethacin 25 mg, q.i.d., 7 days (N = 40)
NSAID (ii): oxyphenbutazone 100 mg, q.i.d., 7 days (N = 43)
Outcomes Total pain score (4-point scale), total physical examination score (fingertip-floor distance, inch), to-
tal functional status score (movements; 4-point scale), paracetamol use, adverse events
Notes 1. LBP of both acute and chronic onset included, no distinction made; no subgroup analysis
Hingorani 1970 
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Methods RCT; double-blind, cross-over; randomisation procedure not described
Participants Population: 50 participants, 32 men, 18 women, mean age 48.4 years
Inclusion criteria: age 20 to 70 years, acute backache necessitating a stay in hospital of at least 3
weeks
Exclusion criteria: concomitant treatment with steroids, gold, or mono-amine oxidase inhibitors,
systemic cause of backache, history of peptic ulcer, possibility of pregnancy
Interventions NSAIDs (i): azapropazone 300 mg q.i.d., 1 week (N = ?)
NSAIDs (ii): ketoprofen 50 mg q.i.d., 1 week (N = ?)
Outcomes No data presented except for adverse events
Notes 1. Both acute and recurrent LBP included, no distinction made.




Methods RCT; double-blind; participants were allotted the next serial number in their diagnostic category
and given the appropriate numbered bottle.
Participants Population and setting: 110 participants with clinically diagnosed prolapsed intervertebral disc
with or without radicular pain attending an outpatient clinic, maximum 60 years of age
Inclusion criteria: acute or chronic LBP, age < 60 years
Exclusion criteria: neoplastic, metabolic, or other bone disease, pregnancy, diabetes, epilepsy,
peptic ulcer
Interventions NSAID (i): indomethacin 25 mg capsules, 3 capsules per day for 2 days, 4 capsules per day next 5
days (N = 25 with nerve root pain, and N = 30 without nerve root pain)
Reference treatment (ii): placebo capsules (N = 25 with nerve root pain, and N = 30 without nerve
root pain)
Outcomes Data on effectiveness in graphs; adverse events
Notes 1. Both acute and acute flare of chronic LBP included, no distinction made; no subgroup analysis




Methods RCT; randomisation according to their military identification numbers
Follow-up time: 10 weeks
Milgrom 1993 
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Participants Population and setting: 70 male infantry recruits with over exertion back pain, 32 with thoracic
and 40 with lumbar pain, mean age 18 years
Inclusion criteria: no history of back pain, no back trauma, back pain exertionally related to carry-
ing loads on the back, not present or markedly improved on non-exertional activities, no sciatica,
no sudden onset
Interventions NSAID (i): ibuprofen 800 mg t.i.d., 7 days (N = 24)
Reference treatment (ii): paracetamol 1000 mg t.i.d., 7 days (N = 24)
Reference treatment (iii): no drug treatment (N = 22)
Outcomes % participants cured after 10 weeks, adverse events
Notes 1. Not LBP, but both lumbar and thoracic pain, no distinction made





Follow-up time: 6 months. Outcome measurements at baseline, 4, 12, and 24 weeks
Participants Population and setting: participants who were assigned to the social security system and living
in the metropolitan area, consulting the ambulatory health centres in Medellin, Colombia, 2009 to
2012
Inclusion criteria: participants (aged 18 to 60 years) with subacute LBP (lasting 4 to 12 weeks) with
or without radiculopathy
Exclusion criteria: a specific cause for the pain (infection, tumour, ankylosing spondylitis, inflam-
matory conditions, or cauda equine syndrome), the presence of red flags, scoliosis > 15 °, depres-
sion or mental illness, history of gastrointestinal bleeding, renal failure, intake of anticoagulants or
antiplatelet drugs, NSAID allergy
Interventions NSAID (I): naproxen capsules, 500 mg per day, 10 days OR celecoxib 200 mg per day, 10 days (N =
45)
Reference treatment (ii): protocolised back pain exercise by a physiotherapist, 3 times a week, 4
weeks, 12 sessions in total (N = 45)
Outcomes VAS, ODI, RMDQ, SF-36 (quality of life), missed workdays, relapses of lumbar pain, additional treat-
ments, medical consultations
Notes 1. Either naproxen or celecoxib was used, no distinction was made, no subgroup analysis present-
ed




Methods RCT; randomised, double-blind, multicentre, multicountry, parallel-group design (3 groups). Ran-
domisation using an interactive-response technology, with a randomisation list in blocks (5 per
block; 2:2:1 ratio). Follow-up: 8 to 10 days. Outcome assessments at day 2, 4, 6, and 8 to 10 days
Predel 2019 
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Participants Population and setting: 635 participants with acute back or neck pain presenting to 19 sites in
Germany or Russia
Inclusion criteria: aged 18 or above, acute back or neck pain (duration > 24 hours but < 21 days)
resulting in pain on movement (POM) score of 5 or higher (0 to 10 NRS) for at least one of five stan-
dardized POM procedures
Exclusion criteria: history of three or more episodes of back or neck pain in the last 6 months, or if
they had chronic back or neck pain (defined as pain for three weeks or longer), if they had pain due
to an identifiable cause, back or neck surgery, or rehabilitation in the last 12 months, use of prohib-
ited medication (including any anti-inflammatory drugs, hepinaroids, or muscle relaxants) within 3
days prior to study entry
Interventions NSAID (i): ibuprofen (400 mg) and caffeine (100 mg; oral), 3 times daily for 5 days
NSAID (ii): ibuprofen (400 mg; oral), 3 times daily for 5 days
Reference treatment (iii): placebo (oral), 3 times daily for 5 days
Outcomes Pain on movement (NRS) between baseline and the morning of day 2. Safety and tolerability mea-
sures. Global assessment of efficacy. Pain at rest (NRS). Disability (ODI)
Notes 1. Mixed population of participants with neck and back pain. The group of back pain participants
for the relevant comparison of NSAID (NSAID (ii); N = 140) versus placebo (reference treatment (iii);
N = 67) was N = 207. The results of these two groups were not compared separately for the sub-
group of back pain (only NSAID (i) vs NSAID (ii), and NSAID (i) vs reference treatment (iii)
2. We contacted the corresponding author to ask for detailed results of the subgroup analysis of




Methods RCT; parallel group design (3 groups); randomisation procedure not described
Follow-up time: 7 days. Outcome measurements at baseline, 1, and 7 days
Participants Population and setting: 122 participants, 57 women, 65 men, aged 15 to 72 years Ambulant out-
patients from 12 general practitioners
Inclusion criteria: acute LBP, current episode longer than 24 hours and less than 28 days
Exclusion criteria: signs of nerve root compression, arthritis, ankylosing spondylitis, spinal infec-
tions, malignancy, renal or hepatic disease, peptic ulcers, pregnant or lactating women, sensitivity
to test medications
Interventions NSAID (i): mefenamic acid 500 mg, one tablet t.i.d. + placebo chlormezazone and paracetamol,
two capsules t.i.d. (N = 40)
Reference treatment (ii): chlormezanone 100 mg and paracetamol 450 mg, two capsules t.i.d. +
placebo mefenamic acid, one tablet t.i.d. (N = 42)
Reference treatment (iii): ethoheptazine 75 mg, meprobamate 150 mg and aspirin 250 mg two
capsules t.i.d. + placebo (either mefenamic acid placebo or chlormezazone + paracetamol placebo)
t.i.d. (N = 40)
Outcomes Pain, adverse events
Notes 1. Mixed population of acute and recurrent LBP (about half of the participants had chronic LBP with
an acute flare), no distinction made
Sweetman 1987 
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Methods RCT, open-label; pilot study (safety/efficacy study); follow-up time: 7 days
Participants Population and setting: 29 participants with acute low back pain in Thailand
Inclusion criteria: age 18 to 65 years, nonspecific acute low back pain (≥ 4/10 NRS) for under 72
hours
Exclusion criteria: history of lumbar and spinal accidents in the previous year or lumbosacral
surgery, history of osteoporosis, immunodeficiency, diabetes mellitus, hypertension, cardiovascu-
lar disease, thyroid/endocrine gland disease and asthma, active ulcer, epilepsy, seizures, liver dis-
ease, renal disease, hypertension, known allergies for ibuprofen or herbal/pollen grain, pregnancy
or lactation, certain co-medication, or recent treatment with test medication
Interventions NSAID (i): NSAIDs; oral Ibuprofen 400 mg, 3 times daily (7 days)
Reference treatment (ii): Thai herbal medicine; oral Ayurved Siriraj Sahatsatara recipe (AVS023)
1350 mg, 3 times daily (7 days)
Outcomes Pain intensity (NRS); disability (ODI); safety (adverse events and blood test)
Notes 1. Study title. A single-blind randomised controlled trial of AVS023 poly-herbal formula for acute
low back pain: a pilot study




Methods RCT; participants were randomly allocated to 2 groups according to the last 2 digits of their hospi-
tal numbers
Follow-up time: 6 weeks. Outcome measurements at baseline and after 1 and 6 weeks
Participants Population and setting: 72 hospital patients with non-surgical low back pain, 20 men, 52 women
Inclusion criteria: non-surgical low back pain including disc syndrome, spondylosis, mild spondy-
lolisthesis, spinal stenosis, and postural back pain, aged 15 years and older
Exclusion criteria: presence of digestive, haematological, hepatic, and renal disorders, hypersen-
sitivity to proprionic acid derivatives, long-term administration of steroids, indication for surgery
Interventions NSAID (i): Loxoprofen 60 mg t.i.d., 6 weeks (N = 37)
NSAID (ii): naproxen 250 mg t.i.d., 6 weeks (N = 35)
Outcomes Therapeutic results according to criteria of the Japanese orthopaedic Academic Society, adverse
events
Notes 1. Duration of LBP not clear
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Methods RCT; single-blind; randomisation procedure not described
Follow-up time: 3 weeks. Outcome measurements at baseline, and after 1, 2, and 3 weeks
Participants Population and setting: 64 ambulant people, 16 men, 48 women
Inclusion criteria: non-surgical lumbago including disc syndrome, spinal stenosis, postural back
pain
Exclusion criteria: need for surgery
Interventions NSAID (i): indomethacin plaster twice a day, 4 weeks plus 1 mg oral vitamin B b.i.d. (N = 30)
NSAID (ii): diclofenac emulgel, 2 cm 4 times a day, 4 weeks plus 1 mg oral vitamin B bid (N = 34)
Outcomes 30-point total rating scale, % of participants with good improvement, safety and usefulness, ad-
verse events
Notes 1. Duration of LBP not clear




Methods Open, prospective, follow-up by simple randomisation
Follow-up time: 3 months
Participants Population: 80 participants, 49 women, 31 men
Interventions Randomization in four groups of 20:
NSAID (i): etoricoxib 90 mg/day (N = 20)
NSAID (ii): nimesulide 100 mg/day (N = 20)
NSAID (iii): diclofenac 100 mg/day (N = 20)
NSAID (iv): meloxicam 15 mg/day (N = 20)
Outcomes Pain, blood pressure, lab tests
Notes 1. Mixed population of back pain, no distinction made in location or in duration
2. We contacted the corresponding author to ask for clarification (21 Septemer 2019)
Zolotovskaya 2015 
b.i.d. = twice a day; LBP = low back pain; ODI = Oswestry Disability Index; NSAID = non-steroidal anti-inflammatory drug; RCT = randomised
controlled trial; q.i.d. = four times a day; RMDQ = Roland-Morris Disability Questionnaire; SF-12/36 = 12 or 36-item Short Form Health Survey;
t.i.d. = three times a day; VAS = visual analogue scale
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title A comparative study of the efficacy and tolerability of fixed dose combination of etoricoxib and
thiocolchicoside and thiocolchicoside alone in patients with painful muscle spasm
Methods RCT, randomised, open-label. Follow-up time: 7 days
Participants Population and setting: 100 participants with painful muscle spasms (such as torticollis, lumbago,
backache) attending the orthopaedic outpatient department of a hospital in Bangalore, India
CTRI/2018/11/016371 
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Inclusion criteria: age 18 to 65 years, with painful muscle spasms, attending the orthopaedic out-
patient department
Exclusion criteria: history of liver and kidney damage, cardiovascular disease, asthma or acid pep-
tic diseases, severe concurrent systemic diseases or anticoagulant therapy, malignancy, osteo-
porosis or a history of spine surgery, pregnancy or lactation, allergies or intolerances to NSAIDs and
skeletal muscle relaxants, treatment with study medication 1 week prior to study enrolment
Interventions NSAID (i): Etoricoxib (60 mg) + thiocolchicoside (4 mg; oral), b.i.d. for 7 days
Reference treatment (ii): Thiocolchicoside (4 mg; oral), b.i.d. for 7 days
Outcomes Pain (VAS). Patients' global assessment in response to treatment
Starting date Not yet recruiting





Trial name or title A comparison of NSAIDs for acute, non-radicular low back pain. A randomised trial
Methods RCT, double-blind, randomised, parallel assignment. Follow-up time: 5 days
Participants Population and setting: 198 participants with acute, new onset low back pain presenting to the
emergency department of a hospital in New York, USA
Inclusion criteria: age 18 to 64 years, with functionally impairing (score > 5 on the 0 to 24 RMDQ)
low back pain of musculoskeletal etiology, non-radicular, non-traumatic, pain duration > 2 weeks
Exclusion criteria: flank pain (originating from tissues lateral to the paraspinal muscles), not avail-
able for follow-up, pregnancy, having a chronic pain syndrome; allergies or intolerances of, or con-
tra-indications to investigational medications
Interventions NSAID (i): Ketorolac 10 mg (oral), 3 times daily (5 days as needed)
NSAID (ii): Ibuprofen 600 mg (oral), 3 times daily (5 days as needed)
NSAID (iii): Diclofenac 50 mg (oral), 3 times daily (5 days as needed)
Participants in all three study arms received an additional 15-minute educational intervention
Outcomes Functional impairment (RMDQ); LBP worsening; LBP frequency; analgesic or NSAID usage
Starting date July 2019; currently recruiting





Non-steroidal anti-inflammatory drugs for acute low back pain (Review)









Cochrane Database of Systematic Reviews
Trial name or title Efficacy of metamizole versus ibuprofen and a short educational intervention versus standard care
in acute and subacute low back pain: a randomised, factorial trial
Methods RCT, randomised, factorial, double-blind, controlled; follow-up time: 14 days for pain, 42 days for
disability
Participants Population and setting: 120 participants with a new low back pain episode presenting to GPs in
the region of Bern, Switzerland
Inclusion criteria: age 18 years or older, seeking care for a new onset of non-specific or specific
LBP (pain duration of less than 12 weeks LBP prior to the baseline visit), the GP plans to prescribe a
non-opioid pain medication for pain control
Exclusion criteria: presence of red flags, active malignancy or history of haematologic disorder,
known intolerance or contraindications against the study medications, immune deficiency or un-
der immunosuppressant treatment, current opioid use, pregnancy
Interventions NSAID (i): Metamizole 0.5 mg (oral), 3 times daily 2 capsules for 4 days, followed by an as needed
regimen (days 4 to 42) + educational intervention
NSAID (ii): Metamizole 0.5 mg (oral), 3 times daily 2 capsules for 4 days, followed by an as needed
regimen (days 4 to 42) + standard care
NSAID (iii): Ibuprofen 500 mg (oral), 3 times daily 2 capsules for 4 days, followed by an as needed
regimen (days 4 to 42) + educational intervention
NSAID (iv): Ibuprofen 500 mg (oral), 3 times daily 2 capsules for 4 days, followed by an as needed
regimen (days 4 to 42) + standard care
Outcomes Pain (NRS). Disability (Core Outcome Measures Index)
Starting date December 2019; currently recruiting





Trial name or title Efficacy of Ayurved SIRIRAJ SAHATTHARA recipe, in patient with acute low back pain, an open-label
randomised controlled trial
Methods RCT, open-label, non-inferiority; follow-up time: 7 days
Participants Population and setting: 90 participants with acute low back pain in Thailand
Inclusion criteria: age 18 to 65 years, nonspecific acute low back pain (≥ 4/10 NRS) for under 72
hours
Exclusion criteria: history of lumbar and spinal accidents in the previous year or lumbosacral
surgery, history of osteoporosis, immunodeficiency, diabetes mellitus, hypertension, cardiovas-
cular disease, thyroid or endocrine gland disease and asthma, active ulcer, epilepsy, seizures, liv-
er disease, renal disease, hypertension, known allergies for ibuprofen or herbal/pollen grain, preg-
nancy or lactation, certain co-medication or recent treatment with test medication
Interventions NSAID (i): NSAIDs; oral Ibuprofen 400 mg, 3 times daily (7 days)
TCTR20151118003 
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Reference treatment (ii): Thai herbal medicine; oral Ayurved Siriraj Sahatsatara recipe (AVS023)
1350 mg, 3 times daily (7 days)
Outcomes Pain intensity (NRS). Disability (ODI). Safety (adverse events and blood test)
Starting date March 2016; currently recruiting
Contact information Somruedee Chatsiricharoenkul, MD; somruedee.cha@mahidol.ac.th
Notes 1. TCTR20141027001 seems to be related to an (already completed) pilot study: A single-blind ran-
domised controlled trial of AVS023 poly-herbal formula for acute low back pain: a pilot study. This
study was followed by the current prospective study (TCTR20151118003) that is currently recruit-
ing, no results are presented yet.
2. We contacted the corresponding author to ask for the current status (21 September 2019)
TCTR20151118003  (Continued)
b.i.d. = twice a day; GP = general practitioner; LBP = low back pain; ODI = Oswestry Disability Index; NSAID = non-steroidal anti-
inflammatory drug; NRS = numeric rating scale; RCT = randomised controlled trial; q.i.d. = four times a day; RMDQ = Roland-Morris Disability
Questionnaire; SF-12/36 = 12 or 36-item Short Form Health Survey; t.i.d. = three times a day; VAS = visual analogue scale
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Comparison 1.   NSAIDs versus placebo





Statistical method Effect size
1 Pain Intensity on 100-mm VAS. Follow-up ≤ 3
weeks








3 Proportion of participants experiencing global
improvement. Follow-up ≤ 3 weeks
5 1201 Risk Ratio (M-H, Random, 95% CI) 1.40 [1.12, 1.75]
4 Proportion of participants experiencing ad-
verse events
6 1394 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.63, 1.18]
 
 
Analysis 1.1.   Comparison 1 NSAIDs versus placebo, Outcome 1 Pain Intensity on 100-mm VAS. Follow-up ≤ 3 weeks.
Study or subgroup NSAID Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Amlie 1987 134 24.4 (35) 132 32.4 (35) 14.37% -8[-16.41,0.41]
Dreiser 2003 122 23.7 (19.4) 61 33.9 (19.4) 22.93% -10.2[-16.16,-4.24]
Dreiser 2003 119 22.9 (18.9) 60 33.9 (18.9) 23.39% -11[-16.87,-5.13]
Hancock 2007 59 23.2 (23.7) 60 28 (26) 13.11% -4.8[-13.74,4.14]
Szpalski 1994 33 5.6 (11.4) 35 7.9 (10.9) 26.2% -2.3[-7.61,3.01]
   
Favours NSAID 2010-20 -10 0 Favours placebo
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Study or subgroup NSAID Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Total *** 467   348   100% -7.29[-10.98,-3.61]
Heterogeneity: Tau2=6.14; Chi2=6.17, df=4(P=0.19); I2=35.18%  
Test for overall effect: Z=3.88(P=0)  
Favours NSAID 2010-20 -10 0 Favours placebo
 
 
Analysis 1.2.   Comparison 1 NSAIDs versus placebo, Outcome 2 Disability (RMDQ 0 to 24). Follow-up ≤ 3 weeks.
Study or subgroup NSAID Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Hancock 2007 58 4.9 (5.8) 60 6 (6.1) 16.46% -1.12[-3.26,1.02]
Dreiser 2003 118 5.2 (4.3) 58 7.3 (4.3) 41.39% -2.1[-3.45,-0.75]
Dreiser 2003 119 5 (4.2) 58 7.3 (4.3) 42.14% -2.3[-3.64,-0.96]
   
Total *** 295   176   100% -2.02[-2.89,-1.15]
Heterogeneity: Tau2=0; Chi2=0.86, df=2(P=0.65); I2=0%  
Test for overall effect: Z=4.56(P<0.0001)  
Favours NSAID 52.5-5 -2.5 0 Favours placebo
 
 
Analysis 1.3.   Comparison 1 NSAIDs versus placebo, Outcome 3 Proportion
of participants experiencing global improvement. Follow-up ≤ 3 weeks.
Study or subgroup NSAID Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Babej-Dolle 1994 27/88 4/43 4.41% 3.3[1.23,8.83]
Babej-Dolle 1994 10/86 3/43 2.94% 1.67[0.48,5.74]
Dreiser 2003 53/119 16/59 13.44% 1.64[1.03,2.61]
Dreiser 2003 48/119 16/59 13.17% 1.49[0.93,2.38]
Hancock 2007 53/120 57/119 21.66% 0.92[0.7,1.21]
Lacey 1984 97/138 67/140 25.44% 1.47[1.2,1.8]
Szpalski 1994 27/33 20/35 18.95% 1.43[1.03,1.99]
   
Total (95% CI) 703 498 100% 1.4[1.12,1.75]
Total events: 315 (NSAID), 183 (Placebo)  
Heterogeneity: Tau2=0.04; Chi2=12.41, df=6(P=0.05); I2=51.64%  
Test for overall effect: Z=2.95(P=0)  
Favours placebo 20.5 1.50.7 1 Favours NSAID
 
 
Analysis 1.4.   Comparison 1 NSAIDs versus placebo, Outcome
4 Proportion of participants experiencing adverse events.
Study or subgroup NSAID Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Amlie 1987 18/138 24/140 31.62% 0.76[0.43,1.34]
Babej-Dolle 1994 1/86 1/43 1.33% 0.5[0.03,7.8]
Favours NSAID 100.1 50.2 20.5 1 Favours placebo
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Study or subgroup NSAID Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Babej-Dolle 1994 4/88 1/43 2.16% 1.95[0.23,16.96]
Dreiser 2003 16/124 10/63 18.9% 0.81[0.39,1.69]
Dreiser 2003 14/122 10/63 17.78% 0.72[0.34,1.53]
Hancock 2007 2/58 6/60 4.14% 0.34[0.07,1.64]
Lacey 1984 18/148 14/150 23.07% 1.3[0.67,2.52]
Szpalski 1994 1/33 0/35 1% 3.18[0.13,75.33]
   
Total (95% CI) 797 597 100% 0.86[0.63,1.18]
Total events: 74 (NSAID), 66 (Placebo)  
Heterogeneity: Tau2=0; Chi2=4.61, df=7(P=0.71); I2=0%  
Test for overall effect: Z=0.92(P=0.36)  
Favours NSAID 100.1 50.2 20.5 1 Favours placebo
 
 
Comparison 2.   Selective COX-2 inhibitors versus non-selective NSAIDs





Statistical method Effect size
1 Change in pain intensity from baseline on 100 mm
VAS. Follow-up ≤ 3 weeks








3 Proportion of patients experiencing gastrointestinal
adverse events






Analysis 2.1.   Comparison 2 Selective COX-2 inhibitors versus non-selective NSAIDs,
Outcome 1 Change in pain intensity from baseline on 100 mm VAS. Follow-up ≤ 3 weeks.
Study or subgroup COX-2 inhibitors Non-selec-
tive NSAID
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Pohjolainen 2000 52 -45 (21) 52 -38 (21) 37.12% -7[-15.07,1.07]
Ximenes 2007 167 -41 (19) 166 -41 (19) 62.88% 0[-4.08,4.08]
   
Total *** 219   218   100% -2.6[-9.23,4.03]
Heterogeneity: Tau2=13.85; Chi2=2.3, df=1(P=0.13); I2=56.53%  
Test for overall effect: Z=0.77(P=0.44)  
Favours COX-2 inhibitors 5025-50 -25 0 Favours non-selective NSAID
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Analysis 2.2.   Comparison 2 Selective COX-2 inhibitors versus non-selective
NSAIDs, Outcome 2 Proportion of patients experiencing adverse events.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pohjolainen 2000 7/52 11/52 21.97% 0.64[0.27,1.51]
Ximenes 2007 48/170 44/170 78.03% 1.09[0.77,1.55]
   
Total (95% CI) 222 222 100% 0.97[0.63,1.5]
Total events: 55 (COX-2 inhibitors), 55 (Non-selective NSAID)  
Heterogeneity: Tau2=0.03; Chi2=1.28, df=1(P=0.26); I2=22.13%  
Test for overall effect: Z=0.14(P=0.89)  
Favours COX-2 inhibitors 200.05 50.2 1 Favours non-selective NSAID
 
 
Analysis 2.3.   Comparison 2 Selective COX-2 inhibitors versus non-selective NSAIDs,
Outcome 3 Proportion of patients experiencing gastrointestinal adverse events.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pohjolainen 2000 3/52 9/52 20.79% 0.33[0.1,1.16]
Ximenes 2007 19/170 27/170 79.21% 0.7[0.41,1.22]
   
Total (95% CI) 222 222 100% 0.6[0.33,1.09]
Total events: 22 (COX-2 inhibitors), 36 (Non-selective NSAID)  
Heterogeneity: Tau2=0.04; Chi2=1.16, df=1(P=0.28); I2=13.83%  
Test for overall effect: Z=1.67(P=0.1)  
Favours COX-2 inhibitors 100.1 50.2 20.5 1 Favours non-selective NSAID
 
 
Comparison 3.   NSAIDs versus paracetamol





Statistical method Effect size
1 Mean difference in pain intensity on various
scales. Follow-up ≤ 3 weeks




2 Proportion of participants experiencing adverse
events






Analysis 3.1.   Comparison 3 NSAIDs versus paracetamol, Outcome 1
Mean di:erence in pain intensity on various scales. Follow-up ≤ 3 weeks.
Study or subgroup NSAID Paracetamol Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Miki 2018 35 -0.5 (2.5) 35 0 (2.5) 24.16% -0.2[-0.67,0.27]
Favours NSAID 10.5-1 -0.5 0 Favours paracetamol
Non-steroidal anti-inflammatory drugs for acute low back pain (Review)









Cochrane Database of Systematic Reviews
Study or subgroup NSAID Paracetamol Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Nadler 2002 106 -0.1 (0.7) 113 0 (0.7) 75.84% -0.09[-0.35,0.18]
   
Total *** 141   148   100% -0.12[-0.35,0.12]
Heterogeneity: Tau2=0; Chi2=0.16, df=1(P=0.69); I2=0%  
Test for overall effect: Z=0.98(P=0.33)  
Favours NSAID 10.5-1 -0.5 0 Favours paracetamol
 
 
Analysis 3.2.   Comparison 3 NSAIDs versus paracetamol, Outcome
2 Proportion of participants experiencing adverse events.
Study or subgroup NSAID Paracetamol Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Nadler 2002 11/106 5/113 2.35[0.84,6.53]
Miki 2018 5/35 1/35 5[0.62,40.64]
Favours NSAID 1000.01 100.1 1 Favours paracetamol
 
 
Comparison 4.   NSAIDs versus other drug treatment





Statistical method Effect size
1 Proportion of participants experiencing global im-
provement. Follow-up ≤ 3 weeks




2 Proportion of participants experiencing adverse
events






Analysis 4.1.   Comparison 4 NSAIDs versus other drug treatment, Outcome 1
Proportion of participants experiencing global improvement. Follow-up ≤ 3 weeks.
Study or subgroup NSAIDs Other drug
treatment
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Brown 1986 16/19 17/21 56.89% 1.04[0.78,1.38]
Innes 1998 33/62 33/60 43.11% 0.97[0.7,1.34]
   
Total (95% CI) 81 81 100% 1.01[0.81,1.25]
Total events: 49 (NSAIDs), 50 (Other drug treatment)  
Heterogeneity: Tau2=0; Chi2=0.13, df=1(P=0.72); I2=0%  
Test for overall effect: Z=0.08(P=0.94)  
Favours NSAIDs 20.5 1.50.7 1 Favours other drugs
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Analysis 4.2.   Comparison 4 NSAIDs versus other drug treatment,
Outcome 2 Proportion of participants experiencing adverse events.
Study or subgroup NSAIDs Other drug treatment Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Brown 1986 3/19 5/21 0.66[0.18,2.41]
Innes 1998 21/62 38/59 0.53[0.35,0.78]
Metscher 2001 13/81 22/79 0.58[0.31,1.06]
Videman 1984 19/35 23/35 0.83[0.56,1.22]
Favours NSAIDs 100.1 50.2 20.5 1 Favours other drugs
 
 
Comparison 5.   NSAIDs versus non-drug treatment





Statistical method Effect size
1 Pain Intensity on 100-mm VAS. Follow-up ≤
3 weeks.
2   Mean Difference (IV, Random, 95% CI) Totals not select-
ed
1.1 NSAIDs versus spinal manipulation 2   Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 Proportion of participants experiencing
global improvement. Follow-up ≤ 3 weeks
2   Risk Ratio (M-H, Random, 95% CI) Totals not select-
ed
2.1 NSAIDs versus spinal manipulation 2   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Proportion of participants experiencing
adverse events
2   Risk Ratio (M-H, Random, 95% CI) Totals not select-
ed
3.1 NSAIDs versus spinal manipulation 2   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 5.1.   Comparison 5 NSAIDs versus non-drug treatment,
Outcome 1 Pain Intensity on 100-mm VAS. Follow-up ≤ 3 weeks..
Study or subgroup NSAIDs Non-drug treatment Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
5.1.1 NSAIDs versus spinal manipulation  
Hancock 2007 59 23.2 (23.7) 59 22.4 (20) 0.8[-7.11,8.71]
von Heymann 2013 37 29.6 (7.7) 38 11.3 (3.2) 18.31[15.62,21]




Analysis 5.2.   Comparison 5 NSAIDs versus non-drug treatment, Outcome 2
Proportion of participants experiencing global improvement. Follow-up ≤ 3 weeks.
Study or subgroup NSAIDs Non-drug treatment Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
5.2.1 NSAIDs versus spinal manipulation  
Favours non-drug treatment 20.5 1.50.7 1 Favours NSAIDs
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Study or subgroup NSAIDs Non-drug treatment Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
von Heymann 2013 21/37 29/35 0.68[0.5,0.94]
Waterworth 1985 14/18 28/38 1.06[0.77,1.44]
Waterworth 1985 14/18 24/34 1.1[0.79,1.53]
Favours non-drug treatment 20.5 1.50.7 1 Favours NSAIDs
 
 
Analysis 5.3.   Comparison 5 NSAIDs versus non-drug treatment,
Outcome 3 Proportion of participants experiencing adverse events.
Study or subgroup Favours NSAIDs Non-drug treatment Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
5.3.1 NSAIDs versus spinal manipulation  
von Heymann 2013 0/37 0/35 Not estimable
Hancock 2007 2/58 5/59 0.41[0.08,2.01]




A D D I T I O N A L   T A B L E S
 
Bias domain Source of Bias Possible answers
Selection (1) Was the method of randomisation adequate? Yes/No/Unsure
Selection (2) Was the treatment allocation concealed? Yes/No/Unsure
Performance (3) Was the participant blinded to the intervention? Yes/No/Unsure
Performance (4) Was the careprovider blinded to the intervention? Yes/No/Unsure
Detection (5) Was the outcome assessor blinded to the intervention? Yes/No/Unsure
Attrition (6) Was the dropout rate described and acceptable? Yes/No/Unsure
Attrition (7) Were all randomised participants analysed in the group
to which they were allocated?
Yes/No/Unsure
Reporting (8) Are reports of the study free of suggestion of selective
outcome reporting?
Yes/No/Unsure
Selection (9) Were the groups similar at baseline regarding the most
important prognostic indicators?
Yes/No/Unsure
Performance (10) Were co-interventions avoided or similar? Yes/No/Unsure
Performance (11) Was the compliance acceptable in all groups? Yes/No/Unsure
Detection (12) Was the timing of the outcome assessment similar in
all groups?
Yes/No/Unsure
Table 1.   Sources of risk of bias 
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Other (13) Are other sources of potential bias unlikely? Yes/No/Unsure




1 A random (unpredictable) assignment sequence. Examples of adequate methods are coin toss (for
studies with 2 groups), rolling a dice (for studies with 2 or more groups), drawing of balls of differ-
ent colours, drawing of ballots with the study group labels from a dark bag, computer-generated
random sequence, pre-ordered sealed envelopes, sequentially-ordered vials, telephone call to a
central office, and preordered list of treatment assignments.
Examples of inadequate methods are: alternation, birth date, social insurance or social security
number, date in which they are invited to participate in the study, and hospital registration num-
ber.
2 Assignment generated by an independent person not responsible for determining the eligibility of
the participants. This person has no information about the persons included in the trial and has no
influence on the assignment sequence or on the decision about eligibility of the participant.
3 Index and control groups are indistinguishable for the participants, or if the success of blinding was
tested among the participants and it was successful.
4 Index and control groups are indistinguishable for the careproviders, or if the success of blinding
was tested among the careproviders and it was successful.
5 Adequacy of blinding should be assessed for each primary outcome separately. This item should be
scored 'yes' if the success of blinding was tested among the outcome assessors and it was success-
ful or:
• for participant-reported outcomes in which the participant is the outcome assessor (e.g. pain,
disability): the blinding procedure is adequate for outcome assessors if participant blinding is
scored 'yes'
• for outcome criteria assessed during scheduled visit and that supposes a contact between partici-
pants and outcome assessors (e.g. clinical examination): the blinding procedure is adequate if par-
ticipants are blinded, and the treatment or adverse effects of the treatment cannot be noticed dur-
ing clinical examination
• for outcome criteria that do not suppose a contact with participants (e.g. radiography, magnetic
resonance imaging): the blinding procedure is adequate if the treatment or adverse effects of the
treatment cannot be noticed when assessing the main outcome
• for outcome criteria that are clinical or therapeutic events that will be determined by the interac-
tion between participants and careproviders (e.g. co-interventions, hospitalisation length, treat-
ment failure), in which the careprovider is the outcome assessor: the blinding procedure is ade-
quate for outcome assessors if item '4' (caregivers) is scored 'yes'
• for outcome criteria that are assessed from data from the medical forms: the blinding procedure
is adequate if the treatment or adverse effects of the treatment cannot be noticed on the extracted
data
6 The number of participants who were included in the study but did not complete the observation
period or were not included in the analysis must be described and reasons given. If the percentage
of withdrawals and dropouts does not exceed 20% for short-term follow-up and 30% for long-term
follow-up, and does not lead to substantial bias, a 'yes' is scored. (N.B. these percentages are arbi-
trary, not supported by literature).
7 All randomised participants are reported and analysed in the group to which they were allocated
by randomisation for the most important moments of effect measurement (minus missing values)
irrespective of non-compliance and co-interventions.
Table 2.   Criteria for a judgement of 'yes' for the sources of risk of bias 
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8 All the results from all prespecified outcomes have been adequately reported in the published re-
port of the trial. This information is either obtained by comparing the protocol and the report, or in
the absence of a protocol, by assessing that the published report includes enough information to
make this judgement.
9 Groups have to be similar at baseline regarding demographic factors, duration and severity of com-
plaints, percentage of participants with neurological symptoms, and value of main outcome mea-
sure(s).
10 If there were no co-interventions, or if they were similar between the index and control groups.
11 The review author determines if the compliance with the interventions is acceptable, based on the
reported intensity, duration, number, and frequency of sessions for both the index intervention
and control intervention(s). For example, physiotherapy treatment is usually administered for sev-
eral sessions; therefore, it is necessary to assess how many sessions each participant attended. For
single-session interventions (e.g. surgery), this item is irrelevant.
12 Timing of outcome assessment should be identical for all intervention groups and for all primary
outcome measures.
13 Other types of biases. For example:
• When the outcome measures were not valid. There should be evidence from a previous or present
scientific study that the primary outcome can be considered valid in the context of the present.
• Industry-sponsored trials. The conflict of interest (COI) statement should explicitly state that the
researchers have had full possession of the trial process from planning to reporting without fun-
ders with potential COI having any possibility to interfere in the process. If, for example, the statisti-
cal analyses have been done by a funder with a potential COI, usually 'unsure' is scored.
Table 2.   Criteria for a judgement of 'yes' for the sources of risk of bias  (Continued)
Published by Furlan 2015; these instructions were adapted from van Tulder 2003, Boutron 2005, and the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
 
 
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
Last searched 7 January 2020
1 MESH DESCRIPTOR Back Pain EXPLODE ALL AND CENTRAL:TARGET
2 dorsalgia AND CENTRAL:TARGET
3 backache AND CENTRAL:TARGET
4 (lumb* or back) next pain AND CENTRAL:TARGET
5 coccyx or coccydynia or spondylosis AND CENTRAL:TARGET
6 MESH DESCRIPTOR Spine EXPLODE ALL AND CENTRAL:TARGET
7 MESH DESCRIPTOR Spinal Diseases EXPLODE ALL AND CENTRAL:TARGET
8 lumbago or discitis AND CENTRAL:TARGET
9 disc near herniat* AND CENTRAL:TARGET
10 disk NEAR herniat* AND CENTRAL:TARGET
11 spinal fusion AND CENTRAL:TARGET
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12 facet near joint* AND CENTRAL:TARGET
13 MESH DESCRIPTOR Intervertebral Disc EXPLODE ALL AND CENTRAL:TARGET
14 postlaminectomy AND CENTRAL:TARGET
15 arachnoiditis AND CENTRAL:TARGET
16 failed near back AND CENTRAL:TARGET
17 MESH DESCRIPTOR Cauda Equina EXPLODE ALL AND CENTRAL:TARGET
18 lumb* near vertebra* AND CENTRAL:TARGET
19 spinal near stenosis AND CENTRAL:TARGET
20 slipped near disc* AND CENTRAL:TARGET
21 slipped NEAR disk* AND CENTRAL:TARGET
22 degenerat* near disc* AND CENTRAL:TARGET
23 degenerat* near disk* AND CENTRAL:TARGET
24 stenosis near spine AND CENTRAL:TARGET
25 stenosis near root AND CENTRAL:TARGET
26 stenosis near spinal AND CENTRAL:TARGET
27 displace* near disc* AND CENTRAL:TARGET
28 displace* near disk* AND CENTRAL:TARGET
29 prolap* near disc* AND CENTRAL:TARGET
30 prolap* near disk* AND CENTRAL:TARGET
31 MESH DESCRIPTOR Sciatic Neuropathy EXPLODE ALL AND CENTRAL:TARGET
32 sciatic* AND CENTRAL:TARGET
33 back disorder* AND CENTRAL:TARGET
34 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR
#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 AND CENTRAL:TARGET
35 nsaid* AND CENTRAL:TARGET
36 MESH DESCRIPTOR Anti-Inflammatory Agents, Non-Steroidal EXPLODE ALL AND CENTRAL:TARGET
37 MESH DESCRIPTOR Cyclooxygenase Inhibitors EXPLODE ALL AND CENTRAL:TARGET
38 MESH DESCRIPTOR Cyclooxygenase 2 Inhibitors EXPLODE ALL AND CENTRAL:TARGET
39 non-steroidal anti inflammat* AND CENTRAL:TARGET
40 non-steroidal antiinflammat* AND CENTRAL:TARGET
41 non-steroidal anti-inflammat* AND CENTRAL:TARGET
42 cyclooxygenase NEAR3 inhibitor* AND CENTRAL:TARGET
43 cyclo-oxygenase NEAR3 inhibitor* AND CENTRAL:TARGET
44 aspirin AND CENTRAL:TARGET
45 acetylsalicyl* AND CENTRAL:TARGET
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46 carbasalate calcium AND CENTRAL:TARGET
47 diflunisal AND CENTRAL:TARGET
48 aceclofenac AND CENTRAL:TARGET
49 alclofenac AND CENTRAL:TARGET
50 diclofenac AND CENTRAL:TARGET
51 indometacin or indomethacin AND CENTRAL:TARGET
52 sulindac AND CENTRAL:TARGET
53 meloxicam AND CENTRAL:TARGET
54 piroxicam AND CENTRAL:TARGET
55 dexibuprofen AND CENTRAL:TARGET
56 dexketoprofen AND CENTRAL:TARGET
57 fenoprofen AND CENTRAL:TARGET
58 flurbiprofen AND CENTRAL:TARGET
59 ibuprofen AND CENTRAL:TARGET
60 ketoprofen AND CENTRAL:TARGET
61 naproxen AND CENTRAL:TARGET
62 tiapro* AND CENTRAL:TARGET
63 metamizol AND CENTRAL:TARGET
64 phenylbutazone AND CENTRAL:TARGET
65 phenazone AND CENTRAL:TARGET
66 propyphenazone AND CENTRAL:TARGET
67 celecoxib AND CENTRAL:TARGET
68 etoricoxib AND CENTRAL:TARGET
69 nabumeton AND CENTRAL:TARGET
70 parecoxib AND CENTRAL:TARGET
71 rofecoxib AND CENTRAL:TARGET
72 celecoxib AND CENTRAL:TARGET
73 valdecoxib AND CENTRAL:TARGET
74 lumiracoxib AND CENTRAL:TARGET
75 parecoxib AND CENTRAL:TARGET
76 vioxx AND CENTRAL:TARGET
77 celebrex AND CENTRAL:TARGET
78 bextra AND CENTRAL:TARGET
79 prexige AND CENTRAL:TARGET
80 arcoxia AND CENTRAL:TARGET
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81 etodolac AND CENTRAL:TARGET
82 floctafenine AND CENTRAL:TARGET
83 meclofenam* AND CENTRAL:TARGET
84 meloxicam AND CENTRAL:TARGET
85 oxaprozin AND CENTRAL:TARGET
86 piroxicam AND CENTRAL:TARGET
87 tenoxicam AND CENTRAL:TARGET
88 tolmetin AND CENTRAL:TARGET
89 #88 OR #87 OR #86 OR #85 OR #84 OR #83 OR #82 OR #81 OR #80 OR #79 OR #78 OR #77 OR #76 OR #75 OR #74 OR #73 OR #72 OR #71
OR #70 OR #69 OR #68 OR #67 OR #66 OR #65 OR #64 OR #63 OR #62 OR #60 OR #61 OR #59 OR #58 OR #57 OR #56 OR #55 OR #54 OR #53
OR #52 OR #51 OR #50 OR #49 OR #48 OR #47 OR #46 OR #45 OR #44 OR #43 OR #42 OR #41 OR #40 OR #39 OR #38 OR #37 OR #36 OR #35
AND CENTRAL:TARGET
90 #89 AND #34 AND CENTRAL:TARGET
91 (2018 OR 2019 OR 2020):YR AND CENTRAL:TARGET
92 #91 AND #90
2015 search in CRS standalone database. The terms ketoprofen and cycooxygenase were added, an alternative spelling for
indometacin was included, and some proximity search operators were revised. There was no date limit because the yield was small.
#1 MeSH descriptor: [Back Pain] explode all trees
#2 dorsalgia
#3 backache
#4 lumbar next pain or coccyx or coccydynia or spondylosis
#5 MeSH descriptor: [Spine] explode all trees
#6 MeSH descriptor: [Spinal Diseases] explode all trees
#7 lumbago and discitis and disc near herniation
#8 spinal fusion
#9 spinal neoplasms
#10 facet near joints
#11 MeSH descriptor: [Intervertebral Disk] explode all trees
#12 postlaminectomy
#13 arachnoiditis
#14 failed near back
#15 MeSH descriptor: [Cauda Equina] explode all trees
#16 lumbar near vertebra*
#17 spinal near stenosis
#18 slipped near (disc* or disk*)
#19 degenerat* near (disc* or disk*)
#20 stenosis near (spine or root or spinal)
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#21 displace* near (disc* or disk*)
#22 prolap* near (disc* or disk*)
#23 MeSH descriptor: [Sciatic Neuropathy] explode all trees
#24 sciatic*
#25 back disorder*
#26 back near pain
#27 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or
#22 or #23 or #24 or #25 or #26
#28 nsaid*
#29 MeSH descriptor: [Anti-Inflammatory Agents, Non-Steroidal] explode all trees
#30 MeSH descriptor: [Cyclooxygenase Inhibitors] explode all trees
#31 MeSH descriptor: [Cyclooxygenase 2 Inhibitors] explode all trees
#32 non-steroidal anti inflammat*
#33 non-steroidal anti-inflammat*
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#80 #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47
or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63 or #64 or #65 or #66 or #67 or
#68 or #69 or #70 or #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79
#81 #27 and #80
#82 #81 in Trials
2014 search. Some duplicate terms were removed.
#1 MeSH descriptor: [Back Pain] explode all trees
#2 dorsalgia
#3 backache
#4 lumbar next pain or coccyx or coccydynia or spondylosis
#5 MeSH descriptor: [Spine] explode all trees
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#6 MeSH descriptor: [Spinal Diseases] explode all trees
#7 lumbago OR discitis OR disc near degeneration OR disc near prolapse OR disc near herniation
#8 spinal fusion
#9 spinal neoplasms
#10 facet near joints
#11 MeSH descriptor: [Intervertebral Disk] explode all trees
#12 postlaminectomy
#13 arachnoiditis
#14 failed near back
#15 MeSH descriptor: [Cauda Equina] explode all trees
#16 lumbar near vertebra*
#17 spinal near stenosis
#18 slipped near (disc* or disk*)
#19 degenerat* near (disc* or disk*)
#20 stenosis near (spine or root or spinal)
#21 displace* near (disc* or disk*)
#22 prolap* near (disc* or disk*)
#23 MeSH descriptor: [Sciatic Neuropathy] explode all trees
#24 sciatic*
#25 back disorder*
#26 back near pain
#27 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or
#22 or #23 or #24 or #25 or #26
#28 nsaid*
#29 MeSH descriptor: [Anti-Inflammatory Agents, Non-Steroidal] explode all trees
#30 MeSH descriptor: [Cyclooxygenase Inhibitors] explode all trees
#31 MeSH descriptor: [Cyclooxygenase 2 Inhibitors] explode all trees
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#79 #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47
or #48 or #49 or #50 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63 or #64 or #65 or #66 or #67 or #68
or #69 or #70 or #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78
#80 #27 and #79
#81 #80 Publication Date from 2013 to 2014, in Trials
2012 search
#1 MeSH descriptor Back Pain explode all trees
#2 dorsalgia
#3 backache
#4 MeSH descriptor Low Back Pain explode all trees
#5 (lumbar next pain) or (coccyx) or (coccydynia) or (sciatica) or (spondylosis)
#6 MeSH descriptor Spine explode all trees
#7 MeSH descriptor Spinal Diseases explode all trees
#8 (lumbago) or (discitis) or (disc near degeneration) or (disc near prolapse) or (disc near herniation)
#9 spinal fusion
#10 spinal neoplasms
#11 facet near joints
#12 MeSH descriptor Intervertebral Disk explode all trees
#13 postlaminectomy
#14 arachnoiditis
#15 failed near back
#16 MeSH descriptor Cauda Equina explode all trees
#17 lumbar near vertebra*
#18 spinal near stenosis
#19 slipped near (disc* or disk*)
#20 degenerat* near (disc* or disk*)
#21 stenosis near (spine or root or spinal)
#22 displace* near (disc* or disk*)
#23 prolap* near (disc* or disk*)
#24 MeSH descriptor Sciatic Neuropathy explode all trees
#25 sciatic*
#26 back disorder*
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#27 back near pain
#28 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19
OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27)
#29 nsaid*
#30 MeSH descriptor Anti-Inflammatory Agents, Non-Steroidal explode all trees
#31 MeSH descriptor Cyclooxygenase Inhibitors explode all trees
#32 MeSH descriptor Cyclooxygenase 2 Inhibitors explode all trees
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#82 (#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46
OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64
OR #65 OR #66 OR #67 OR #68 OR #69 OR #70 OR #71 OR #72 OR #73 OR #74 OR #75 OR #76 OR #77 OR #78 OR #79 OR #80 OR #81)
#83 (#28 AND #82), from 2007 to 2012
Appendix 2. MEDLINE search strategies
Last searched 7 January 2020
1 randomized controlled trial.pt.
2 controlled clinical trial.pt.
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10 or/1-9
11 (animals not (humans and animals)).sh.
12 10 not 11
13 dorsalgia.tw,kf.
14 exp Back Pain/
15 backache.tw,kf.













29 aspirin.tw,kf. or exp Aspirin/
30 acetylsalicyl*.tw,kf.
31 exp Salicylic Acid/
32 carbasalate calcium.tw,kf.
33 diflunisal.tw,kf. or exp Diflunisal/
34 aceclofenac.tw,kf.
35 alclofenac.tw,kf. (
36 diclofenac.tw,kf. or exp Diclofenac/
37 (indometacin or indomethacin).tw,kf. or exp Indomethacin/
38 sulindac.tw,kf. or exp Sulindac/
39 meloxicam.tw,kf.
40 piroxicam.tw,kf. or exp Piroxicam/
41 dexibuprofen.tw,kf.
42 dexketoprofen.tw,kf.
43 fenoprofen.tw,kf. or exp Fenoprofen/
44 flurbiprofen.tw,kf. or exp Flurbiprofen/
Non-steroidal anti-inflammatory drugs for acute low back pain (Review)









Cochrane Database of Systematic Reviews
45 ibuprofen.tw,kf. or exp Ibuprofen/
46 ketoprofen.tw,kf. or exp Ketoprofen/
47 naproxen.tw,kf. or exp Naproxen/
48 tiapro*.tw,kf.
49 metamizol.tw,kf. or exp Dipyrone/
50 phenylbutazone.tw,kf. or exp Phenylbutazone/







58 exp cyclooxygenase inhibitors/ or exp cyclooxygenase 2 inhibitors/












71 etodolac.tw,kf. or exp Etodolac/
72 floctafenine.tw,kf.




77 piroxicam.tw,kf. or exp Piroxicam/
78 tenoxicam.tw,kf.
79 tolmetin.tw,kf. or exp Tolmetin/
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80 or/58-79
81 57 or 80
82 12 and 24 and 81
83 limit 82 to yr=2018-2020
84 limit 82 to ed=20181112-20200107
85 83 or 84
2017 search. The .mp. field was changed to .tw,kf. and the study design filter was revised.
1 randomized controlled trial.pt.
2 controlled clinical trial.pt.








11 (animals not (humans and animals)).sh.
12 10 not 11
13 dorsalgia.tw,kf.
14 exp Back Pain/
15 backache.tw,kf.
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29 aspirin.tw,kf. or exp Aspirin/
30 acetylsalicyl*.tw,kf.
31 exp Salicylic Acid/
32 carbasalate calcium.tw,kf.
33 diflunisal.tw,kf. or exp Diflunisal/
34 aceclofenac.tw,kf.
35 alclofenac.tw,kf.
36 diclofenac.tw,kf. or exp Diclofenac/
37 (indometacin or indomethacin).tw,kf. or exp Indomethacin/
38 sulindac.tw,kf. or exp Sulindac/
39 meloxicam.tw,kf.
40 piroxicam.tw,kf. or exp Piroxicam/
41 dexibuprofen.tw,kf.
42 dexketoprofen.tw,kf.
43 fenoprofen.tw,kf. or exp Fenoprofen/
44 flurbiprofen.tw,kf. or exp Flurbiprofen/
45 ibuprofen.tw,kf. or exp Ibuprofen/
46 ketoprofen.tw,kf. or exp Ketoprofen/
47 naproxen.tw,kf. or exp Naproxen/
48 tiapro*.tw,kf.
49 metamizol.tw,kf. or exp Dipyrone/
50 phenylbutazone.tw,kf. or exp Phenylbutazone/







58 exp cyclooxygenase inhibitors/ or exp cyclooxygenase 2 inhibitors/
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71 etodolac.tw,kf. or exp Etodolac/
72 floctafenine.tw,kf.




77 piroxicam.tw,kf. or exp Piroxicam/
78 tenoxicam.tw,kf.
79 tolmetin.tw,kf. or exp Tolmetin/
80 or/58-79
81 57 or 80
82 12 and 24 and 81
83 limit 82 to yr=2016-2017
84 limit 82 to ed=20160114-20170719
85 83 or 84
Search strategy for 2015 and 2016 in MEDLINE In-Process & Other Non-Indexed Citations. Last searched 14 January 2016. In 2015,
the study design filter was edited, some truncated terms were revised, the term "cyclooxygenase adj3 inhibitor* was added, and
an alternative spelling for indometacin was included.
1 randomized controlled trial.ti,ab.
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26 non-steroidal antiinflammat$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
27 non-steroidal anti-inflammat$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading
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46 naproxen.mp.
47 tiapro$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol
































79 56 or 78
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80 12 and 24 and 79
81 limit 80 to yr=2015-2016
82 limit 80 to ed=20150624-20160114
83 81 or 82
2014 search strategy
1 randomized controlled trial.ti,ab.






















24 Anti-Inflammatory Agents, Non-Steroidal.mp.
25 nsaids.mp.





Non-steroidal anti-inflammatory drugs for acute low back pain (Review)













































Non-steroidal anti-inflammatory drugs for acute low back pain (Review)























79 56 or 78
80 11 and 23 and 79
2012 search strategy
1 randomized controlled trial.pt.










12 (animals not (humans and animals)).sh.
13 11 not 12
14 dorsalgia.ti,ab.
15 exp Back Pain/
16 backache.ti,ab.
17 exp Low Back Pain/
18 (lumbar adj pain).ti,ab.
19 coccyx.ti,ab.
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27 exp Anti-Inflammatory Agents, Non-Steroidal/
28 nsaids.mp.
29 non-steroidal anti inflammat$.mp.
30 non-steroidal anti-inflammat$.mp.
31 aspirin.mp. or exp Aspirin/
32 acetylsalicyl$.mp.
33 exp Salicylic Acid/
34 carbasalate calcium.mp.
35 diflunisal.mp. or exp Diflunisal/
36 aceclofenac.mp.
37 alclofenac.mp.
38 diclofenac.mp. or exp Diclofenac/
39 indometacin.mp. or exp Indomethacin/
40 sulindac.mp. or exp Sulindac/
41 meloxicam.mp.
42 piroxicam.mp. or exp Piroxicam/
43 dexibuprofen.mp.
44 dexketoprofen.mp.
45 fenoprofen.mp. or exp Fenoprofen/
46 flurbiprofen.mp. or exp Flurbiprofen/
47 ibuprofen.mp. or exp Ibuprofen/
48 ketoprofen.mp. or exp Ketoprofen/
49 naproxen.mp. or exp Naproxen/
50 tiapro$.mp.
51 metamizol.mp. or exp Dipyrone/
52 phenylbutazone.mp. or exp Phenylbutazone/
53 phenazone.mp. or exp Antipyrine/
54 propyphenazone.mp.
Non-steroidal anti-inflammatory drugs for acute low back pain (Review)



























72 etodolac.mp. or exp Etodolac/
73 floctafenine.mp.
74 exp Meclofenamic Acid/
75 meclofenamate.mp.
76 meloxicam.mp.
77 naproxen.mp. or exp Naproxen/
78 oxaprozin.mp.
79 piroxicam.mp. or exp Piroxicam/
80 tenoxicam.mp.
81 tolmetin.mp. or exp Tolmetin/
82 or/60-81
83 59 or 82
84 13 and 26 and 83
85 limit 84 to yr="2007 - 2012"
86 limit 84 to ed=20070601-20120524
87 85 or 86
Appendix 3. Embase search strategy
Last searched 7 January 2020
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1 Randomized Controlled Trial/
2 exp Controlled Clinical Trial/
3 Controlled Study/
4 Double Blind Procedure/






11 ((controlled adj7 study) or (controlled adj7 design)).ti,ab.
12 (crossover or cross-over).ti,ab.
13 (compare or compared or comparing or comparison or comparative).ti,ab.





19 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
20 human/ or normal human/ or human cell/
21 19 and 20
22 19 not 21












35 exp Nonsteroid Antiinflammatory Agent/
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39 exp Acetylsalicylic Acid/
40 acetylsalicyl*.tw,kw.
41 carbasalate calcium.tw,kw. or exp Carbasalate Calcium/
42 diflunisal.tw,kw. or exp DIFLUNISAL/
43 aceclofenac.tw,kw. or exp ACECLOFENAC/
44 alclofenac.tw,kw. or exp ALCLOFENAC/
45 diclofenac.tw,kw. or exp DICLOFENAC/
46 exp INDOMETACIN/ or (indometacin or indomethacin).tw,kw.
47 sulindac.tw,kw. or exp SULINDAC/
48 meloxicam.tw,kw. or exp MELOXICAM/
49 exp PIROXICAM/ or piroxicam.tw,kw.
50 dexibuprofen.tw,kw. or exp DEXIBUPROFEN/
51 dexketoprofen.tw,kw. or exp DEXKETOPROFEN/
52 exp FENOPROFEN/ or fenoprofen.tw,kw.
53 flurbiprofen.tw,kw. or exp FLURBIPROFEN/
54 ibuprofen.tw,kw. or exp IBUPROFEN/
55 ketoprofen.tw,kw. or exp KETOPROFEN/
56 naproxen.tw,kw. or exp NAPROXEN/
57 tiapro*.tw,kw.
58 metamizol.tw,kw. or exp Dipyrone/
59 phenylbutazone.tw,kw. or exp PHENYLBUTAZONE/
60 phenazone.tw,kw. or exp PHENAZONE/
61 exp PROPYPHENAZONE/ or propyphenazone.tw,kw.
62 celecoxib.tw,kw. or exp CELECOXIB/
63 etoricoxib.tw,kw. or exp ETORICOXIB/
64 exp Nabumetone/ or nabumeton.tw,kw.
65 parecoxib.tw,kw. or exp PARECOXIB/
66 or/35-65
67 exp Cyclooxygenase 2 Inhibitor/
68 ((cyclooxygenase adj3 inhibitor*) or (cyclo-oxygenase adj3 inhibitor*)).tw,kw.
69 rofecoxib.tw,kw. or exp ROFECOXIB/
70 valdecoxib.tw,kw. or exp VALDECOXIB/
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71 lumiracoxib.tw,kw. or exp LUMIRACOXIB/
72 etoricoxib.tw,kw. or exp ETORICOXIB/






79 etodolac.tw,kw. or exp ETODOLAC/
80 floctafenine.tw,kw. or exp FLOCTAFENINE/
81 exp Meclofenamic Acid/
82 meclofenam*.tw,kw.
83 oxaprozin.tw,kw. or exp OXAPROZIN/
84 exp PIROXICAM/ or piroxicam.tw,kw.
85 tenoxicam.tw,kw. or exp TENOXICAM/
86 tolmetin.tw,kw. or exp TOLMETIN/
87 or/67-86
88 66 or 87
89 23 and 34 and 88
90 limit 89 to yr=2018-2020
91 limit 89 to em=201846-202001
92 90 or 91
2017 search. The study design filter and some truncated terms were revised and the .tw,kw. field was searched instead of .mp.
1 Randomized Controlled Trial/
2 exp Controlled Clinical Trial/
3 Controlled Study/
4 Double Blind Procedure/






11 (controlled adj7 (study or design or trial)).ti,ab.
12 (crossover or cross-over).ti,ab.
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13 (compare or compared or comparing or comparison or comparative).ti,ab.





19 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
20 human/ or normal human/ or human cell/
21 19 and 20
22 19 not 21
















39 exp Acetylsalicylic Acid/
40 acetylsalicyl*.tw,kw.
41 carbasalate calcium.tw,kw. or exp Carbasalate Calcium/
42 diflunisal.tw,kw. or exp DIFLUNISAL/
43 aceclofenac.tw,kw. or exp ACECLOFENAC/
44 alclofenac.tw,kw. or exp ALCLOFENAC/
45 diclofenac.tw,kw. or exp DICLOFENAC/
46 exp INDOMETACIN/ or (indometacin or indomethacin).tw,kw.
47 sulindac.tw,kw. or exp SULINDAC/
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48 meloxicam.tw,kw. or exp MELOXICAM/
49 exp PIROXICAM/ or piroxicam.tw,kw.
50 dexibuprofen.tw,kw. or exp DEXIBUPROFEN/
51 dexketoprofen.tw,kw. or exp DEXKETOPROFEN/
52 exp FENOPROFEN/ or fenoprofen.tw,kw.
53 flurbiprofen.tw,kw. or exp FLURBIPROFEN/
54 ibuprofen.tw,kw. or exp IBUPROFEN/
55 ketoprofen.tw,kw. or exp KETOPROFEN/
56 naproxen.tw,kw. or exp NAPROXEN/
57 tiapro*.tw,kw.
58 metamizol.tw,kw. or exp Dipyrone/
59 phenylbutazone.tw,kw. or exp PHENYLBUTAZONE/
60 phenazone.tw,kw. or exp PHENAZONE/
61 exp PROPYPHENAZONE/ or propyphenazone.tw,kw.
62 celecoxib.tw,kw. or exp CELECOXIB/
63 etoricoxib.tw,kw. or exp ETORICOXIB/
64 exp Nabumetone/ or nabumeton.tw,kw.
65 parecoxib.tw,kw. or exp PARECOXIB/
66 or/35-64 (519934)
67 exp Cyclooxygenase 2 Inhibitor/
68 ((cyclooxygenase or cyclo-oxygenase) adj3 inhibitor*).tw,kw.
69 rofecoxib.tw,kw. or exp ROFECOXIB/
70 valdecoxib.tw,kw. or exp VALDECOXIB/
71 lumiracoxib.tw,kw. or exp LUMIRACOXIB/
72 etoricoxib.tw,kw. or exp ETORICOXIB/






79 etodolac.tw,kw. or exp ETODOLAC/
80 floctafenine.tw,kw. or exp FLOCTAFENINE/
81 exp Meclofenamic Acid/
82 meclofenam*.tw,kw.
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83 oxaprozin.tw,kw. or exp OXAPROZIN/
84 exp PIROXICAM/ or piroxicam.tw,kw.
85 tenoxicam.tw,kw. or exp TENOXICAM/
86 tolmetin.tw,kw. or exp TOLMETIN/
87 or/67-86
88 66 or 87
89 23 and 34 and 88
90 limit 89 to yr="2016-2017"
91 limit 89 to em=201602-201729
92 90 or 91
2015 search. The study design filter was revised, some truncated terms were revised, the term "cyclooxygenase adj3 inhibitor* was
added, and an alternative spelling for indometacin was included.
1 Randomized Controlled Trial/
2 exp Controlled Clinical Trial/
3 Controlled Study/
4 Double Blind Procedure/






11 ((control$ or compar$ or prospectiv$ or clinical) adj25 (trial or study)).mp.
12 (crossover or cross-over).mp.
13 factorial$.mp.
14 (followup or follow-up).mp.
15 placebo$.mp.
16 random$.mp.
17 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).mp.
18 volunteer$.mp.
19 or/1-18
20 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
21 human/ or normal human/ or human cell/
22 20 and 21
23 20 not 22
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36 exp Nonsteroid Antiinflammatory Agent/
37 nsaids.mp.
38 non-steroidal anti-inflammator$.mp.
39 exp Acetylsalicylic Acid/
40 acetylsalicyl$.mp.
41 carbasalate calcium.mp. or exp Carbasalate Calcium/
42 diflunisal.mp. or exp DIFLUNISAL/
43 aceclofenac.mp. or exp ACECLOFENAC/
44 alclofenac.mp. or exp ALCLOFENAC/
45 diclofenac.mp. or exp DICLOFENAC/
46 exp INDOMETACIN/ or (indometacin or indomethacin).mp.
47 sulindac.mp. or exp SULINDAC/
48 meloxicam.mp. or exp MELOXICAM/
49 exp PIROXICAM/ or piroxicam.mp.
50 dexibuprofen.mp. or exp DEXIBUPROFEN/
51 dexketoprofen.mp. or exp DEXKETOPROFEN/
52 exp FENOPROFEN/ or fenoprofen.mp.
53 flurbiprofen.mp. or exp FLURBIPROFEN/
54 ibuprofen.mp. or exp IBUPROFEN/
55 ketoprofen.mp. or exp KETOPROFEN/
56 naproxen.mp. or exp NAPROXEN/
57 tiapro$.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade
name, keyword]
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58 metamizol.mp. or exp Dipyrone/
59 phenylbutazone.mp. or exp PHENYLBUTAZONE/
60 phenazone.mp. or exp PHENAZONE/
61 exp PROPYPHENAZONE/ or propyphenazone.mp.
62 celecoxib.mp. or exp CELECOXIB/
63 etoricoxib.mp. or exp ETORICOXIB/
64 exp Nabumetone/ or nabumeton.mp.
65 parecoxib.mp. or exp PARECOXIB/
66 or/36-65
67 exp Cyclooxygenase 2 Inhibitor/
68 ((cyclooxygenase or cyclo-oxygenase) adj3 inhibitor*).mp.
69 rofecoxib.mp. or exp ROFECOXIB/
70 valdecoxib.mp. or exp VALDECOXIB/
71 lumiracoxib.mp. or exp LUMIRACOXIB/
72 etoricoxib.mp. or exp ETORICOXIB/






79 etodolac.mp. or exp ETODOLAC/
80 floctafenine.mp. or exp FLOCTAFENINE/
81 exp Meclofenamic Acid/
82 meclofenam$.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device
trade name, keyword]
83 oxaprozin.mp. or exp OXAPROZIN/
84 exp PIROXICAM/ or piroxicam.mp.
85 tenoxicam.mp. or exp TENOXICAM/
86 tolmetin.mp. or exp TOLMETIN/
87 or/67-86
88 66 or 87
89 24 and 35 and 88
90 limit 89 to yr="2014-2015"
91 limit 89 to em=201414-201525
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92 90 or 91
2014 search strategy. The study design filter was adjusted.
1 Clinical Article/
2 exp Clinical Study/)
3 Clinical Trial/
4 Controlled Study/
5 Randomized Controlled Trial/
6 Major Clinical Study/
7 Double Blind Procedure/
8 Multicenter Study/
9 Single Blind Procedure/
10 Phase 3 Clinical Trial/
















27 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).mp.
28 trial.mp.
29 (versus or vs).mp.
30 or/15-29
31 14 or 30
32 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
33 human/ or normal human/ or human cell/
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34 32 and 33
35 32 not 34












48 exp Nonsteroid Antiinflammatory Agent/
49 nsaids.mp.
50 non-steroidal anti-inflammatory.mp.
51 exp Acetylsalicylic Acid/
52 acetylsalicyl$.mp.
53 carbasalate calcium.mp. or exp Carbasalate Calcium/
54 diflunisal.mp. or exp DIFLUNISAL/
55 aceclofenac.mp. or exp ACECLOFENAC/
56 alclofenac.mp. or exp ALCLOFENAC/
57 diclofenac.mp. or exp DICLOFENAC/
58 exp INDOMETACIN/ or indometacin.mp.
59 sulindac.mp. or exp SULINDAC/
60 meloxicam.mp. or exp MELOXICAM/
61 exp PIROXICAM/ or piroxicam.mp.
62 dexibuprofen.mp. or exp DEXIBUPROFEN/
63 dexketoprofen.mp. or exp DEXKETOPROFEN/
64 exp FENOPROFEN/ or fenoprofen.mp.
65 flurbiprofen.mp. or exp FLURBIPROFEN/
66 ibuprofen.mp. or exp IBUPROFEN/
67 ketoprofen.mp. or exp KETOPROFEN/
68 naproxen.mp. or exp NAPROXEN/
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69 tiapro$.mp.
70 metamizol.mp. or exp Dipyrone/
71 phenylbutazone.mp. or exp PHENYLBUTAZONE/
72 phenazone.mp. or exp PHENAZONE/
73 exp PROPYPHENAZONE/ or propyphenazone.mp.
74 celecoxib.mp. or exp CELECOXIB/
75 etoricoxib.mp. or exp ETORICOXIB/
76 exp Nabumetone/ or nabumeton.mp.
77 parecoxib.mp. or exp PARECOXIB/
78 or/48-77
79 exp Cyclooxygenase 2 Inhibitor/
80 rofecoxib.mp. or exp ROFECOXIB/
81 valdecoxib.mp. or exp VALDECOXIB/
82 lumiracoxib.mp. or exp LUMIRACOXIB/
83 etoricoxib.mp. or exp ETORICOXIB/






90 etodolac.mp. or exp ETODOLAC/
91 floctafenine.mp. or exp FLOCTAFENINE/
92 exp Meclofenamic Acid/
93 meclofenam$.mp.
94 oxaprozin.mp. or exp OXAPROZIN/
95 exp PIROXICAM/ or piroxicam.mp.
96 tenoxicam.mp. or exp TENOXICAM/
97 tolmetin.mp. or exp TOLMETIN/
98 or/79-97
99 78 or 98
100 36 and 47 and 99
101 limit 100 to yr="2013 - 2014"
102 limit 100 to em=201314-201414
103 101 or 102
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2013 search strategy. The study design filter was revised.
1 Clinical Article/
2 exp Clinical Study/
3 Clinical Trial/
4 Controlled Study/
5 Randomized Controlled Trial/
6 Major Clinical Study/
7 Double Blind Procedure/
8 Multicenter Study/
9 Single Blind Procedure/
10 Phase 3 Clinical Trial/
















27 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).mp.
28 trial.mp.
29 (versus or vs).mp.
30 or/15-29
31 14 and 30
32 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
33 human/ or normal human/ or human cell/
34 32 and 33
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35 32 not 34











47 exp Low Back Pain/
48 or/37-47
49 exp Nonsteroid Antiinflammatory Agent/
50 nsaids.mp.
51 non-steroidal anti-inflammatory.mp.
52 exp Acetylsalicylic Acid/
53 acetylsalicyl$.mp.
54 carbasalate calcium.mp. or exp Carbasalate Calcium/
55 diflunisal.mp. or exp DIFLUNISAL/
56 aceclofenac.mp. or exp ACECLOFENAC/
57 alclofenac.mp. or exp ALCLOFENAC/
58 diclofenac.mp. or exp DICLOFENAC/
59 exp INDOMETACIN/ or indometacin.mp.
60 sulindac.mp. or exp SULINDAC/
61 meloxicam.mp. or exp MELOXICAM/
62 exp PIROXICAM/ or piroxicam.mp.
63 dexibuprofen.mp. or exp DEXIBUPROFEN/
64 dexketoprofen.mp. or exp DEXKETOPROFEN/
65 exp FENOPROFEN/ or fenoprofen.mp.
66 flurbiprofen.mp. or exp FLURBIPROFEN/
67 ibuprofen.mp. or exp IBUPROFEN/
68 ketoprofen.mp. or exp KETOPROFEN/
69 naproxen.mp. or exp NAPROXEN/
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70 tiapro$.mp.
71 metamizol.mp. or exp Dipyrone/
72 phenylbutazone.mp. or exp PHENYLBUTAZONE/
73 phenazone.mp. or exp PHENAZONE/
74 exp PROPYPHENAZONE/ or propyphenazone.mp.
75 celecoxib.mp. or exp CELECOXIB/
76 etoricoxib.mp. or exp ETORICOXIB/
77 exp Nabumetone/ or nabumeton.mp.
78 parecoxib.mp. or exp PARECOXIB/
79 or/49-78
80 exp Cyclooxygenase 2 Inhibitor/
81 rofecoxib.mp. or exp ROFECOXIB/
82 valdecoxib.mp. or exp VALDECOXIB/
83 lumiracoxib.mp. or exp LUMIRACOXIB/
84 etoricoxib.mp. or exp ETORICOXIB/






91 etodolac.mp. or exp ETODOLAC/
92 floctafenine.mp. or exp FLOCTAFENINE/
93 exp Meclofenamic Acid/
94 meclofenam$.mp.
95 oxaprozin.mp. or exp OXAPROZIN/
96 exp PIROXICAM/ or piroxicam.mp.
97 tenoxicam.mp. or exp TENOXICAM/
98 tolmetin.mp. or exp TOLMETIN/
99 or/80-98
100 79 or 99
101 36 and 48 and 100
102 limit 101 to yr="2012 - 2013"
103 limit 101 to em=201218-201314
104 102 or 103
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2012 search strategy
1 Clinical Article/
2 exp Clinical Study/
3 Clinical Trial/
4 Controlled Study/
5 Randomized Controlled Trial/
6 Major Clinical Study/
7 Double Blind Procedure/
8 Multicenter Study/
9 Single Blind Procedure/
10 Phase 3 Clinical Trial/
















27 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).mp.
28 trial.mp.
29 (versus or vs).mp.
30 or/15-29
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35 Animal Experiment/
36 33 or 34 or 35
37 32 not 36
38 31 not 36
39 37 and 38











51 exp Low Back Pain/
52 or/41-51
53 exp Nonsteroid Antiinflammatory Agent/
54 nsaids.mp.
55 non-steroidal anti-inflammatory.mp.
56 exp Acetylsalicylic Acid/
57 acetylsalicyl$.mp.
58 carbasalate calcium.mp. or exp Carbasalate Calcium/
59 diflunisal.mp. or exp DIFLUNISAL/
60 aceclofenac.mp. or exp ACECLOFENAC/
61 alclofenac.mp. or exp ALCLOFENAC/
62 diclofenac.mp. or exp DICLOFENAC/
63 exp INDOMETACIN/ or indometacin.mp.
64 sulindac.mp. or exp SULINDAC/
65 meloxicam.mp. or exp MELOXICAM/
66 exp PIROXICAM/ or piroxicam.mp.
67 dexibuprofen.mp. or exp DEXIBUPROFEN/
68 dexketoprofen.mp. or exp DEXKETOPROFEN/
69 exp FENOPROFEN/ or fenoprofen.mp.
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70 flurbiprofen.mp. or exp FLURBIPROFEN/
71 ibuprofen.mp. or exp IBUPROFEN/
72 ketoprofen.mp. or exp KETOPROFEN/
73 naproxen.mp. or exp NAPROXEN/
74 tiapro$.mp.
75 metamizol.mp. or exp Dipyrone/
76 phenylbutazone.mp. or exp PHENYLBUTAZONE/
77 phenazone.mp. or exp PHENAZONE/
78 exp PROPYPHENAZONE/ or propyphenazone.mp.
79 celecoxib.mp. or exp CELECOXIB/
80 etoricoxib.mp. or exp ETORICOXIB/
81 exp Nabumetone/ or nabumeton.mp.
82 parecoxib.mp. or exp PARECOXIB/
83 or/53-82
84 exp Cyclooxygenase 2 Inhibitor/
85 rofecoxib.mp. or exp ROFECOXIB/
86 valdecoxib.mp. or exp VALDECOXIB/
87 lumiracoxib.mp. or exp LUMIRACOXIB/
88 etoricoxib.mp. or exp ETORICOXIB/






95 etodolac.mp. or exp ETODOLAC/
96 floctafenine.mp. or exp FLOCTAFENINE/
97 exp Meclofenamic Acid/
98 meclofenam$.mp.
99 oxaprozin.mp. or exp OXAPROZIN/
100 exp PIROXICAM/ or piroxicam.mp.
101 tenoxicam.mp. or exp TENOXICAM/
102 tolmetin.mp. or exp TOLMETIN/
103 or/84-102
104 83 or 103
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105 40 and 52 and 104
106 limit 105 to yr="2007 - 2012"
107 limit 105 to em=200712-201220
108 106 or 107
Appendix 4. Search strategies for clinical trials registries and PubMed
Clinical Trials.gov
Last searched 7 January 2020
Search terms field: back pain and NSAIDS
First posted from 11/12/2018 to 01/07/2020
2014 search






Last searched 7 January 2020






Last searched 14 January 2016
((nsaids OR non-steroidal anti-inflammator* OR non-steroidal antiinflammator* OR aspirin OR acetylsalicyl* OR salicylic acid OR
carbasalate calcium OR diflunisal OR aceclofenac OR alclofenac OR diclofenac OR indomethacin OR indometacin OR sulindac OR
meloxicam OR piroxicam OR dexibuprofen OR dexketoprofen OR fenoprofen OR flurbiprofen OR ibuprofen OR ketoprofen OR naproxen OR
tiapro* OR metamizol OR phenylbutazone OR phenazone OR propyphenazone OR celecoxib OR etoricoxib OR nabumeton OR parecoxib
OR cyclooxygenase inhibitor* OR cyclo-oxygenase inhibitor* OR rofecoxib OR celecoxib OR valdecoxib OR lumiracoxib OR etoricoxib OR
parecoxib OR vioxx OR celebrex OR bextra OR prexige OR arcoxia OR etodolac OR floctafenine OR Meclofenamic Acid OR meclofenamate OR
meloxicam OR oxaprozin OR piroxicam OR tenoxicam OR tolmetin) AND (back pain OR sciatica OR lumbar pain OR lumbago OR dorsalgia OR
backache OR back disorder*) AND (pubstatusaheadofprint OR publisher[sb] or pubmednotmedline[sb])) limit to 2015/06/24-2016/01/14
Appendix 5. The GRADE approach to evidence synthesis
The quality of evidence will be categorized as follows, using the GRADE approach (GRADE Working Group 2004; Guyatt 2008; Furlan 2015):
• High (⊙⊙⊙⊙): further research is very unlikely to change the confidence in the estimate of eFect.
• Moderate (⊙⊙⊙○): further research is likely to have an important impact on the confidence in the estimate of eFect, and may change
the estimate.
• Low (⊙⊙○○): further research is very likely to have an important impact on the confidence in the estimate of eFect and is likely to
change the estimate.
• Very low (⊙○○○): very little confidence in the eFect estimate.
• No evidence: no RCTs were identified that addressed this outcome.
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The quality of the evidence for a specific outcome can be reduced by one or more levels, depending on the performance of the studies (that
measured that particular outcome) on five domains. The evidence available to answer each sub-question will be graded on the domains
in the following manner:
1. Study design and risk of bias
Only randomized controlled trials were included. Special attention was drawn to adequacy of allocation concealment, blinding and follow-
up. The risk of bias of included trials was assessed independently by two review authors, based on criteria described in in the updated
method guidelines of CBN (Furlan 2015). First, each of the criteria was scored as 'yes', 'no', or 'unsure' (Table 1; Table 2). Second, a judgement
was made on the domain level. Finally, an overall judgement of the risk of bias of each study was reached by consensus. We downgraded
the evidence by one level if > 25% of the participants were included from studies with an overall judgement of a high risk of bias.
2. Inconsistency
The evidence was downgraded by one level when heterogeneity or variability in results was substantial (I2 > 50%), or if there were
inconsistent findings, e.g. large diFerences in treatment eFect estimates, or in the direction of eFect across studies.
3. Indirectness
Indirectness refers to the generalizability of the study population, the chosen intervention, and the outcomes, e.g. the extent to which the
study population in the trials is representative of those defined in the inclusion criteria of the review. The evidence was downgraded one
level when there was an uncertainty about generalizability of the results.
4. Imprecision
Studies with small sample sizes may lead to imprecision of results, with few events and wide confidence intervals (CIs) around the eFect
estimate. The evidence was downgraded by one level if the results were considered imprecise due to either (1) or (2); or by two levels if
both were applicable. 1) When the sample size was small, with few events and a wide CI; if there was only one study that could be included
in the comparison; or if there was more than one trial but the total number of events was less than 300 for dichotomous data, or if the
number of participants was less than 400 for continuous data. No precise cutoF exists for 'insuFicient' data, but these numbers were used
as a general rule of thumb (Furlan 2015; Mueller 2007). 2) If the 95% CI around the pooled estimate of eFect includes both a) no eFect and b)
appreciable benefit or appreciable harm in dichotomous outcomes (threshold is a relative risk reduction or relative risk increase of > 25%),
or if the 95% CI includes both a) no eFect and b) the upper or lower confidence limit crosses an eFect size (standardized mean diFerence)
of 0.5 in either direction in continuous outcomes.
5. Publication bias
The quality of evidence would be downgraded by one level if a funnel plot suggested publication bias. However, in this review, the amount
of studies in the meta-analysis of each specific comparison was not large enough to develop a funnel plot or draw conclusions concerning
potential publication bias.
W H A T ' S   N E W
 
Date Event Description
7 January 2020 New citation required but conclusions
have not changed
This is an update of a previously published review on NSAIDS for
low back pain (LBP) (Roelofs 2008). The reviews on chronic LBP
(Enthoven 2016), and sciatica (Rasmussen-Barr 2016), have been
published. This review focuses on acute LBP. We included 32 tri-
als.
7 January 2020 New search has been performed We performed a new search and added six new trials to the re-
view. We used the updated Cochrane Back and Neck method
guideline (Furlan 2015). We had changes in authorship: WH van
der Gaag and WTM Enthoven were added to the author team;
RJPM Scholten and RA Deyo resigned.
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authors. Data extraction and analysis were performed by WH van der Gaag and PDDM Roelofs. WH van der Gaag wrote the initial draI of
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
This review is an update of a previously published review on non-steroidal anti-inflammatory drugs (NSAIDs) for non-specific low back
pain (van Tulder 2000). A protocol was published in 1997 for the original review, but not for this review, which focused on NSAIDS for
acute low back pain (LBP). There were some changes to the 1997 protocol that we specified in the methods and will describe here. In
general, we followed the guidance of Furlan 2015 along with the Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). In the protocol, only randomised and double-blind controlled trials were included, in the current review we included all types of
RCTs. The protocol identified five comparisons, the first two of which remained (NSAIDs versus placebo and NSAIDs versus paracetamol).
We considered NSAIDs versus placebo the main comparison. The protocol included two additional comparisons, NSAIDs versus narcotic
analgesics, and NSAIDs versus muscle relaxants, which we combined into one broader comparison of NSAIDs versus other drug treatment.
We added a comparison of selective COX-2 inhibitor NSAIDs versus non-selective NSAIDs, and a comparison of NSAIDs versus non-drug
treatment. We removed the comparison of NSAIDs versus NSAIDs plus muscle relaxants, since there was no contrast for NSAIDs in this
comparison.
We added adverse events as a fiIh primary outcome measure. We did not include the secondary outcome measures that were mentioned
in the protocol (physiological outcomes, generic functional status, and medical consumption), and we specified the timing of follow-up
(minimal follow-up duration of one day, and at least one outcome assessment in the first three weeks), since this review concerned people
with acute LBP.
The protocol did not state any age limits. The current methods included studies with subjects aged 18 years or older, because we aimed to
identify all studies focusing on adults. However, in practice, we still included a study if age limits were not mentioned, if there were no age
limits, or if subjects aged 16 or above (instead of 18) were included. Usually, only a small minority of the study population were younger
than our 18-year limit in these cases.
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Electronic databases for the searches were added or removed as described under Electronic searches.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Acute Pain  [*drug therapy];  Anti-Inflammatory Agents, Non-Steroidal  [adverse eFects]  [*therapeutic use];  Cyclooxygenase 2 Inhibitors
 [adverse eFects]  [therapeutic use];  Disability Evaluation;  Low Back Pain  [*drug therapy];  Pain Measurement;  Placebos  [therapeutic
use];  Randomized Controlled Trials as Topic
MeSH check words
Adolescent; Adult; Aged; Humans; Middle Aged
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